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Abstract 
 
I.M. Antyborzec  
“Neurotrophin Receptor p75 Affords Clearance of Amyloid Beta in Alzheimer’s 
Disease and Provides Targeting Route to Basal Forebrain Cholinergic Neurons” 
 
Basal forebrain cholinergic neurons (BFCNs) are one of the most affected neuronal 
populations in Alzheimer’s disease (AD). They exclusively express p75 neurotrophin 
receptor (p75
NTR
) during adulthood, known also to bind non-neurotrophic ligands 
including amyloid beta (Aβ), which is mainly responsible for neuronal damage in 
AD.  
 
Immuno-histochemistry and Western blot analysis as well as fluorescent and 
confocal laser scanning microscopy were utilized in this study to identify and 
functionally characterize BFCNs in culture and in vivo. Stereotactic injections into 
the rat brain were used to chemically-induce AD and later to introduce lentivirus 
targeted to BFCNs. 
 
Selective internalization of p75
NTR
 (labelled with 192-IgG-Cy3) and fluorescent 
(Alexa 488-labelled) Aβ (1-42) was observed in live cultured BFCNs. Parameters of 
endocytosis and combined trafficking of these two molecules were analyzed as well 
as their distribution in compartments of BFCNs. Although Aβ entry routes remains 
elusive, the destination of p75
NTR
 cargo points to lysosomes, suggesting a novel role 
of p75
NTR
 in Aβ clearance by cholinergic cells. This was also true in saporine-
induced (192-IgG-SAP) in vivo AD rat model, in which increase of Aβ (1-42) was 
observed in cortical and hippocampal structures of brain, thus confirming the role of 
BFCNs in clearance of Aβ. Interestingly in further experiments Aβ (1-42) oligomers 
significantly reduced p75
NTR
 endocytosis in a dose-dependent manner, suggesting 
new homeostatic role of p75
NTR
 in Aβ uptake.  P75NTR also prove to facilitate transfer 
of lentiviral vectors to BFCNs in vitro and vivo. 192-IgG-lentivirus injected into the 
lateral ventricle of rat brain yielded selective expression of GFP in cholinergic 
neurons in medial septum and diagonal bands of Brocca regions. 
 
New functions of p75
NTR
 described in this thesis make significant contribution to the 
knowledge of AD. Also novel strategy described herein can be utilized further for 
targeted delivery of neurotherapeutics to BFCNs with possible minimal off-side 
effects.  
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1.1. History of Alzheimer’s disease  
 
The first case study of AD was presented during a lecture given on the 4
th
 of 
November 1906 at the Conference in Tübingen (south-west Germany) by a 
neuropathologist - Dr. Alois Alzheimer. He reported observations made in his patient 
Auguste D., whose sickness he followed since her admittance to the mental hospital 
in Frankfurt. Auguste D. experienced devastated symptoms of aphasia, 
disorientation, paranoia, hallucinations and pronounced psycho-social impairment 
that progressed to her death at 53 years of age. Dr. Alzheimer took her brain for post-
mortem analysis and discovered “peculiar changes” in neurophybrils later called 
neurophybrillary tangles and “miliary foci” in the cortex, currently known as 
amyloid beta (Aβ) plaques. His report on these histopathological alterations did not 
get much attention initially, but was emphasized in Emil Kraeplin’s Handbook of 
Psychiatry in 1910 under the acronym of Alzheimer’s disease. For the next 50 years, 
cases similar to Auguste D. were considered as normal part of aging until it was 
confirmed that synapse loss is the major correlate of cognitive decline and shown 
that the number of plagues and tangles correlate with severity of the disease (Deutsch 
1971; Katzman, 1976). Soon after a reduction in the number of cholinergic neurons 
of BF was discovered (Bowen et al., 1976; Davies and Maloney, 1976), combined 
with a decrease of choline acetyltransferase (ChAT) activity in the cerebral cortex 
(Bartus et al., 1982). This stream of research continued to yield knowledge about 
other cholinergic markers associated with AD (Bierer et al., 1995). Parallel studies 
revealed considerable down-regulation of nicotinic cholinergic receptors (nAChRs) 
in the cortex (Araujo et al., 1988; Sihver et al, 1999). About the same time, nicotinic 
and muscarinic agonists were developed (Sunderland et al, 1988) and clinical trials 
began. That resulted in the first drug - tacrine (Cognex) approved by the Food and 
Drug Administration (FDA), developed by Warner-Lambert in 1993 and followed by 
Aricept (Donepezil) in 1996. Since then, the era of acetylcholinesterase inhibitors 
(AChEIs) has started and despite limited success of these drugs, they remain to this 
day a main FDA-approved option for the treatment of clinical and pre-clinical AD. 
Apart from AChEIs, FDA approved Memantine in 2003, which acts as an antagonist 
of N-methyl-D-aspartate (NMDA) receptor (Chapter 1.6). Other potential 
therapeutics are currently in clinical trials, with their effects largely mediated via 
modulation of the activity of enzymes involved in the cleavage of amyloid precursor 
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protein (APP) (β and γ secretase inhibitors) or prevention of the aggregation of toxic 
Aβ species (anti-aggregants) as well as targeting amyloid plagues directly (through 
active or passive immunization).  
 
1.2. Risk factors for AD  
 
Both genetic and environmental risk factors can contribute to the development of 
AD. Genetic factors are mainly accountable for early onset of familial AD (FAD), 
which is responsible for less than 10% of all AD cases. They follow Mendelian 
pattern of inheritance, represented more precisely by autosomal dominant mutations 
in the genes for APP on chromosome 21, presenilin 1 (PSEN 1) on chromosome 14 
or presenilin 2 (PSEN 2) on chromosome 1 (Schellenberg et al, 1992;  Levy-Lahad et 
al., 1995; Prince and Sisodia 1998). Point mutations in these three genes lead to over-
production of Aβ protein, which accumulates in pathological amounts and forms 
aggregates in the brains of AD patients. These genetic data have been also 
considered as the strongest supportive evidence for amyloid hypothesis of AD 
(Chapter 1.5.).  
As regards to the genetic bases for late onset of AD, they are less known and mostly 
connected to apolipoprotein E (APOE). APOE is polymorphic protein (with three 
major isoforms APOE 2, APE 3, APOE 4) essential for the normal catabolism of 
triglyceride-rich lipoprotein constituents (Nishimura et al., 2014). The highest 
genetic risk of AD is associated with allele 4 of APOE on chromosome 19 
(Kingwell, 2013) with around 40 – 80 % of affected patients possessing at least one 
copy of this allele, which can increase the chance of developing AD 2-5 fold, 
whereas having two alleles raises this possibility more than 5 times. However, the 
presence of allele 4 of APOE does not necessarily predispose to developing the 
disease. There are populations (e.g. Nigerian) that reveal no link between APOE 4 
and the incidence of AD (Osuntokun et al., 1995). Moreover and to complicate the 
apolipoprotein story, another allele of APOE (allele 2) is found to be protective in 
many AD cases. Currently-running genome wide association studies (GWAS) 
analyse millions of single nucleotide polymorphism (SNPs) in search of the genes 
responsible for the disease. A catalogue of these GWAS has been complied and is 
available to the public at:  http://www.alzgene.org/largescale.asp with up-to-date 
rank list of odd ratios for each genetic risk factor. In addition, meta-analysis has been 
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performed for each gene, for which there are at least two independent association 
studies; these data are also available online. They suggest the incomplete penetrance 
of genetic risk factors associated with late AD, leaving room for epigenetic and 
environmental stimuli that may contribute to the development of the disease. 
On the other hand, the vast majority of sporadic AD cases (almost 95 %) occurs 
without involving any obvious genetic risks. They develop with time and mostly 
manifest after 65 years of age. Age as a risk factor actually doubles the possibility of 
getting AD after 65; therefore, aging is still the main and best known condition for 
developing the disease (Mattson and Magnus, 2006). The number of  AD cases raises 
rapidly in aging global population according to Alzheimer’s association (Fargo, 
2014). The group with the highest risk of AD, those older than 85, is currently the 
fastest growing age group in the developed countries. It is estimated that the number 
of people with AD actually doubles by mid-century. However, it is essential to 
remember that AD is not a normal part of aging and advanced age alone is not 
sufficient to cause the disease. Beside age, the other so-called lifestyle risk factors 
are also important for the disease process. These may include exercise (Smith et al., 
2014), diet (Solfrizzi et al., 2011), education and occupation (Garibotto et al., 2008; 
2013) or other putative risks which involve smoking and alcohol consumption, 
(Piazza-Gardner, 2013; Durazzo et al., 2014) or traumatic brain injury (Weiner et al., 
2014).  
The above characteristics of risk factors for sporadic and familial AD cases is 
simplified and it is important to bear in mind the complexity of the disease that 
allows early onset symptoms to appear without the evidence of Mendelian 
transmission as well as existence of late symptoms of AD with familial clustering.  
 
1.3. Clinical symptoms, forms of AD and current diagnosis  
 
The memory deficit in AD follows a particular pattern known as Ribot’s law (Ribot, 
1881) in which recently acquired memories are more vulnerable to loss than longer 
established ones. The patients show anterograde dementia (difficulty in learning new 
information) or retrograde amnesia (difficulty in retrieving previously learned 
information), displaying preserved memory for information from the remote past. 
Short-term memory deficits begins early in the disease process with common 
symptoms including asking the same question repeatedly, forgetting important 
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appointments or difficulties in finding words. However at this stage the person seems 
to be normal, because the social skills remain largely intact (Solomon and Murphy, 
2008). As the disease progresses, working memory becomes impaired. This form of 
memory is responsible for reasoning and comprehension as well as goal-oriented 
active monitoring and manipulation of information or behavior in the presence of 
interfering processes (Becker and Morris, 1999). Spatial memory responsible for real 
time navigation into familiar or unknown environment also becomes impaired early 
in AD (Nitz, 2009). Higher cognitive functions, which include the executive 
(planning, problem solving, verbal and abstract reasoning, multi-tasking, judgment) 
or attention control (integration, processing, disposal, and retrieval of information) 
are also affected (Budson and Solomon, 2012). Progressive deterioration of cognition 
and memory functions cause that patients are usually unable to take care of 
themselves in later stages of the disease. Their motor coordination and general 
locomotion become affected and daily activities impaired, which may lead to 
complete incapacitation. The disease finishes with total loss of cognitive functions 
and close to complete memory and behavioural loss.  
Such developments are devastating not only for the patient but equally difficult for 
family members or caregivers. A person with AD may eventually fail to recognize 
one's own spouse and children. The rate of AD progression widely differs from case 
to case with average 5 years from diagnosis to death, although the neuropathological 
process itself can start 10-20 years prior to the appearance of first clinical signs. 
Recognizing the harbingers of AD as opposed to changes associated with normal 
aging is very important, as an early diagnosis can help in the management of the 
disease.  
By convention, several stages of AD are defined, which include pre-dromal, 
moderate and severe stages, with borders between these phases, and appropriate 
guidelines for the clinicians how to qualify them remaining a matter of debate 
(Dubois et al., 2010). Pre-dromal (pre-symptomatic) stage of dementia also called as 
mild cognitive impairment (MCI) does not necessarily evolve into clinical AD. 
Generally,  memory tests are performed as indicators of AD severity, followed by 
magnetic resonance imaging (MRI) to measure the white matter hyper-intensity 
versus total brain matter as well as intracranial and hippocampal volumes (Borson et 
al., 2005; Archana and Ramakrishnan, 2014). Also, positron emission tomography 
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(PET) is used to observe the amyloidosis in brains of AD affected people or those in 
high risk groups (Grimmer et al., 2009).  
Research continues on the developments of cerebrospinal fluid (CSF) or less invasive 
blood plasma biomarkers for AD diagnosis (Laske 2011; Kang et al., 2014). One of 
the prime aims and challenges nowadays is to diagnose AD early enough, so that the 
patient could benefit from the disease modifying therapies available prior to the onset 
of extensive neurodegenerative alterations with irreversible functional impairments 
(Nordberg, 2015).  
In summary, it is worth stressing that AD, one of the worst chronic progressive 
neurodegenerative illness accompanied by global intellectual debilitation, followed 
by death, is largely of unknown origin and further research is urgently needed to find 
out its underlying causes and provide reliable and effective treatment with 
rehabilitation. 
 
1.4. Pathological hallmarks of AD and their correlation with the disease  
 
Clinical manifestations of AD are caused by pathological changes in specific brain 
areas. Among the main neuropathological changes, the senile plaques and 
neurofibrillary tangles (NFTs) are the most frequently described since Alois 
Alzheimer’s first case study of AD in 1901.  
Amyloid plaques are extracellular deposits of aggregated Aβ peptides with two most 
common variants –Aβ40 and Aβ42 (Glenner et al., 1984). They are surrounded by 
large dystrophic neurites, which can also be present within the senile plagues (Cras et 
al., 1991), hypertrophic astrocytes and activated microglia as well as other 
inflammatory cells. Heparan sulfate proteoglycan and apolipoprotein E also associate 
with the plaques (Fukuchi et al., 1998; Sanan et al., 1994). Among other elements, 
the complement cascade like α-1-antichymotrypsin, lysosomal proteases or anti-
oxidant enzymes constitute a minority of these structures (Abraham et al., 1988; 
Lemere et al., 1995; McLellan et al., 2003). Strong staining for AChE activity is also 
revealed in the plaques due to the local distortion of cholinergic fibers network 
(Alvarez et al., 1997). Senile plaques deposition occurs early in the disease process 
and proceeds slowly. The accumulation of amyloid plaques does not always correlate 
with severity of cognitive deficit and memory loss of AD (McLean et al., 1999, 
Perez-Nievas et al, 2013).  
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Deposition of Aβ associated with cerebral vasculature is frequently found in AD 
(Glenner and Wong, 1984). This so called vascular dementia is caused by blockage 
or damage and leaking of blood vessels, which deprive small areas of brain from 
blood and oxygen, often causing local strokes with neurodegeneration and cognitive 
decline (Iadecola, 2004). It is currently unsolved which proportions of dementia are 
caused by plaques and associated damage or vascular pathology, with some 
arguments that the latter accelerates the damage driven by amyloid (Kester et al., 
2014). In the past, evidence of vascular dementia was used to exclude a diagnosis of 
AD (and vice versa). This is no longer valid since pathological evidence shows both 
types of brain changes commonly co-exist creating so called mixed dementia 
(Jellinger and Attems, 2007; Schneider et al., 2007).  
As opposed to amyloid plaques, NFTs are represented largely by intra-neuronal 
inclusions, that can be found both in association with fibrilliar amyloid plaques or 
apart from them (e.g. in frontotemporal dementia). NFTs are composed of 
microtubule-associated proteins (MAPs) - tau in their hyperphosphorylated form. 
Normally this protein plays an important role in cytoskeleton formation and stability 
by reversible phosphorylation and dephosphorylation (Weingarten et al., 1975). If 
phosphorylated tau is not dephosphorylated, it is unable to bind other microtubules, 
which results in polymerization of the phosphorylated tau to the straight filaments. 
These are then cross-linked by glycosylation to form paired helical fragments (PHF), 
found in NFTs (Grundke-Iqbal et al., 1986). NFTs correlate better than plaques with 
cognitive decline (Arriagada et al., 1992; Giannakopoulos et al., 2003). However, 
more recent theories postulate a main role of soluble tau in AD (Berger et al., 2007; 
Lasagna-Reevers et al., 2011). 
In addition to these two mentioned above pathological features, extensive loss of 
neurons and degeneration of nerve terminals are also reported in AD. Cell death 
occurs mostly by apoptotic or necrotic processes triggered by proteases such as 
caspases and calpains (Wang, 2000; Mattson, 2000). BF cholinergic neurons studied 
in parts of this work are especially vulnerable to AD (Chapter 1.5.3.2.). However, the 
synaptic changes are observed long before cell loss (Knobloch and Mansuy, 2009; 
Bosch and Hayashi, 2012). They are central to the disease process and correlate best 
with the severity of dementia (DeKosky and Scheff, 1990; Arendt 2009, Koffie et al., 
2011). Both, Aβ and tau contribute to the synapse degeneration (Bloom 2014). 
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1.5. Main hypothesis of AD 
1.5.1. Amyloid cascade hypothesis  
 
Amyloid cascade hypothesis is the prevailing hypothesis in the field of AD. It views 
over-production or deficit of Aβ clearance as proximal cause of both SAD and FAD. 
The production of Aβ and its accumulation into the toxic species deposited in brain 
in the form of plaques are key elements of this hypothesis (Hardly and Selkoe 2002, 
Golde and Janus, 2005). Genetic correlation of presenilins and APP mutations 
(Chapter 1.3.) with AD strongly favours the main role of Aβ in AD. However, the 
presence of amyloid plaques does not always correlate with cognitive decline. 
Therefore, the original hypothesis has been modified, emphasizing the pathogenic 
role of non fibrilliar Aβ in form of oligomers, postulated to be the primary cause of 
cognitive impairment of AD (Selkoe 2008). This hypothesis is based on observation 
that mental decline precedes the appearance of fibrilliar Aβ in transgenic mouse 
models of AD (Billings at all, 2005) and that there is a strong positive correlation 
between the levels of soluble Aβ and severity of dementia (McLean, 1999). The 
amyloid cascade hypothesis also implicates Aβ in the initiation of pathological 
processes associated with impairments of MAP tau functions and cell loss. 
 
1.5.1.1. Generation of amyloid β (Aβ) in brain, its toxicity and clearance  
 
The molecular events that lead to Aβ production in brain are governed by a series of 
endoproteases that cleave transmembrane amyloid precursor protein (APP). APP can 
be processed via amyloidogenic pathway, through sequential proteolysis by β and γ 
secretases (Shoji et al., 1992) as shown in Figure 1. or in a non amyloidogenic way 
by metalloproteases TACE or ADAM family (ADAM 10 or 17), which possess α-
secretase activity. They cleave APP within the Aβ domain to produce soluble sAPPα 
ectodomain and the membrane-bound C83 fragment; the latter is then cleaved by γ-
secretase to produce the non-toxic p3 part (Słomnicki and Leśniak, 2008). It is 
reported that α and β secretases compete directly for APP cleavage (Skovronsky et 
al., 2000). β-secretase, also known as BACE-1 (β-APP cleaving enzyme), is 
membrane bound type 1 protein mainly localized in endosomes, lysosomes and the 
trans-Golgi network (Capell et al., 2000). The other variant of this aspartyl protease 
known as BACE-2 shows lower expression in neurons but it is widely expressed in 
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peripheral tissues (Bennett et al., 2000). β-secretase generates the amino N-terminus 
of Aβ peptide, leaving membrane-bound carboxy-terminal fragment (CTFβ 99 amino 
acids long) to be cleaved by γ secretase between 38 and 43 residues. The APP 
cleavage can occur within the Golgi network as well as during the re-internalization 
of APP within endosomes (Koo and Squazzo, 1995; Hartman et al., 1997). The γ-
secretase itself is a multimeric protein complex consisting of presenilin-1 (PSEN1) 
and presenilin-2 (PSEN2) catalytic subunits, nicastrin, Aph-1 and PEN-2 (Kimberly 
et al. 2003). Depending on the exact point of cleavage, different length of amyloid 
beta peptides are generated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Aβ (1-40) is the predominant isoform and accounts for 70 % of total Aβ pool 
(Fraering, 2007). A smaller proportion of Aβ produced as Aβ(1-42) has a greater 
tendency for misfolding with oligomerization (into dimers, trimers, tetramers, 
dodecamers and higher order oligomers). Aβ oligomers subsequently aggregate into 
soluble protofibrils, which are maturating further into fibrils and forming amyloid 
plaques (Glabe, 2008). These are mostly found in neocortex and hippocampus of AD 
affected brains (Masters et al., 1985). It was shown that Aβ oligomerization occurs in 
the endosomal compartments as well as during interaction with lipid bilayers, 
especially cholesterol and glycosphingolipid-rich lipid rafts (Takahashi et al., 2004; 
Kim et al., 2006). However, Aβ aggregation and fibrillization pathways can be 
independent and distinct (Necula et al., 2007). This means that Aβ oligomers are not 
 
  
 
 
(i) The first cleavage is realized in APP 
extracellular domain by α or β-secretase 
activity and releases soluble N-terminal 
fragments sAPPα or sAPPβ. 
 
 
 
(ii) Thereafter, γ-secretase generates p3 or 
β-amyloid (40-42) as a result of intra-
membrane digestion.  
 
 
 
(iii) Simultaneously, in both cases, the C-
terminal fragment called APP Intracellular 
Domain (AICD) is released into the 
cytoplasm. 
Figure 1. Proteolytic processing of APP (Słomnicki and Leśniak, 2008). 
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an obligate intermediate of insoluble fibrils. Soluble Aβ oligomeric species are 
reported to be the most neurotoxic (Selkoe, 2004) and they are a major cause of 
memory impairment according to the amyloid cascade hypothesis (Chapter 1.5.1).  
Excitotoxicity due to over-excitation of NMDA receptors has been implicated as a 
central mechanism by which Aβ causes neuronal damage; however, there is no proof 
of direct Aβ binding to these receptors (Lai and McLaurin, 2010). Recent findings 
indicate that Aβ oligomers influence neurons indirectly, by induction of astrocytic 
glutamate release, which in turn activates neuronal NMDA receptors. An excessive 
influx of calcium through these receptors activates nitric oxide synthase, which 
produces toxic levels of NO that correlate with synaptic spine loss in initial phase of 
AD (Talantova et al., 2013). Also, other receptors are implicated in Aβ-mediated 
synaptotoxicity. For example, metabotropic glutamate receptors (mGluRs) facilitate 
Aβ induction of long term depression (LTD) (Walsh et al., 2002), or α7 nAChRs 
trigger a down-regulation of the ERK2/MAPK pathway, associated with memory 
formation (Dineleyetal., 2001). This can suggest that different receptors mediate 
dissimilar aspects of Aβ toxicity.  However, other receptor-mediated mechanism of 
Aβ toxicity are also possible. For example, Aβ may alter membrane property by 
forming pores, which promotes calcium influx into neurons,  resulting in disruption 
of Ca
2+
 homeostasis (Kawahara, 2010) (Chapter 1.5.1.2.). It is also possible that Aβ 
create clusters at the membrane that may reduce the level of scaffolding proteins like 
PSD-95, which stabilize the glutamate receptors on the membrane (Dinamarca et al., 
2012). Additionally, intracellular Aβ is implicated in the disruption of axonal 
transport mediated by glycogen synthase kinase (GSK-3β) (Decker et al., 2010). The 
other generic explanation for the toxicity of intracellular Aβ aggregates involves the 
sequestration of vital proteins for the cell, that results in the cellular dysfunction and 
apoptosis (Selkoe, 2003). Aβ is also known to trigger hyper-phosphorylation of tau 
and the formation of NFTs (Amadoro et al., 2011). However, how exactly Aβ causes 
neurotoxicity in AD remains a matter of debate. The factors known to increase Aβ 
production and therefore neurotoxicity involve genetic mutations in Aβ precursor 
(APP) or the enzymes involved in Aβ production (presenilins) (Haass et al., 1995; 
Jankowsky et al., 2004). Also, some enzymes associated with acetylcholine turnover 
are known to play an important role in neurotoxicity induced by Aβ. For example, 
Aβ-AChE complexes associated with amyloid plaques (Alvarez et al., 1997) are 
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more toxic than amyloid fibrils alone. AChE interacts with the growing amyloid 
fibrils and accelerates the assembly of Aβ peptides. 
It is worth mentioning that Aβ peptides can be generated as a part of normal 
metabolism of APP (Seubert et al., 1992). They have been implicated in 
physiological regulation of synaptic activity (Kamenetz et al., 2003). However, their 
precise function in healthy brains is unclear. It is known that unaggregated Aβ 
peptides in low concentrations (0.1 – 1 μM) may exert neuro-protective effects as 
they activate PI-3-K pathway and inhibit GKS-3β (Giuffrida et al., 2009). 
The clearance of Aβ from brain is an important process regulating the Aβ 
homeostasis, with its disruption leading towards pathological accumulation of 
neurotoxic species of this peptide in AD brain. The mechanisms of removal Aβ 
peptides have been extensively studied and they involve: receptor-mediated transfer 
of Aβ to intra-vascular space by LRP receptors, efflux of soluble Aβ from brain 
parenchyma to the blood by adenosine triphosphate pump (Shibata et al., 2000; Lam 
2001) and local break down of Aβ through neprilysin (NEP) (Iwata et al., 2000). 
However, none of these processes can explain the preferential accumulation of Aβ in 
certain brain regions and especially the vulnerability of cholinergic neurons in AD 
(Mesulam 2004). In this study, we provide converging evidence suggesting that 
BFCNs play an important role in Aβ removal, due to p75NTR being particularly 
enriched in the axons of these cells. Binding of soluble Aβ by p75NTR promotes its 
sorting to lysosomes of cholinergic cells for degradation (Chapters 4.7.).   
 
1.5.1.2. Calcium hypothesis of AD 
 
Intracellular calcium (Ca
2+
) plays crucial role in many processes and is essential for 
functioning of key enzymes (such as kinases, phosphatases and proteases), so its 
altered homeostasis can account for age-related aberrations, leading towards 
neurodegeneration and AD. Physiological levels of free cytoplasmic Ca
2+
 is 
maintained between 20 to 100 nM in neuron at rest, and when activated it reaches up 
to 1.5 – 2.0 mM within micro domains (Llinas et al., 1995; Corona et al., 2011). The 
fine balance of intracellular Ca
2+
 is maintained by its regulated influx and efflux 
through Ca
2+
 channels and pores as well as by the exchange/sequestration of Ca
2+
 by 
the internal stores [endoplasmic reticulum (ER) and mitochondria]. In addition, Ca
2+
 
binding proteins (CBPs) such as parvalbumin, calbindin or calretinin determine the 
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dynamics of free Ca
2+
 inside neurons (Schwaller, 2010). The schematic of neuronal 
Ca
2+
 signalling is shown on Figure 2 (Grienberger and Konnerth, 2012). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altered Ca
2+
 homeostasis observed in AD could be the earliest and one of the 
primary causes of neurodegeneration (Hartmann et al., 1994, Kawahara et al., 2011). 
It is already known that increase of Ca
2+
 induces changes in the number and 
morphology of spines and synapses (Kato-Negishi et al., 2003), the alterations 
widely described in AD (Koffie et al., 2011). 
Many studies have shown that Aβ directly interferes with Ca2+ and disrupts activity 
of ionotropic glutamate receptors (Alberdi et al., 2010), nAChRs (Parri and Dineley, 
2010), IP3R (Cheung et al., 2010) as well as the P, Q , or L-type channels (Nimmrich 
et al., 2008; Ueda et al., 1997) or ER-Ca
2+
 stores (Green et al., 2008) and 
mitochondrial function (Leuner et al., 2007). Reduced Ca
2+
-buffering capacity by 
CBPs results in inactivation of calcineurin and calpains pathways by Ca
2+
 influx 
Figure 2. Neuronal calcium signalling (Grienberger and Konnerth, 2012). Sources of Ca
2+
 influx: 
AMPA, NMDA, nAChR, voltage-gated calcium channels (VGCC), and transient receptor potential 
type C (TRPC) channels. Calcium release from internal stores is mediated by inositol trisphosphate 
receptors (IP3R) and ryanodine receptors (RyR). IP3R can be activated by mGluR. Ca
2+
 efflux is 
mediated by the plasma membrane calcium ATPase (PMCA), the sodium-calcium exchanger (NCX), 
and the sarco-/endoplasmic reticulum calcium ATPase (SERCA). Also, the mitochondria are 
important for neuronal calcium homeostasis. 
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through NMDA receptors (Shankar et al., 2007, Cavallucci et al., 2013). These 
pathways lead to the risk of developing neurofibrillary tangles (NFTs) (Grynspan et 
al., 1997), dendritic spine loss and swelling of dystrophic neurites (Wu et al., 2010). 
Furthermore, recent studies indicate that Aβ oligomers can directly induce Ca2+ entry 
through disturbance of plasma membrane structure and formation of Ca
2+
 permeable 
pores (Demuro et al., 2010; Kawahara et al., 2010). Consequently, this leads to the 
creation of reactive oxygen species (ROS) and induce other adverse effects similar to 
those usually observed after exposure of neurons to Aβ.  
Genetic mutations in PSEN (Crusts and Broeckhoven, 1998) causing FAD are also 
linked to the dysregulation of neuronal Ca
2+
. The reason for this phenomenon was 
found recently (Supnet and Bezprozvanny, 2011) as PSEN normally function as low-
conductance passive ER Ca
2+
 leak channels, independent of γ-secretase activity. 
Their mutations therefore, cause loss of ER Ca
2+
 leak function and an exaggerated 
Ca
2+
 release from overloaded ER stores. This is associated with the increased 
production of Aβ (Green et al., 2007). Conversely, other passive Ca2+ channels called 
calcium homeostasis modulator 1 (CALHM1), which are mainly associated with ER, 
promote the α-secretase pathway (Green and LaFerla, 2008). 
Altogether these changes indicate that aging neurons experience significant 
dysregulation of Ca
2+
 handling. Altered Ca
2+
 homeostasis affects production of 
pathological proteins (Aβ and tau) and these may further exacerbate Ca2+ function, 
having strong impact on the development of AD. 
 
1.5.1.3. Mitochondrial dysfunction and oxidative stress hypothesis  
 
The accumulation of Aβ has been found within structurally-damaged mitochondria 
isolated from AD brains (Hirai et al., 2001). Key mitochondrial enzymes were found 
affected; consequently, electron transport, oxygen consumption and ATP production 
were impaired. These discoveries prompted the hypothesis that mitochondria are 
focal point for synaptic dysfunction observed in AD (Caspersen et al., 2005). Both 
Aβ and tau have been implicated in the impairment of mitochondrial respiration. Aβ 
was found to form complexes with alcohol dehydrogenase (Lustbader et al., 2004) 
and block complex-III and IV dependent respiration leading to an aggravated 
mitochondrial impairment, whereas tau was found to preferentially impair complex-I 
of the respiratory chain (Eckert et al., 2014). 
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Closely connected with mitochondrial dysfunction is the oxidative stress hypothesis 
of AD. This is based on the fact that dysfunctional mitochondria release hydrogen 
peroxide into the cytosol, where it participates in metal ion hydroxyl radical 
formation. Elevated levels of these metal ions (iron, copper, zinc) and aluminium are 
linked with the reactive oxygen species that mediate damage and neurodegeneration 
(Praticco, 2008). Oxidative stress is also defined as an imbalance between the 
generation of reactive oxygen/nitrogen species (ROS/RNS) and the cells ability to 
neutralize them by the anti-oxidant defence. The other sources of ROS and RNS in 
brain are astrocytes and microglia (Akama and Van Eldik, 2000; Colton et al., 2000). 
 
1.5.2. Tau hypothesis of AD 
 
Tau hypothesis of AD links Aβ and tau pathology by postulating that Aβ toxicity is 
tau dependent. The hypothesis is based on tau and tyrosine protein kinase Fin 
interaction upon which Fin-kinase, localized to the dendritic compartments, 
phosphorylates N-methyl-D-aspartate (NMDA) receptors and mediates their 
interaction with postsynaptic density protein 95 (PSD95), which is required for Aβ 
toxicity (Ittner and Götz, 2011). On the other hand, the exposure of Aβ triggers 
progressively increased phosphorylation of tau, causing its accumulation in somato-
dendritic compartments of the affected neurons. Hyper-phosphorylated tau has even 
faster affinity for Fin compared to normal MAP tau. Along with their independent 
harmful effects, Aβ and tau have been postulated to amplify each other’s cytotoxic 
effects.  
 
1.5.3. Cholinergic hypothesis of the geriatric memory dysfunction  
 
The hypothesis was put forward in 1982 (Bartus et al., 1982) and is based on the fact 
that functional disturbances in cholinergic activity occurring in the brains of healthy 
but elderly adults are responsible for learning and memory deficits in demented 
individuals. These changes are attributed to region-dependent decrease of ChAT 
activity at both protein and mRNA levels (Bowen et al., 1976; Davies and Maloney 
1976) with a decline in the activity of high-affinity choline (Rylett et al., 1983) and 
ACh release (Nilsson et al., 1986). According to this hypothesis the population of 
cholinergic cells is the earliest affected in AD  (Davies and Maloney, 1976; 
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Whitehouse et al., 1981; Mesulam et al., 1983; McGeer et al., 1984; Geula et al., 
1998; Härtig et al., 2002) and the most vulnerable to neuropathological changes 
occurring during the disease. Gene expression alterations and impairments in 
intracellular signalling or cytoskeletal transport may mediate the atrophy of 
cholinergic cells, leading to the age-related cognitive decline and memory loss. 
Gradual deficit in cholinergic functions caused by dendritic, synaptic, and axonal 
degeneration as well as a decrease in the trophic support of these neurons are also 
observed in other dementing disorders, including Parkinson's disease (Rochester et 
al., 2012), Down-syndrome (Sweeney et al., 1989), progressive supranuclear palsy 
(Ruberg et al., 1985), Jakob–Creutzfeld disease (Kudo et al., 2013), Korsakoff's 
syndrome (Nardone et al., 2010) and traumatic brain injury (Hong et al., 2012).  
 
1.5.3.1. Organization of cholinergic system with emphasis on basal forebrain BF  
 
The cholinergic system plays number of important roles that include: control of 
cerebral blood flow (Sato et al., 2004), sleep-wake cycle (Lee et al., 2005), attention, 
arousal, motivation, executive functions, memory and conscious awareness (Woolf, 
1997; Perry et al., 1999), behavioural state control, reward and plasticity (Semba, 
2000). The integrity of cholinergic neurons is particularly important for cognitive 
processes and deterioration of their connections has been implicated in the 
pathophysiology of AD (Chapter 1.5.3.). In CNS, these neurons create the most 
rostral neuromodulatory system with the capacity to modulate information 
processing across the entire cortical mantle (Sarter et al., 2005). Anatomical 
organization and connectivity of cholinergic neurons have been extensively studied 
with use of immuno-cytochemical methods for detection of cholinergic markers 
(Mesulam and Hoesen 1976; Bigl et. al., 1982; Woolf and Butcher, 1991) and 
injections of various tracers into the rodent’s brain (Jones and Yang, 1985; Luiten et 
al., 1987; Härtig et al, 1998; Chandler et al., 2013; Bloem et al., 2014). A clear and 
phylogenetically conserved antero-posterior organization of cholinergic system is 
well known and reflected in the BF, located close to the medial and ventral surfaces 
of the cerebral hemispheres and innervating limbic and cortical brain areas. BF is 
subdivided from rostral to caudal order as illustrated in Figure 3: the medial septum 
(MS) (also designated as Ch1 cholinergic group by Mesulam et al.,1983), the nuclei 
of the diagonal band of Broca (DBB) with vertical and horizontal limbs (VDBB 
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(Ch2) or HDBB (Ch3) respectively), basal magnocellular complex (Ch4), which 
comprises cholinergic neurons of the ventral pallidum (VP), the magnocellular 
preoptic nucleus (MCPO), the substantia innominata (SI) and the magnocellular 
basal nucleus (MBN) (Semba, 2000), an area known as nucleus basalis of Meynert 
(NBM) in primates and human brain (Koelliker, 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The contribution of projections of each BF subdivision varies within the 
telencephalic target area (Figure 3). The medial septal group of cholinergic neurons 
(ms, vdb) project to the hippocampus and para-hippocampal gyrus, while the nucleus 
basalis group (hdb, bas, si) innervate all parts of the neocortex, parts of limbic cortex 
and the amygdala. Loss of cholinergic neurons of medial septum and nucleus basalis 
of Meynert were mostly reported in the neurodegeneration of AD type (Whitehouse 
et al., 1981; Mesulam 2004; Mufson et al., 2007, Liu et al., 2015). The greatest loss 
of cholinergic activity is seen in the temporal lobe, which houses the hippocampus 
and entorhinal cortex. These structures play an important role in learning and 
memory, being also a primary target for neurodegeneration in AD. Significant 
shrinkage of these regions was noted on MRI scans of human diseased brains 
(Dickerson et al., 2001). The other group of central cholinergic nuclei – pedunculo-
Figure 3. Schematic representation of BF cholinergic circuit (Woolf, 1991). Abbreviations: ms - 
medial septum, vdb-vertical diagonal band, hdb –horizontal diagonal band, bas-nucleus basalis, si - 
substantia innominata, ldt-laterodorsal tegmental nuclei, ppt- pedunculopontine tegmental nuclei 
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pontine tegmental (PPT) and latero-dorsal nucleus (LDT,) act through thalamic 
intralaminar nuclei and provides only a minor innervation of the cortex (Schliebs and 
Arendt, 2006). Moreover, cholinergic projection neurons comprise also motor 
neurons in the spinal cord (cranial nerves 3-7 and 9-12) as well as cholinergic 
neurons in the sympathic and parasympathic nervous system (Martinez-Murillo and 
Rodrigo, 1995). 
 
1.5.3.2. BF cholinergic neurons (BFCNs) – cells vulnerable in AD 
 
Ontogenetically, cholinergic neurons differentiate from paraventricular neuronal 
precursor cells and arise first in the mouse basal forebrain circa embryonic day (E) 
11, expressing cholinergic markers by E16 (Schnitzler et al., 2008). BFCNs extend 
their efferents toward hippocampal and cortical targets during the first postnatal 
weeks of development, when they critically depend on NGF supply and express 
neurotrophin receptors (TrkA and p75
NTR
). Cholinergic neurons express also other 
receptors including adrenergic, glutamatergic, GABAergic (De Souza Silva et al., 
2006; Gao et al., 1995; Zaborszky et al., 2004) as well as the receptors for estrogens 
and endocannabinoids (Harkany et al, 2003). Morphologically, these cells are the 
largest neurons in the forebrain and are classified into three types: multipolar, bipolar 
and triangular cells (Pongrac and Rylett, 1998). Trophic dependence on NGF 
remains important for the maintenance of their phenotypes and contents of 
neurotransmitters even in the mature and fully differentiated central nervous system 
(CNS) (Niewiadomska et al., 2002). It is worth to mention that NGF is not 
synthetized by BFCNs but it is supplied by target neurons and delivered to their cell 
body via uptake and retrograde axonal transport from cortical areas. Besides NGF, 
other peptides like pituitary adenylate cyclase-activating polypeptide (PACAP) were 
shown to promote survival of septal cholinergic neurons in vitro and in vivo after 
injury (Takei et al., 2000). Galanin, another peptide produced by cholinergic 
neurons, was reported to have trophic effect on BFCNs and can even compensate for 
lack of acetylcholine (ACh) in AD (O’Meara et al., 2000; Jhamandas et al., 2002).  
The synthesis of ACh and its release from BFCNs is essential for normal learning, 
memory and attention (Winkler et al., 1995; Rasmusson 2000; Hasselmo, 2006). The 
ability to utilize acetyl-CoA for ACh synthesis is unique feature of BFCNs (Tucek, 
1985). The acetyl CoA comes from pyruvate formed from glucose. Therefore, 
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cholinergic cells present higher demand for energy production and are more sensitive 
than other neurons to energy deprivation (Szutovicz, 2000). Choline is the second 
component critical for ACh biosynthesis and its uptake is considered as a rate 
limiting step in this process (Haga, 1971). The one-step reverse reaction is catalysed 
by choline acetyltransferase (ChAT) and the opposite process by acetylcholinesterase 
(AChE), which converts ACh into the inactive metabolites: choline and acetate. Once 
produced, ACh is packaged into synaptic vesicles via a vesicular ACh transporter 
(vAChT). Action potentials trigger the release of ACh into the synaptic cleft, where 
ACh binds to its receptors located on the post- and pre-synaptic membranes. Two 
types of acetylcholine receptors, muscarinic (mAChRs) and nicotinic (nAChRs), take 
part in this process (Nakayama et al., 1995; Rouse et al., 2000) (Figure 4). ACh may 
also spill out of synaptic contacts and produce volume transmission within the 
hippocampus via non-synaptic signalling (Yamasaki et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generally, nAChRs are ionotropic ACh - gated cation channels, while mAChRs are 
G protein – coupled receptors. Both families of these receptors regulate cognitive 
processes and are affected in AD ( Bartus et al., 1982; Coyle et al., 1983; Whitehouse 
et al., 1986; Shimohama et al., 1986). Ionotropic nAChRs comprise of five subunits, 
each consisting of four transmembrane domains, that are arranged symmetrically 
around a hydrophilic central pore, mediating the flow of cations K
+
, Na
+
 and Ca
2+
. In 
the human nervous system, there are eight α subunits (α2-α7, α9, α10) and three β 
 
Figure 4. Schemat of acetylcholine synthesis and 
signalling (Soreq and Seidman, 2001). 
 
 
The metabolism of ACh involves two enzymes: 
ChAT for synthesis this neurotransmitter from 
Acetyl-CoA and choline and acetylcholinesterase 
(AChE) for degradation. Vesicular ACh transporter 
(vAChT) package ACh into synaptic vesicles. 
Muscarinic M2 receptors (M2) on the presynaptic 
membrane regulate ACh release via a negative 
feedback response. At the postsynaptic site, M1 
receptors transduce signals through a pathway 
involving diacylglycerol (DAG), inositol-1,4,5-
trisphosphate (Ins(1,4,5)P3) and a Ca
2+ 
-dependent 
protein kinase (PKC). ACh is hydrolysed in the 
synaptic cleft by AChE-S tetramers. AChE-R 
monomers would remain soluble within the 
synaptic cleft. A high-affinity choline-uptake 
mechanism returns choline to the presynaptic 
neuron. 
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subunits (β2-β4) that assemble in different combinations to generate a variety of 
nAChR subtypes (Albuquerque et al., 2009, Gotti et al., 2006, Gotti et al., 2009). The 
α4β2 or α7 are the most abundant form of nAChRs in mammalian brain, with the 
latter reported to interact with Aβ (Wang et al., 2000; Liu et al., 2001), leading to the 
speculations that Aβ might be internalised with this receptor (Nagele et al., 2002), 
which however was not confirmed by the later studies (Small et al., 2007). Soluble 
Aβ(1-42) was reported to activate α4β2 and modulate postsynaptic transmission in 
septo-hippocampal neurons (Chin et al., 2007). However, other studies did not 
support this physiological action (Lilja et al., 2011). Recently new nAChRs subtype- 
α7β2 was found in rodent and human hippocampal interneurons and BFCNs, highly 
sensitive to functional inhibition by pathologically-relevant concentrations of 
oligomeric Aβ (Liu et al., 2009, Moretti et al., 2014). 
In regards to metabotropic mAChRs, these are made up of seven transmembrane 
spanning regions bound to intracellular G proteins and activated when G protein alter 
the activity of one or more ion channels in the nerve cell membrane (Caulfield 1993; 
Brown et al., 1997). Five subtypes of  mAChR (M1–M5) are widely distributed 
throughout the central nervous system and periphery (Levey, 1993). It has been 
shown the post-synaptic M1 receptor, which is expressed throughout the cortex and 
hippocampus plays a key role in regulating cognition and stimulates non-
amyloidogenic APP processing (Nitsch et al., 1992; Anagnostaras et al., 2003), while 
M2 subtype inhibits sAPPα generation (Farber et al., 1995). M2 receptor knock-out 
mice show also deficits in behavioural flexibility, working memory, and 
hippocampal plasticity (Seeger et al., 2004). Range of nicotinic and muscarinic 
receptors agonists and antagonists were developed for AD treatment so far (Ren et 
al., 2007; Yang et al., 2012; Melancon et al., 2013; Gao et al., 2014; Fisher et al., 
2016).  
The activity of ChAT and consequently the synthesis of ACh is decreased in AD 
(Davies and Maloney, 1976; Perry et al., 1978). ACh is known to promote non-
amyloidogenic APP processing and reduce tau phosphorylation (Hellström-Lindahl, 
2000). In addition, the reduction of AchE was observed in AD brains (Bowen et al., 
1976). However AChE inhibitors, which potentiate cholinergic function, have met 
with only limited success (Greig et al., 2013) and are further investigated (Rahim et 
al., 2015; Leong et al., 2016).  
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In addition to ACh, individual BFCNs also release glutamate (Allen et al., 2006). 
Glutamate excites BFCNs through NMDA receptors and can drive them into 
rhythmic burst discharge (Khateb et al., 1992), while normally these neurons exhibit 
a rather slow firing pattern (Duque et al., 2000). The highest firing rate of cholinergic 
neurons is observed in the wake state as compared to slow-wave sleep or rapid eye 
movement (REM) sleep. The discharge of cholinergic neurons is positively 
correlated with gamma activity (30-60 Hz) and negatively correlated with delta 
activity (1-3 Hz) during sleep-waking cycle (Hassani et al., 2009). Stimulation of 
cholinergic cells elicits an oscillatory theta rhythm in the hippocampus that occurs 
during periods of learning (McQuiston 2010). Additionally, 70 % of rostral BF 
cholinergic neurons in rat possess NADPH – diaphosphorase activity required for 
nitric oxide (NO) formation. The same neuronal population contains galanin; 
however, these substances are not present in higher primates and human. The human 
BF instead has been shown to contain large neurons expressing tyrosine hydrolase 
(TH) in 1.5 % of total magnocellular neurons (Semba, 2000). 
 
1.5.3.2.1. Functional characteristics and dynamics of p75
NTR
 in BFCNs 
 
P75
NTR
 (CD271) is a sixteenth member of the tumour necrosis factor receptor 
superfamily (TNFRSF), encompassing overall twenty five participants (Gruss, 1996). 
Genes for this receptor are located on chromosome 17 in humans and chromosome 
11 in mice (Huebner et al., 1986). Like all members of TNFRSF, p75
NTR
 contains an 
extracellular chain of cysteine rich domains (CRD) that have the ability to bind 
different ligands. They are attached to the cleavable “stalk” of 28 amino acids (aa). 
The single transmembrane region of p75
NTR
 is highly conserved among the species 
and it is responsible for creating homodimers of this receptor. The juxtamembrane 
domain, called also “chopper domain” and the carboxy-terminal domain, called 
“death domain” are localized intracellulary. They contain multiple O-glycosylated 
(juxtamembrane domain), palmitoylated and phosphorylated sites (“death domain”), 
useful in the receptor signalling (Barker et a., 1994, Underwood et al., 2008). 
Although the “death domain” of p75NTR contains six-α helices typical for TNFRSF, it 
differs from the other members of this group, because it possess TNF receptor 
associated factor (TRAF)-interacting motifs and potential G-protein activation site, 
which classify it as Type-II death domain, allowing to multiple signal transduction 
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pathways (Dempsey et al., 2003). The schematic representation of p75
NTR
 domains is 
illustrated on Figure 5 below. 
 
         
          
 
 
 
            
          FL-p75       s-p75 
 
Figure 5. Schematic representation of  p75
NTR
 isoforms (Dechant and Barde, 2002).  
FL-p75 -full length p75 neurotrophin receptor; s-p75 short isoform of  p75 neurotrophin receptor             
 
Figure 5 shows two naturally-occurring forms of p75
NTR
: full length FL-p75
NTR
and 
its short isoform s-p75
NTR
 (Dechant and Barde, 1997). The shorter version results 
from alternative splicing or post-synthetic proteolysis and lacks three of four cysteine 
repeats in the extracellular ligand binding domain (Lee et al., 1992), which affects 
binding abilities of this receptor. 
Homologs of p75
NTR
 are highly conserved among the species. The receptor is found 
in fish, amphibians and birds [they are called neurotrophin receptor homolog 1 
(NRH1)] as well as in mammals [variously called NRH2, 75-like apoptosis-inducing 
death domain protein (PLAIDD) or neurotrophic alike death domain protein 
(NRADD)] (Murray et al., 2004; Frankowski et al., 2002; Sasai et al., 2004; Wang et 
al., 2003). Mice lacking both FL-p75
NTR
 and s-p75
NTR
 show up to 40% lethality, 
presumably as a result of damage to the blood vessels, because p75 receptor is found 
in smooth muscle cells of blood veins. (von Schack et al., 2001). In brain, p75
NTR
 is 
mainly expressed during neuronal development and in adult CNS it is restricted to a 
few neuronal populations (Richardson et al., 1986). Cholinergic neurons of BF, 
which are strongly affected by Alzheimer’s disease express p75NTR throughout their 
lifetime (Kiss et al., 1988; Woolf et al., 1989). Additionally, re-expression of p75
NTR
 
occurs in hippocampus in conditions involving neuronal injury and in many 
neurodegenerative disorders including AD (Schor, 2005; Volosin et al., 2008). 
Although p75 receptor was first discovered as a receptor for nerve growth factor 
(NGF) (Herrup and Schooter, 1973), it is now established that it binds to all 
 Cysteine – rich domain 
Stalk domain   
  Transmembrane region 
 
 Juxtamembrane domain 
    Death domain – related domain 
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neurotrophins (NTs): brain derived neurotrophic factor (BDNF), neurotrophin 3 
(NT3), neurotrophin 4 (NT4) with similar nanomolar affinity (Kd = 10
-9
 M) (Bibel et 
al., 1999) (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of neurotrophins binding to p75
NTR
 (Chao, 2003). Abbreviations: 
NGF - nerve growth factor; BDNF - brain derived neurotrophic factor; NT3, 4 – neurotrophin 3,4; Trk 
A,B,C - tropomyosin-related tyrosine kinase A,B,C. 
 
Released typically at synapses, these neurotrophins govern neuronal growth and 
survival as well as control the neuronal death during development (Kalb, 2005). 
Furthermore, like neurotransmitters, they can affect neuronal membrane permeability 
for sodium and potassium ions and excitability of neurons (Poo, 2001). 
Neurotrophins are synthesized in a precursor form as pro-neurotrophins, consisting 
of N-terminal prodomain and a C-terminal mature domain. They are cleaved to 
generate their mature form by furin or pro-convertases 1 and 2 (PC1 and PC2) at 
highly conserved sites (Seidah et al., 1996). Proteolytic processing of neurotrophins 
is believed to be crucially involved in neurodegenerative diseases (Peng et al., 2004) 
and their precursors have been reported to accumulate during AD (Fahnestock et al., 
2001). Pro-neurotrophins bind to p75
NTR
 with higher affinity (nanomolar range) than 
mature neurotrophins (e.g. pro-NGF has 5 times higher affinity for p75 receptor than 
the mature NGF) (Lee et al., 2001). The high affinity binding site of pro-
neurotrophins is formed by complex of p75
NTR
 with sortilin; the latter interacts with 
pro-domain while p75
NTR
 binds to the mature portion of pro-neurotrophins (Nykjaer, 
et al., 2004). 
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Figure 7. Schematic illustration of p75
NTR
 co-receptor sortilin (Skeldal et al., 2011). 
 
The schematic illustration of sortilin in Figure 7 (Skeldal et al., 2011) shows an 
unusual structure of this receptor, belonging to vacuolar protein sorting 10 protein 
(Vps10p) family. Sortilin possess the unique ligand binding domain forming 10-
bladed β-propeller on the extracellular “stalk”, that connects to the cytoplasmic tail 
through short transmembrane domain (Nykjaer and Willnow, 2012). In addition to 
binding of pro-neurotrophins, sortilin has been identified as a novel apolipoprotein E 
(APOE) receptor in neurons (Carlo et al., 2013). This is important because APOE 
has been regarded as the most important genetic risk factor for sporadic AD cases 
(Corder et al.,1993) (Chapter 1.2.). Recently, a role of sortilin has been implied in the 
clerance of Aβ peptides bound to APOE (Carlo et al., 2013).  
P75
NTR
 is often associated with other members of neurotrophin receptor family -   
tropomyosin-related tyrosine kinase (Trk) receptors, creating double-receptor 
complexes as illustrated in Figure 8 (Chao, 2003). In complex with TrkA, p75
NTR
 
forms high affinity binding sites (more than 100-fold higher than p75
NTR
) for mature 
neurotrophins (Hempstead et al., 1991). 
 
 
  
 
 
 
 
 
Figure 8. Schematic illustration of  high affinity binding site created by p75
NTR
 and Trk receptors 
(Chao, 2003). 
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So far, three members of Trk receptors family were identified: TrkA, TrkB and TrkC 
(Klein et al., 1991; Lamballe et al., 1991). Trk receptors family exhibits high ligand 
specificity: TrkA, TrkB and TrkC bind NGF, BDNF/NT4 and NT3, respectively 
(Figure 6). The extracellular domains of Trk receptors contain two cysteine-rich 
regions flanking a leucine-rich repeat, followed by two immunoglobulin (IgG)-like 
domains, the juxtamembrane region and tyrosine kinase domains as illustrated in 
Figure 9 (Dechant and Barde, 2002). Binding of neurotrophin homodimers causes 
Trk receptor dimerization and auto-phosphorylation of tyrosine residues (Figure 8). 
Phosphorylated tyrosines act as docking sites for signalling molecules which regulate 
cell growth and survival through Ras, phosphatidyloinositol 3-kinase (PI3-K) and 
phospholipase Cγ (PLCγ) pathways (Kaplan and Stephens, 1994). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic representation of Trk receptors family (Dechant and Barde, 2002). Trk A,B, C – 
tropomyosin-related tyrosine kinase A, B, C  
 
Trk receptors display molecular diversity as some splice variants lack the 
intracellular tyrosine kinase domain (Middlemas et al., 1991). The truncated forms 
can have directed signalling activity influencing growth and survival of neurons e.g. 
truncated TrkB receptor can inhibit neurotrophin signaling by sequestering or 
trapping NTs, thus preventing their binding (Biffo et al., 1995); this may contribute 
to the deficits in BDNF/TrkB signaling and neuronal plasticity in schizophrenia 
(Wong et al., 2013). On the other hand elevated expression of TrkB-Shc (another 
isoform of TrkB) is found in hippocampus of AD patients suggesting its function as a 
compensatory response in neurons to promote their survival (Wong et al., 2012). 
The ability of p75
NTR
 to bind dimeric ligands like neurotrophins is an unusual feature 
of the tumour necrosis factor receptor subfamily TNFRSF; however, the most 
 
 Cysteine-rich domain 
 Leucine-rich repeat 
 
 IgG-like domain 
 
 Juxtamembrane domain 
 
Tyrosine kinase domain 
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interesting function of p75
NTR
 is that it can directly or indirectly bind to non-
neurotrophic ligands as exemplified in Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic drawing of p75
NTR
 binding to different non-neurotrophic ligands (Butowt and 
von Bartheld, 2003). A. Β-AM – beta amyloid, NTs – neurotrophins, PrP – prion peptides, RVG – 
rabies virus glycoprotein, WGA - wheat germ agglutinin. B. CTB – cholera toxin binding, GT1b, 
GM1 – gangliosides, TeT – tetanus toxin, Trk – tropomyosin related kinase. C. MAG – myelin 
associated glycoprotein, NogoR – Neurite outgrowth inhibitor receptor, Nogo66 – ligands recognized 
by 66-amino acid fragment of Nogo, OMGP – oligodendrocyte – myelin glycoprotein, ProNGF – pro 
nerve growth factor   
 
Pro-neurotrophins presumably bind to the same site at the second and third cysteine 
rich domain (CRD) on p75
NTR
 as do the mature neurotrophins, while wheat germ 
agglutinin (WGA), commonly used neuronal tracers, binds to N-glycosylated site at 
the end of first CRD domain of p75
NTR
, the same domain that binds also rabies virus 
glycoprotein (RVG). The sites for prion proteins (PrP) and Aβ peptides attaching to 
p75
NTR
 remain unknown (Butowt and von Bartheld, 2003; Della-Bianca et al., 2011; 
Devarajan and Sharmila 2014). Some of the above ligands after internalization by 
p75
NTR
 undergo axonal transport along microtubule tracts; e.g. NGF. In this case 
receptor-ligand complex is transported retrogradely and exerts its trophic effects 
upon arrival to the cell body (Johnson et al., 1987; Harrington et al., 2011; Marlin 
and Li, 2015). The pathways of many other p75
NTR
 ligands are under investigation. 
Potential internalization of Aβ through p75NTR is of special relevance to Alzheimer’s 
disease as this neurotoxic peptide is found in post-mortem brain tissues of AD 
patients in the form of amyloid plaques (Cummings annnd Cotman, 1995) as well as 
intracellulary (LaFerla et al., 2007). There is also literature suggesting direct role of 
 
A                                    B                                                C                        D 
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p75
NTR
 in the seeding of amyloid plaques (Zhou and Wang, 2011; Wang et al., 
2011).  
In regards to p75
NTR
 processing, the receptor  undergoes two-step regulated intra-
membrane proteolysis (RIP), schematically illustrated in Figure 11 (Chao, 2003). 
The first cut is catalysed by tumour necrosis factor α-converting protease 
(TACE/ADAM-17), which is a desintegrin metalloprotease and releases the 
ectodomain piece and C-terminal fragment (CTF), containing transmembrane and 
cytoplasmic domains (Kanning et al., 2003). The CTF fragment is further processed 
by a presenilin-dependent γ-secretase, liberating intracellular domain fragment 
(ICD). ICD is suspected to be involved in activation or repression of neurotrophin 
related genes (Frade, 2006) or be responsible for the role of p75
NTR
 in cell cycle 
regulation (Skeldal et al., 2011). These cleavages are strikingly similar to APP 
processing (Introduction Chapter 1.5.1.1.). 
 
 
 
 
 
 
 
 
 
 
Figure 11. Schematic illustration of  p75
NTR
 cleavage (Chao, 2003). 
 
Cleavage of p75
NTR
 occurs mostly after ligand binding [it can also be induced by 
protein kinase C (PKC) activators such as e.g. the phorbol ester 12-myristate 13-
acetate (PMA)]. In case of NTs, cleavage of p75
NTR
 requires Trk activity. It was 
shown that inhibition of TrkA completely abrogates both p75-CTF and p75-ICD 
production (Urra et al., 2007). Regulation of p75
NTR
 cleavage might be also 
dependent on the cell type, as different cells express different amounts of 
metalloproteases. Recent findings show that RIP of p75
NTR
 depends on dimerization 
of the receptor, influenced by transmembrane sequences and TrkA but not ligands 
binding (Sykes et al., 2012). 
Generally, the functionality of p75
NTR
 mostly depends on ligand this receptor binds 
to, its co-receptors as well the cell type in which it is expressed (Skeldal et al., 2011). 
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The p75
NTR
 is capable of activating multiple intracellular pathways, signalling cell 
survival or cell death. Typical effectors associated with apoptotic pathways are 
proteases of the caspase family, Jun N-terminal kinase (JNK) and p53 (Kenchappa  
et al., 2010). Other pathways involve neurotrophin receptor interacting factors 
(NIRF) and the production of ceramide (Dobrowsky et al., 1994). Anti-apoptotic 
signalling of p75
NTR
 is mainly associated with binding of p75
NTR
 to Trk receptors; 
however, pro-survival signalling of p75
NTR
 independent of Trk is also possible. Main 
routes include PI3-K/Akt (Roux et al., 2001) or NF-κB activation (Yoon et al., 
1998). All these life-death decisions are very complex in nature. They depend a lot 
on crosstalk between p75
NTR
 and Trk receptors signalling which can modify p75
NTR 
action.  
In addition to promoting cell survival or directly enhancing cell death, p75 receptor 
modulates axonal elongation and plays a role in activity-dependent synaptic 
plasticity of neurons. The p75
NTR
 influence axonal elongation positively by binding 
mature neurotrophins or inhibiting axonal elongation by activation of GTP-
dependent Rho protein (Yamashita et al., 1999). A similar effect is caused by binding 
of p75
NTR
 to myelin associated glycoprotein (MAG), indirectly through GT1b 
ganglioside. MAG activates Rho in p75
NTR
-dependent fashion (Domeniconi et al., 
2005). Also, Nogo receptor that associates with p75
NTR
 can bind MAG and other 
myelin-associated inhibitors of axonal elongation (like: Nogo-66 and OmgP as 
shown on Figure 30), which results in growth inhibition of neuronal processes (Wang 
et al., 2002). 
p75
NTR
 was also found to co-localize with hyperphosphorylated tau protein in AD 
patients (Hu et al., 2002). There are even reports suggesting that phosphorylation of 
tau occurs in p75
NTR
-dependent manner (Saez et al., 2006). Whether p75
NTR
 is 
involved in the formation of neurofibrillary tangles, the other pathological hallmarks 
of AD, remains unknown and needs to be investigated in more detail. 
 
1.5.4. Other BF neuronal populations that contribute to AD pathology  
 
Although cholinergic system plays a number of physiological functions in brain, 
(Chapter 1.5.3.1) all these effects are exerted in cooperation with other systems of 
BF. In fact, cholinergic corticopoetal neurons in rodents represent only about 20% of 
the total BF cell population (Zaborsky, 2012). Other neuronal populations also 
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contribute to the cell loss during the AD (from the 30% decrease in the total number 
of neurons in aging only 11-15% are cholinergic) (Semba, 2000). 
Apart from BFCNs, γ-amino butyric acid (GABA) neurons (GABAergic) and other 
peptide-containing neurons are present in BF (Semba, 2000). GABAergic neurons 
develop around E17 and they express glutamic acid decarboxylase (GAD) (Bender et 
al., 1996). Also, parvalbumin has been reported to be a selective marker of these 
cells in MS and DBB regions of rat (Freund, 1989). GABAergic neurons are usually 
distributed more laterally than cholinergic neurons e.g. in the horizontal limbs of the 
diagonal band of Brocca or magnocellular preoptic areas (Brashear et al., 1986). 
They are large multipolar cells in MS with a tendency to become much smaller 
caudally. Importantly, they do not show reduction during aging (Semba, 2000) and 
are resistant to ischemia and epilepsy (Brady and Mufson, 1997). GABAergic 
neurons in rat BF also express NGF mRNA, suggesting that they can provide local 
trophic support to BFCNs. GABAergic neurons possess Kv3.1 potassium channels 
that contribute to the fast spiking abilities of these cells (Henderson et al., 2010). 
Generally, they are inhibitory neurons with Ca
2+
 buffering properties that reduce 
Ca
2+
-dependent K
+
 outward current.  
Rodent GABAergic BF neurons receive glutamatergic inputs from cells which use 
glutamate as a fast excitatory neurotransmitter (Hur and Zaborszky, 2005). Because 
glutamate is precursor for GABA synthesis, it cannot serve as a definite marker for 
glutamatergic neurons. The only reliable markers for glutamatergic cells are 
vesicular glutamate transporters (Vglut 1 or 2) (Takamori, 2000). The glutamatergic 
neurons are present in BF as local inter-neurons (Hajszan et al., 2004) but a small 
proportion of them also projects to hippocampus. Dysfunction of glutamatergic 
neurons is proposed as another hypothesis of AD (Chapter 1.5.5). Also, alterations in 
both ionotropic (e.g. NMDA, AMPA) and metabotropic glutamate receptors (such as 
mGluRs 1 or 5) suggest that glutamatergic neurons play a central role in higher 
cognitive processes (Paula-Lima et al., 2013, Caraci et al., 2012).  
In addition to cholinergic, GABAergic and glutamatergic neurons, peptide containing 
neurons co-exist in BF. For instance substance P and neurokinin B mRNA were 
detected in 26% of magnocellular BF neurons in humans (Semba, 2000). These 
neurons can be stained with calbindin in rodents. Both parvalbumin and calbindin as 
well as calretinin belong to a family of small acidic proteins with high affinity for 
Ca
2+
 binding. The major role of these Ca
2+ 
binding proteins (CBPs) is the buffering 
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and transport of [Ca
2+
]
 
and the regulation of various Ca
2+
-activated kinases. As 
cellular degeneration is often accompanied by impaired calcium homeosthasis 
(Chapter 1.5.1.2.), a protective role of CBPs has been postulated (Heizmann and 
Braun, 1992). 
More recently, neuropeptide Y (NPY) has been described in projection neurons and 
interneurons of BF. NPY is often co-localized with GABA and acts as a potent 
inhibitory peptide with ability to inhibit cholinergic neurons via Y1 receptors 
(Gaykema et al., 1989). Recent reports suggest that NPY may be a neuroprotective 
agent against Aβ neurotoxicity (Corce et al., 2012).  
Similarly somatostatin presynaptically inhibits both glutamate and GABA release 
onto BF neurons (Moiyama and Zaborszky, 2006). Neocortical neurons containing 
somatostatin decrease in AD, while those immuno-reactive for neuropeptide Y 
appear preserved (Dawbarn et al., 1986; Palop et al., 2011).  
Likewise galanin is found in both septo-hippocampal cholinergic projections and 
non-cholinergic neurons (Melander et al., 1985), but it presence varies among the 
species and is not found in human cholinergic projections. In rodents, this peptide 
was found to inhibit synaptic transmission in the hippocampus and impair spatial 
memory (Elvander et al., 2004). 
 
1.5.5. Glutamatergic theory of AD  
 
The dysfunction of glutamatergic neurotransmission with resultant cytotoxic effects 
is also hypothesized to be involved in the etiology of AD. This is based largely on 
post-mortem evidence indicating reduced binding and uptake of D[3H]aspartate as 
well as loss of a number of other putative markers, such as phosphate-activated 
glutaminase activity, glutamate concentration and the number of pyramidal cell 
perikarya, correlating well with the severity of dementia (Palmer and Gershon, 
1990). Over-stimulation of nerve cell by glutamate eventually causes cell apoptosis, 
disrupts synaptic plasticity [f.e long term potentiation (LTP)] and impairs learning 
and memory (Sheng and Ertürk, 2013; Park et al., 2015). Targeting the glutamatergic 
system, specifically NMDA receptors, offers a novel approach to treatment in view 
of the limited efficacy of the existing drugs targeting the cholinergic system 
(Molinuevo et al., 2005; Martinez-Coria et al., 2010) (Chapter 1.6). 
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1.5.6. Dysregulation in aminergic neurotransmitters systems in AD pathology 
 
In addition to dysregulation of cholinergic system (mentioned in Chapter 1.5.3.1), 
aminergic neurotransmitter systems are reported also to be altered in AD. These 
include catecholamines, which are active amines containing catechol (active benzene 
with two hydroxyl side groups) with norepinephrine (NE), called also noradrenaline, 
epinephrine (Epi), known as adrenaline, with both produced largely by long range 
projection neurons of locus coeruleus (LoC) (Heneka et al., 2010). Alterations have 
also been reported in dopaminergic neurons (DA) of midbrain (Grace and Onn, 
1989). Likewise, indolamines, synthetized from tryptophan are affected in AD. 
These include: serotonin (5-HT) from raphe nuclei (Anden et al., 1965) or melatonin 
mainly generated by pineal gland (Wu et al., 2003). Other neurotransmitters like 
orexin (recognized as hypocretin) and histamine from certain nuclei of hypothalamus 
also contribute to the disease (Brown et al., 2010, Panula et al., 1984).  
The vigorous changes in noradrenergic and to lesser extend in adrenergic systems are 
documented in post mortem samples from AD patients (Mann, 1998), with 
progressive loss of LoC neurons reported in AD, which may contribute to the 
important non-cognitive behavioural impairments such as depression and wandering 
(Palmer et al., 1987, Mravec et al., 2014). The widespread projections of LoC 
neurons are involved in generation of stress responses, which become affected in 
AD. Several studies suggest that  LoC system increases the ability to process relevant 
stimuli while suppressing responses to irrelevant stimuli (Berridge and Waterhouse, 
2003). All this is important in the context of AD as LoC neurons degenerate at an 
even faster rate than cholinergic neurons of BF (Zarow et al., 2003).  
Changes in dopaminergic system are mainly localized to the dopaminergic receptors 
rather than to dopaminergic innervation. The dopaminergic neurons project through 
the medial forebrain bundle to the dorsal striatum (nigrostriatal projection) and to the 
basal forebrain, ventral striatum and cortex (meso-limbocortical projection) 
(Ikemoto, 2007). DA produced mainly in two areas of brainstem - substantia nigra 
and ventral tegmental area (VTA) stimulates arousal and attention and supports 
locomotor and exploratory, reward-seeking behaviours during waking (Alcaro et al., 
2007). The role of DA in sleep-wake regulation is less studied. Post-mortem 
concentrations of DA have been repeatedly found to be unaltered in the cerebral 
cortex of patients with AD (Palmer and DeKosky, 1993) but there is loss in D2 
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receptor binding in the areas that correlate with the appearance of traditional 
neuropathology (plaques and tangles) (Joyce et al., 1998).  
More variable than the effects seen in adrenergic systems are serotonergic 
dysfunctions in AD (Bowen et al., 1983). The neurons of the midbrain raphe nuclei 
that give rise to ascending projections to the forebrain and cortex, release 5-HT. An 
autopsy studies has shown reduced concentrations of 5-HT and 5-HIAA, the 
principal metabolite of 5-HT as well as diminished 5-HT uptake in AD patients 
(Palmer et al., 1987). The decline of serotonergic transmission is paralleled by the  
reduction (30-40%) in number of 5-HT-positive neurons in the medial and dorsal 
raphe nuclei; however, the magnitude of this neuronal loss does not correlate with 
the density of NFTs (Chen et al., 2000). 
The hypocretin/oxerin neurons of the posterior hypothalamus innervate the whole 
brain and spinal cord and send especially dense projections to the aminergic cell 
group e.g., the tuberomammillary nucleus (TMN), raphe nucleus, LoC and VTA 
(Peyron et al., 1998; Sakurai 2007). The interplay between orexins and 
catecholamines has implications for physiological regulation of behavioural state, 
plasticity and memory functions (Eriksson et al., 2010). 
 
1.5.7. Default mode network hypothesis and spreading of AD pathology 
 
The default mode network (DMN) is a task negative network, preferentially active at 
the awake rest of brain, when individual is not focused on the external environment. 
It is associated with episodic and autobiographical memory retrieval as well as with 
other internally driven processes such as mind wandering or future planning, when 
cognitive tasks that demand external stimuli are diminished (Greicius et al., 2003; 
Fox et al., 2005). The DMN is an evolutionarily old and conserved system present in 
humans and non-human primates (Mantini et al., 2011) and rodents (Upadhyay et al., 
2011), with the appearance of last being currently debated. The DMN is anatomically 
defined and contains interconnected parts of the medial temporal lobe, part of the 
medial prefrontal cortex, the posterior cingulate and retrosplenial cortex along with 
the adjacent ventral precuneus and medial, lateral and inferior parietal cortexes 
(Gusnard and Raichle 2001; Greicius et al 2004). Dearangments of functional 
relationship between mentioned above brain areas of DMN occur in the early stages 
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of dementia as examined by functional magnetic resonance imaging (fMRI) 
(Sepulcre et al., 2013). 
The most interesting is a striking overlap between areas of Aβ deposition and DMN 
(Buckner at al., 2005; Mormino et al., 2011). It is shown that AD pathology 
accumulates preferentially in DMN even before the symptoms emerge. Senile 
plaques deposition proceeds slowly begining in the neocortex through the allocortex 
and diencephalon to the striatum and BF cholinergic nuclei, followed by progression 
to the brainstem nuclei and finally to the cerebellum (Thal et al., 2002). This 
phenomenon is believed to relate to the metabolic properties or activity patterns of 
DMN. It has been demonstrated that Aβ level increase following stimulation of the 
brain (Cirrito et al., 2005, Selkoe 2006). Also, glycolysis (changing glucose into cell 
energy) correlates well with distribution of Aβ plaques (Mintun et al., 2006). 
According to this view, memory systems may be preferentially affected, because 
they play central role in resting brain activity as a part of DMN (Buckner et al., 
2008). In the case of AD, resting-state activity may accelerate the formation of 
disease pathology. Also, neuron to neuron transfer of soluble Aβ oligomers was 
proved in several brain structures (Nath et al., 2012). According to this theory, 
neurotoxic Aβ accumulate in cells that show later beading of tubulin and endosomal 
leakage. The spread of NFTs is also known to occur via anatomical connections 
(Harris et al., 2010). NFTs progress in more hierarchical and fixed fashion, which  
begins from the enthorinal cortex and proceeds to medial temporal limbic areas, the 
hippocampus in particular and pariental lobe, to spread later to the selected regions 
of frontal cortex and cingulate gyrus (Braak and Braak 1991). Understanding these 
processes is the most important for deciphering the disease processes and designing 
therapeutics for clinical applications.  
 
1.6. Current treatments of AD 
 
Currently available therapies for AD are divided into pharmacological and non-
pharmacological ones, with both methods providing only palliative and ameliorative 
treatments to slow the progression of the disease (Sugino et al., 2015).  
At this point, AChEi remain the most effective and the first medications approved by 
FDA for AD therapy (Chapter 1.1.). Three commonly prescribed AChEi include: 
donepezil hydrochloride (Aricept; Eisai Inc, Woodcliff Lake, New Jersey or its 
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generics); rivastigmine tartrate (Exelon; Novartis Pharmaceuticals Corp, Basel, 
Switzerland or its generics) and galantamine hydrobromide (Razadyne [formerly 
Reminyl]; Janssen Pharmaceutica NV, Beerse, Belgium). All these drugs exert their 
therapeutic effects by slowing degradation of ACh in non-affected neurons, in which 
they irreversibly bind AChE, thus compensating for cholinergic neurons that are 
injured or lost as the illness progresses (Birks, 2006). These provide a considerable 
step forward over the first anti-cholinesterase based drug - tacrine hydrochloride 
(Cognex; Shionogi Inc, Florham Park, New Jersey) approved in 1993 and withdrawn 
subsequently from US market in 2012, due to complicated dosage schedule and 
adverse effects e.g. risk of hepatotoxicity. Current AChEIs are easer in dosage and 
have better safety profiles. They are most effective when applied early in the disease.  
Another therapeutic - memantine hydrochloride (marketed under the brands Axura 
and Akatinol by Merz, Namenda by Forest Pharmaceutical, Ebixa and Abixa by 
Lundbeck and Memox by Unipharm) is the most recent FDA medication approved in 
2003 for the treatment of patients with moderate to severe AD. Memantine is a non-
competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor (Lipton, 
2005). It works by blocking NMDA receptor, thus providing neurons with time-
limited protective mechanisms against excess of  glutamate, which injured neurons 
release into the synaptic cleft, flooding the cell with calcium and causing cell damage 
and death (Budson and Solomon, 2012; Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Schematic representation of memantine mechanism of action (Budson and Solomon, 
2012). A – pathologically activation of NMDA receptors leading to excitotoxicity and chronic 
neurodegeneration; B – Action of memantine, which blocks NMDA receptor with a higher affinity 
than Mg
2+
 and  inhibits the prolonged influx of Ca
2+
.       
 
Key: 
A 
B 
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Memantine can be prescribed in combination with cholinesterase inhibitors and it is a 
common strategy to initiate treatment with AChEi and to add memantine as the 
patient begins to show further decline in cognition (Matsunaga et al., 2014; 
Matsuzono et al., 2015). Memantine is generally well tolerated. The most common 
adverse effects include confusion, dizziness, drowsiness, headache, insomnia, 
agitation, and hallucinations. In addition to the effects on NMDA receptor, 
memantine acts a non-competitive antagonist at different neuronal nAChRs, 
especially α7 and serotonergic 5-HT3 receptors, with the clinical significance of 
these interactions remaining unknown. Moreover, memantine was also found to act 
as agonist at the dopamine D2 receptor; however, the mechanisms of such off-target 
effects are not entirely clear (Nakaya et al., 2011). 
Another group of tested medications like statins tackle cardio-vascular dementia, 
which is often co-existing with AD and, therefore, believed to drive healthy brain 
towards AD type (Mendoza-Oliva et al., 2014). Also, non-steroidal anti-
inflammatory drugs or hormone replacement therapies found their applications in 
Alzheimer’s disease research and therapy (Lehrer, 2014).  
Other approaches that have been utilized in clinical trials are designed to prevent 
aggregation of toxic Aβ species (anti-aggregants), as well as target amyloid plagues 
directly through active or passive immunization (Galimberti et al., 2013, Menting 
and Claassen, 2014; Wu et al., 2015). Recently developed embryonic stem cells and 
optimized induced pluripotent stem cells (iPSCs) technology provide a promising 
platform to create reliable models, not only for better understanding the 
etiopathological process of AD, but also for efficient anti-AD drugs screening and 
transplantation (Yang et al., 2016; Zhang et al., 2016, Bali et al., 2016). Trials with 
NGF-expressing autologous fibroblasts implanted to forebrain of AD patients 
brought encouraging outcome (Tuszynski et al., 2005). Likewise NGF gene therapy 
using ex vivo or in vivo gene transfer continuous worthy for AD treatment 
(Tuszynski et al., 2015). 
Beside all of these pharmacological approaches, non-pharmacological interventions 
aim to improve the quality of life of AD affected patients or compensate memory 
loss are being developed. They range from improvements in care, counselling, 
education, physical and mental exercise, musical therapy to vitamins, herbs, Ginko 
Biloba  and other diet supplements (Sun et al., 2007; Birks and Grimley Evans, 2009; 
Simmons-Stern et al., 2012; Hernández et al., 2014).   
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1.7. Objectives of the study 
 
Functional disruption and loss of BFCNs are believed to contribute significantly to 
the pathogenesis and clinical manifestation of AD, characterized by a severe deficit 
of high integrative brain functions with impaired synaptic transmission and plasticity 
(Selkoe 2008; Walsh et al., 2002). However, the mechanism of progressive cognitive 
impairments and memory deficiencies responsible for the disease progression is not 
yet understood (Blennow et al., 2006). Dysregulation of p75
NTR
, the receptor 
exclusively expressed in BFCNs (Härtig et al., 1998; Fombonne et al., 2009) have 
been suggested to determine the selective vulnerability of cholinergic system during 
early AD.  
 
Based on these data, the primary objective of this study was to provide insights to the 
biology and function of p75
NTR
 in basal forebrain cholinergic neurons, by looking at 
endo/exocytosis of this receptor and mechanism that govern its internalization and 
exit. The relevant research platform had to be developed.  
 
Although neurotoxic Aβ is known to bind multiple targets (Verider and Penke, 
2004), it is the interaction with p75
NTR
 that mediates neuronal death (Sotthibundhu et 
al., 2008). Therefore second objective of this study was to investigate p75
NTR
 and Aβ 
interaction with main impact on the study of the precise entry route of p75
NTR
 and Aβ 
oligomers into BFCNs as well as detailed analysis of the parameters of their 
trafficking and co-localization in subcellular compartments of these cells. 
 
Final goal of this work was to exploit p75
NTR
 as a possible molecular target for 
delivery of potential therapeutics to BFCNs for AD treatment.  
 
In addition, chemical induction of AD pathology in rats was proposed to create 
animal model for testing potential neurotherapeutics, that can protect BFCNs against 
Aβ damage.  
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Chapter II. Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All experiments that involve use of rodents were approved by the Research 
Ethics Committee at Dublin City University and licenced by the Department of 
Children and Health, Ireland. 
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2.1. Immuno-cytochemistry (IC) 
 
Immuno-cytochemistry technique, commonly used in neuroscience, is based on 
antibody-antigen interaction with protein labelling. The work described throughout 
this study involved immunocytochemical staining procedures that were utilized in 
many experiments to visualize both cholinergic and non-cholinergic neurons as well 
as their projecting fibres or other structures of interest. Additionally Nissl method 
(Nissl, 1894) was used to highlight general structures of some parts of brain, which 
play a role in the processes involving modulatory influence of cholinergic 
innervations.  
 
2.1.1. Preparation of tissues for IC  
 
Brain extraction for IC has been undertaken under deep (lethal) anaesthesia of the 
animal with perfusion (Chapter 2.1.3), followed by slicing of the tissue. Therefore, 
all the buffers, surgery tools and perfusion pump had to be prepared in advance. 
Special care has been taken to remove the air bubbles from the tubing and perfusion 
pump to ensure easy flow of the solution before starting each experiment.  
 
2.1.2. Sedation and anaesthesia of experimental animals  
 
Deep (sub-lethal) anaesthesia of the rat was performed with intraperitoneal injection 
(i.p.) of sodium pentobarbital (Euthatal, Pfizer) at the dose of 200 mg/kg, preceded 
by subcutaneous (s.c.) injection of medetomidine (Domitor®, Pfizer) at the dose 0.4 
mg/kg. The absence of tail pinch response was taken as an indicative of deep 
anaesthesia, prior to the perfusion. Only after complete loss of tail pinch response 
was the surgery performed. 
 
2.1.3. Transcardial perfusion 
 
Transcardial perfusions were necessary for removal of blood from brain tissue as 
blood can interfere with IC. The process entails perfusion of the cardiovascular 
system for delivery of fixative into the brain. Transcardial perfusions were performed 
prior to all immunocytochemical procedures (Materials and Methods Chapters 2.1.6. 
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– 2.1.8.). Briefly, under deep anaesthesia (according to anaesthesia procedure – 
Chapter 2.1.2.), rats were placed on operating platform and immobilized with the 
surgery tools. The skin and abdominal wall below the diaphragm were lifted with 
forceps and muscles cut using blunt scissors to avoid damage of the interior organs. 
An incision was made along the border of the diaphragm muscle to expose the heart. 
Then ¼ inch of the 25G needle was inserted into the left ventricle of the beating heart 
and the right atrium cut with sharp scissors. PBS, pH=7.4 (0.1~150 ml) was pumped 
slowly at 3ml/min rate until the blood was cleared. The solution was then changed 
for 4% paraformaldehyde (PFA) buffered with PBS (0.1 M), pH=7.4 with care to 
avoid air bubbles in the tubing; this fixative (100 ml) was also pumped slowly at 3 
ml/min. The brain afterwards was removed from the skull and post-fixed in 4% PFA 
in 4°C overnight. In order to avoid freezing artefacts, the brains were cryo-protected 
by equilibration with 30 % sucrose (S7903, Sigma-Aldrich) solution in PBS in 4°C 
overnight to ensure that the tissue completely sunk in the Falcon tube. 
 
2.1.4. Slicing of rodent brain 
 
Cryo-protected brains were removed from sucrose after 24 h or more (when entire 
brain sunk in 30% sucrose in PBS) and glued on freezing stage of slicing microtome 
(Leica, CM3050 S) with Tissue-TeK O.C.T compound (4583, Sakura Finetek). Then 
sliced (usually 30 – 50 µm coronal sections) and immediately collected into PBS, pH 
7.4. or PBS with 0.1 % sodium azide in case of longer storage in the cold room, at 
4°C.  
 
2.1.5. Direct immuno-chemical staining of BFCNs using fluorescent anti-p75
NTR
 
antibodies and labelled Aβ 
 
This procedure involved the use of flour labelled primary antibodies or proteins, 
which bind and label targeted antigen / acceptors. The method is quick as it utilizes 
only one molecule for an antigen detection and non-specific reaction are limited. In 
this work, I used 192-IgG-Cy3 or Cy3-labeled anti-murine NGFr IgG directed 
against low affinity p75 neurotrophin receptor (p75
NTR
) in rats or mice, respectively; 
also, HiLyte Fluor β-amyloid (1-42) coupled with Alexa 488 (characterised in next 
section) and anti-p75
NTR
-LentiGFP were used. These flour labelled proteins were 
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applied directly to BF in culture for in vitro work or injected icv into 21 days old rats 
for in vivo evaluation. Unilateral injections were made in experiments with 192-IgG-
Cy3 (2 μl; 0.4 mg/ml) and anti-p75NTR-LentiGFP (5 μl; 7.0x106 IUs/ml), using 
stereotactic coordinates as follows: AP = -0.8 mm, ML = 1.2 mm, DV = 3 mm or 
bilateral for HiLyte Fluor β-amyloid (1-42) also to the ventricle (Levites et al., 2006; 
Zussy et al., 2013; Chen et al., 2015). For in vitro experiments, 4.7 nM of 192-IgG-
Cy3; 0.3 µM HiLyte Fluor Aβ (both exposed for 2h) or 1 µl anti-p75-LentiGFP 7 x 
10
8
 Lvs/ml (exposed 48h) were used (in 2 ml of medium).  
 
2.1.5.1. Characteristics of anti-p75
NTR
 antibodies and labelled Aβ peptides used 
in direct fluorescence staining in vitro and in vivo 
 
The anti-p75
NTR
 antibodies (FL-01 and FL-05, Advanced Targeting Systems) were 
used in the present study to monitor p75
NTR
 endocytosis in rat and mice primary BF 
tissue cultures as well as to characterise BFCNs in vivo. The Aβ labelled peptides 
(64572, AnaSpec) were utilized for intraventricular (icv) injections to follow the 
deposition of Aβ (1-42) in brain structures as well as they were applied to BF tissue 
culture model to track the trafficking process of Aβ (1-42) in live cells. Both: the 
anti-p75
NTR
 antibodies and Aβ peptides are available commercially (Table 1 and 2) 
and possess fluorochromes attached to them, that are excited at particular 
wavelengths 548 nm (Cy3) and 501 nm (HiLyteFluor
TM
 488). They   are able to emit 
signal at 561 nm (Cy3) and 527 nm (HiLyteFluor
TM
 488) respectively.  
 
 
 
 
 
 
 
    Cat no., Company Antibody name; 
(Isotype) 
Host Dilution used 
 
FL-01, Advanced 
Targeting 
Systems 
 
192-IgG-Cy3; 
(IgG1) 
 
Mouse 
monoclonal 
 
0,72 mg/ml (1:100) immuno-
cytochemistry; 
5 µl of 0.4 mg/ml for icv 
 
FL-05, Advanced 
Targeting 
Systems 
 
Cy3-labeled Anti-
murine NGFr IgG 
 
Rabbit 
polyclonal 
 
25μg (1:100) 
Immuno-cytochemistry 
Table 1. Characteristics of anti-p75
NTR
 antibodies used in direct fluorescence staining in vitro and  
              in vivo. 
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2.1.6. Indirect immuno-chemical staining of neurons  
 
Indirect immuno-chemical staining is two-step method that utilizes non-conjugated 
primary antibody that binds to the antigen of interest (first step) and a secondary 
antibody, coupled with fluorescent dye or an enzyme e.g. horseradish peroxidase 
(HRP) which gives a signal after contact with its substrate 3,3’-diaminobenzidine 
(DAB) (second step). This method is more versatile than direct staining because the 
variety of antibodies from the same species can be used with the same conjugated 
secondary antibody. This procedure is also more sensitive than direct method as 
several antibodies are likely to react with number of different epitopes of the primary 
antibody, thus amplifying the signal (more enzyme molecules are attached per each 
target site) (Boenish et al., 2001). In this study indirect immune-labelling was used to 
characterise BF brain slices or to visualise neurons and their connections or 
compartments in fixed neuronal cultures in vitro. 
Briefly, free floating brain sections or culture dishes were washed in PBS, pH=7.4 
and pre-incubated in 0.4% Triton X-100  (T9284, Sigma-Aldrich) diluted in PBS (0.1 
M) for 1h. Then mixture of 5% BSA (A2153, Sigma-Aldrich) and 2% serum of the 
host in which secondary antibody was raised, blocked the non-specific binding sites 
(1h). The diluted primary antibody against the antigen of interest (Table 3.) was 
applied overnight at room temperature in the same blocking solution with 0.4% 
Cat no., 
Company 
Peptide name; 
molecular weight 
Amino acid sequence 
of the peptide 
Dilution used 
 
64572, 
AnaSpec 
 
Β-Amyloid (1-42) 
HiLyte Fluor 488 
labelled; MW=4775,1 
 
Hilyte™ Fluor488 - Asp - 
Ala - Glu - Phe - Arg - His - 
Asp - Ser - Gly - Tyr - Glu - 
Val - His - His - Gln - Lys - 
Leu - Val - Phe - Phe - Ala - 
Glu - Asp - Val - Gly - Ser - 
Asn - Lys - Gly - Ala - Ile - 
Ile - Gly - Leu - Met - Val - 
Gly - Gly - Val - Val - Ile - 
Ala – OH 
 
2-5 μl (1mg/ml) 
Table 2. Characteristics of Aβ peptide used in direct fluorescent staining in vitro and in vivo. 
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Triton X-100 in PBS (0.1 M). Slices were then rinsed with 5 changes of PBS (5 min 
each) before incubation with secondary antibody labelled with fluorochrome at 
specified dilutions (Table 3.) for 1h at room temperature in the dark room. 
 
 
After this stage, sections were washed in PBS, pH=7.4 and mounted on charged glass  
slides, air-dried in the dark room and coverslipped with Vectashield mounting 
medium (H-1400 , Vector Lab.) before viewing.  
 
Primary antibody 
cat no, Company 
 
 
Primary IgG 
dilution 
 
Secondary antibody 
cat no, Company 
 
Secondary IgG 
dilution 
 
goat  anti-ChaT 
AB 144P, Millipore 
 
1:100 
 
Ab6737, Abcam 
(FITC) or  
Ab150136, Abcam 
 
1:1000 
 
mouse anti-calbindin ab9481, 
Abcam 
 
1:200 
 
A11004, Invitrogen 
(Alexa Fluor 568) 
 
 
1:2500 
 
mouse anti-parvalbumin 
P3088, Sigma-Aldrich 
 
1:250 
 
A11005, Invitrogen, 
(Alexa Fluor 594) 
 
 
1:2500 
 
rabbit anti-neurofilament 200, 
N4142, Sigma-Aldrich 
 
1:300 
 
A11034, Invitrogen 
(Alexa Fluor 488) 
 
 
1:2500 
 
rabbit anti-EE1 
07-1820, Millipore 
 
 
1:100 
 
A11034, Invitrogen 
(Alexa Fluor 488) 
 
1:1000 
 
goat anti-Rab11 (C-19) 
sc-6565, Santa Cruz 
 
 
1:100 
 
A-11078, Invitrogen 
(Alexa Fluor 488) 
 
1:1000 
 
rabbit anti-Rab7 (H-50) 
sc-10767, Santa Cruz 
 
 
1:100 
 
A-11078, Invitrogen 
(Alexa Fluor 488) 
 
1:1000 
 
rabbit anti-Lamp1 
SAB3500285, Sigma-Aldrich 
 
 
1:100 
 
A11034, Invitrogen 
(Alexa Fluor 488) 
 
1:1000 
 
Anti-streptavidin, 
Sc-52235, Santa Cruz 
 
 
1:100 
 
A-21121, Invitrogen 
(Alexa Fluor 488) 
 
1:1000 
 
Anti-amyloid (1-42), 
55922, AnaSpec 
 
 
1:200 
 
 
A-11029,Invitrogen 
(Alexa Fluor 488) 
 
1:1000 
Table 3. Optimised dilutions of  primary and secondary antibodies experimentally established for each 
type of neuronal labelling. 
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In case of HRP staining, peroxidase blocking solution was added to the slices after 
staining with primary antibody. The slices were rinsed with 0.05% Tween 20 (P1379, 
Sigma) in PBS tree times by 2 min, before the addition of secondary antibody 
coupled with HRP for 1h. After rinsing in PBS, DAB kit containing HRP substrate 
(SK-4100, Vector Lab.) was applied. This step was followed by monitoring of slices 
under the light microscope until satisfied intensity of the staining was developed. 
Stained sections were mounted on glass slides and air-dried. Afterwards, they were 
dehydrated in 75% ethanol (EtOH) (E7023, Sigma) followed by 95% EtOH and 
100% EtOH over few minutes each and cleared with Xylene (534056, Sigma) two 
times for 5 minutes. Finally they were coverslipped with DPX (06522, Sigma). 
 
2.1.7. Indirect fluorescence double labelling 
 
Double immuno-staining of cell cultures or tissue sections with use of  unconjugated 
primary antibodies requires that those antibodies are raised in different species and 
that secondary antibodies recognize one of these species exclusively. This method 
utilizes the same principles as indirect IC staining (Chapter 2.1.6), but primary 
antibodies (for two different antigens) are added sequentially. When first immuno-
chemical staining is finished, 10% serum (of the same host as the host of secondary 
antibody from the first staining) is applied to cover the effect of this visualisation. 
Second staining starts from the blocking step with Triton X-100 followed by the 
normal procedure as described in Chapter 2.1.6. f.e in case of ChAT/parvalbumin 
double labelling first IgG goat anti-ChaT (AB 144P, Millipore) (Table 3) was 
developed with FITC antibody (Ab6737, Abcam) and then blocked by 10% goat 
serum (G9023, Sigma-Aldrich) in PBS, pH=7,4 for half an hour. Secondly, mouse 
anti-parvalbumin IgG (P3088, Sigma-Aldrich) was applied and developed with 
Alexa Fluor 594 (A11005, Invitrogen) (Table 3) as described in Chapter 2.1.6.  
 
2.1.8. Controls for immuno-cytochemistry  
 
For the internal control of staining in each experiment the primary antibody step was 
omitted, while utilizing further the same staining protocol. In some experiments, 
cultured neurons from other brain areas than BF were used as controls (e.g. 
58 
 
hippocampal culture to establish the right dose of 192-IGg-Cy3 for experiments on 
BF). 
 
2.1.9. Nissl staining protocol  
 
Nissl staining was used to identify neuronal structures in brain, which are important 
for memory process. The staining was performed with use of Spraque-Dawley rats’ 
brain after perfusion as described in Chapter 2.1.3. Coronal brain sections (50µm) 
were obtained and mounted on glass slides. After drying, the slides were de-waxed 
by immersion in Xylene (534056, Sigma-Aldrich) (2 or 3 changes of 3 min each) and 
re-hydrated in 100% EtOH (34935, Sigma-Aldrich), 3 min each. Then sections were 
submerged in freshly prepared Nissl stain solution containing 1% w/v of cresyl violet 
(C-1791, Sigma-Aldrich, 10g/L) and 1% v/v glacial acid (10ml/L) for 5-10 min. Next 
step involved rinsing slides with ddH2O 2-5 times for few seconds. Staining in 
warmed cresyl violet solution (warm up in 37-50 ºC) was found to improve 
penetration and enhance staining, particulary of thicker (30 um) sections. Afterwards, 
slides were immersed in 50% EtOH for 5s and moved to 70% EtOH for a count of 5 
before putting them to 95% EtOH solution.  
Distaining of the slides was performed in 100% EtOH to a level determined under 
light microscope to the satisfactory visualization. The Nissl substance (rough 
endoplasmic reticulum) should appear in dark blue due to the staining of ribosomal 
RNA with aniline dye, giving the cytoplasm a mottled appearance. Individual 
granules of extra-nuclear RNA, named Nissl granules (ribosomes) and DNA present 
in the nucleus stains in a similar colour. Stained sections were then cleared in Xylene 
(2 times for 5 minutes), mounted in DPX (06522, Sigma-Aldrich) and left to dry. 
 
2.2. Microscopy 
 
Three types of microscopes were utilized in my research depending on the 
experimental purpose. Light microscope (Nikon Eclipse TS 100) was used to observe 
the development of BFCNs, HEK 293 or 293FT cells, hippocampal and mixed tissue 
cultures as well as to monitor HRP or Nissl staining. Fluorescent microscope 
Olympus IX71 allowed imaging with visualization of fluorescent stainings and 
documentation of the effectiveness of viral expression of GFP in BFCNs.  
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The best quality images were captured with a confocal laser scanning microscope 
LSM 710 Zeiss (Argon and Helium/Neon lasers) using 40x oil objective with 
suitable filter sets and excitation wavelengths. Separation of emission spectra was 
ensured with cut off filters e.g.: for Alexa 488 fluor green 505-550, for Cy3 fluor red 
550–630 nm, for DAPI blue 405-480 nm. Emitted fluorescence signals were sampled 
at spatial resolution of 30 nm/pixels with 1.5 μs dwell time. LSM710 was also used 
to acquire stack images in Z- dimension for 0.5 µm thick optical sections. To ensure 
that identical data are obtained, the acquisition parameter were kept. Usually all 
microscope settings were saved and re-used. Time lapse imaging with LSM710 
allowed monitoring of p75
NTR
 (192-IgG-Cy3) and Aβ (Alexa 488) trafficking in live 
cells in vitro. 
 
2.2.1. Measurement of co-localization of fluorescent markers 
 
Co-localization of HiLyte fluor (Alexa 488) Aβ (1-42) and 192-IgG-Cy3 in BF 
cultures was assessed with laser scanning microscope (LSM 710, Carl Zeiss), which 
automatically measured and calculated the co-localization parameter and overlap 
coefficients (ZEN-2008 software), based on algorithm, which assesses the presence 
of two flours  within the same pixel (Manders et al., 1993) (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Measurement of co-localization coefficient by LSM710. Colocalization coefficients were 
measured for each channel (M1, M2). They were calculated by summing the pixels in the colocalized 
region (Quadrant 3) and then dividing by the sum of pixels either in Channel 1 (Quadrant 1 + 
Quandrant 3) or in Channel 2 (Quadrant 2 + Quadrant 3).  Each pixel has a value of 1. The 
colocalization coefficient values ranged from 0 to 1. Single labelled control samples were imaged with 
the same microscope settings as the double label experimental samples. Exact (X,Y) coordinates on the 
scatter plot were determined by using the control samples and they were kept constant for the analysis 
of the double-label experimental samples.   
   
  
 
 
 
60 
 
The parameters, which influence the intensity of the image remain the same for all 
experiments. These include: objective (40X), the power of the laser, excitation 
wavelength and parameters of the detectors with appropriate cut-off filters (Chapter 
2.2) as well as an acquisition speed settings. The type of mounting media was kept 
constant for all control and experimental samples as different types may exhibit 
varying levels of autofluorescence. Similarly, imaging through different types of 
material, such as glass coverslips versus a plastic bottom dishes was avoided, 
because it could influence the brightness and signal to noise ratio. Special dishes for 
LSM microscopy (81151, Ibidi) were utilized. Around 100 frames in total were 
analysed for each experiment. Values of fluorescence intensities were averaged off-
line, using Excel; mean signal intensities and standard deviation from means with 
standard error  were calculated. 
 
2.2.2. Cells counting procedure 
 
This study used a non-stereological, two dimensional quantification of neurons. Most 
often cells were counted manually with use of a counting tool from Photoshop CS4 
programme vs.11. Cells counting was performed on equally thick sections (35µm), 
where neurons were visualised by indirect fluorescence or HRP labelling as 
described in Chapter 2.1.6. In case of cholinergic neurons, counts of FITC- and Cy3-
stained cells were used versus all those visualised with DAPI. The results were 
verified by a randomly-chosen second researcher, blinded to the study. In some 
cases, Image G threshold macro was used to verify cell numbers. The data analysis 
was performed afterwards (Chapter 2.4.). 
 
2. 3. Western blot (WB) analysis of cholinergic markers in BF 
2.3.1. Dissection of rat brain for WB  
 
The post experimental extraction of brain as well as control tissues were performed 
after decapitation of rodents under deep anaesthesia. An overdose of sodium 
pentobarbital (i.p.; 200 mg/kg) was used for sub-lethal anaesthesia. In some cases 
this was combined with medetomidine injection (s.c.; 0.4 mg/kg) in order to 
minimize the distress of the animal. The depth of anaesthesia was checked by the 
absence of tail pinch response. Then brains were removed from the cranial cavity and 
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placed on petri dish for dissection. For most of the experiments, BF, hippocampus 
(H) and prefrontal cortex (PC) areas were collected. The tissue was immediately 
placed on ice in buffer containing 0.5% Nonidet (74385, Sigma-Aldrich) and mix of 
protease inhibitors (Appendix 5.1). This detergent is powerful enough to study 
cytoplasmic and membrane–bound proteins without breaking the nuclear membrane. 
The tissues were then homogenised and kept 30 min on ice with vortexing every few 
minutes before centrifugation at (14Kxg) 10 min at 4ºC and stored in -20ºC. The 
supernatant was taken for further analysis and  protein concentration was determined 
prior to the WB with standard Bradford (500-0006, BioRad) or PierceTM BCA 
(23227, Pierce) protein assay.  
 
2.3.2. Development and analysis of WB 
 
Protein extracts were mixed with loading buffer (10482055, Life Tech.) and  heated 
10 min at 95ºC. They were subsequently loaded on 12% NuPage Bis-Tris gel in 
known concentrations, previously defined with Bradford protein assay. Separation of 
proteins was carried out by applying 170 V in denaturing conditions (SDS-PAGE); 
polyacrylamide gels were then transferred (wet blot) approximately 4 h onto pVDF 
membrane (IPVH20200, Millipore) at 4°C with 40 mV current. The membrane was 
blocked for 0.5 hour with 5% milk (70166, Sigma) in TBST (Appendix 5.1). Then 
the relevant secondary antibody was applied overnight at room temperature. 
Depending on secondary antibody, the DAB Impact kit (SK-4105, Vector Labs.) was 
used (for secondary antibodies coupled with HRP) or combination of nitroblue 
tetrazolium chloride (NBT) (N6876, Sigma) and 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) (B6149, Sigma) in AP buffer (Appendix 7.1.), pH= 9.5 (in case of 
secondary antibodies coupled with alkaline phosphatase). The detected bands were 
then analysed in G:BOX from SynGene with the use of GeneTools programme. 
Semi-log plot tool was used to assign correct size of the bands. The plots were 
obtained from data normalized versus the same area of interest. 
 
2.4. Data analysis  
 
Different analytical approaches were utilized depending on experimental purpose and 
the techniques used. The experimental measurements were expressed as mean ± SE 
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with statistical significance assessed using paired or unpaired Student’s t-test. The 
difference between samples was defined as significant if p value was less than 0.05. 
In experiments involving multiple repeated comparisons, one way ANOVA was 
applied for the assessment of significance. 
 
2.5. Primary BF neuronal cultures   
2.5.1. Coating of cell culture dishes 
 
Depending on experimental purpose, culture dishes made of different materials were 
used e.g. glass bottom dishes for DIC microscopy or polystyrene dishes for culturing 
cells aimed for WB procedures (81158 Ibidi, 734-0005, BD Falcon). For confocal 
microscopy, specific Ibidi dishes (cat no 81151) were utilized. All dishes were 
coated with 0.01% poly-L-lysine (100µg/ml, Sigma, P4832) to promote adhesion of 
the cells. Poly-L-lysine was applied to the surface of each dish for 1 h and then 
washed away. Dishes were left to dry at room temperature and subsequently rinsed 
with sterile H2O after that. Plating medium (2 ml)  dependent on the tissue culture 
type (see below) was applied into each dish and the dishes were pre-incubated at 5% 
CO2 in 37°C before applying neuronal cells. 
 
2.5.2. Isolation of BF from embryonic or  postnatal rodents brain 
 
Primary BF tissue cultures were obtained from embryonic C57/BL6 or CD-1 mice or 
(E18) or postnatal Sprague-Dawley rats (p0) according to previously established 
protocols, optimized for our conditions (Nakajima et al., 1985; Pongrac and Rylett, 
1988; Schnitzler et al., 2008, Banker and Gosslin, 1998).  
For embryonic mice, the surgery was carried out under deep, ketamine-induced 
anaesthesia with use of Velatar, PfizerTM (i.p., 120 mg/kg) (Figure 14B). To avoid 
distress of the mice, animals were sedated with isofluran prior to i.p injection (5% 
isofluran, 1L/min oxygen) (Figure 14A). The depth of anaesthesia was verified by 
checking of the tail pinch response (Figure 14C). A longitudinal incision through the 
skin first and then through the abdominal muscle of the animal was performed 
(Figure 14D). When opened, the uterus was removed from abdominal cavity on the 
sterile dish (Figure 14E, 14F). Than embryos were dissected and placed in cold 
sterile Hank’s Balanced Salt Solution (HBSS) (14170, Life Tech.) supplemented 
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with 10 mM HEPES buffer (H4034, Sigma) and 1% penicillin/streptomycin (15140-
122, Life Tech) (Figure 14 G). The dam was euthanized by rapid decapitation under 
ketamine anaesthesia. Embryonic heads were isolated (Figure 14H, 14I) and brains 
dissected out (Fig. 14J – N). The BF was isolated in sterile conditions and kept on ice 
in dissecting media enriched with 25 mM of glucose (49163, Sigma). Removal of 
meninges was critical step during the whole procedure. The media was exchanged 
for 0.05% trypsin/EDTA (25300054, Life Tech.), pH=7.4-6, 270-310 mOsm/kg and 
incubated with extracted brain tissue around 10 min at 37°C to allow dissociation of 
the cells. Afterwards benzonease (E1014, Sigma) was added for 5 min and then all 
material centrifuged (5 min, 180g). The pellet was re-suspended with plating medium 
containing 1:1 [mixture of Dulbecco’s modified Eagle’s medium (DMEM) (D6429, 
Sigma) : F12 (N6658, Sigma); (1:1)] and dissecting medium supplemented with 5% 
foetal bovine serum (FBS) (F2442, Sigma). The dissociation of cells was facilitated 
by brief, gentle trituration (around 12-15 times) with glass fire-polished Pasteur 
pipette before another centrifugation for 5 min (180 g). The medium was then 
refreshed and cells plated at a density of 0.5–1.0 x 105 cells/cm2 onto 35 mm glass 
dishes coated with poly-L-lysine. Standard tryptan blue method for cell counting was 
used to establish proper plating density. 
Cells were cultured in serum-supplemented medium for 1 h to facilitate the initial 
attachment of neurons to the substratum and to inactivate proteolytic enzymes  
released from damaged cells during trituration (FBS contains protease inhibitors, 
such as α1-antitrypsin and α2-macroglobulin, which inhibit the trypsinization 
process). The medium and unattached cells were removed and replaced by serum 
free medium containing (1:1) DMEM: Neurobasal (21103-049, Life Tech.) with 2% 
B27 supplement (17504-044, Life Tech.), 50 ng/ml NGF (mouse, 2.5S; N6009, 
Sigma) and 1% penicillin/streptomycin. The dishes with cells were placed in 
humidified incubator at 5% CO2, 37°C. Quick dissection time and using proper cell 
surface adhesion materials were very important for success of this procedure . The 
best cells adhesion was observed with Ibidi dishes coated with 0.01% poly L-lysine 
(Chapter 2.5.1.). After 48 hours of incubation, cytosine β-D-arabinofuranoside 
hydrochloride (C1768, Sigma) was added to inhibit the growth of other non-neuronal 
and glial cells. Culture media was refreshed every 5 days, each time only half of the 
medium was replaced. All media were previously sterilised by passing through 
0.22µm syringe filter.  
64 
 
In regards to new-born rats, postanatal (P0) rat brains were isolated into the 
dissecting medium (already mentioned above) and minced with the use of sterile 
medical needles before changing of dissecting medium to the plating one (same as 
for embryonic cultures). Then the same protocol for BF cultures was applied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 14. Isolation of brain from mice embryo. A. Mouse anaesthetised with isofluran. B. i.p. 
injection of ketamine. C. Pinch tail  response check. D. Abdominal incision. E. Uterine with embryos 
inside the mouse. F. Uterine removed on sterile Petri dish. G. Separated embryos on ice. H. Isolation 
of embryo  head. I. Embryo head under dissection microscope ready for brain isolation. 
 
  
Figure 15. Isolation of BF from rodent brain. J. Incision of the head’s skin. K. Embryo brain visible 
after  skin removal. L. Half of the meninges removed (right side). M. Removal of the brain . N. 
Mouse brain ready for dissection. O. Opened hemispheres. Arrow points to the septum area. 
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2.6. Production of lentiviral particles  
2.6.1. Transformation of competent cells 
 
DH5α competent cells derived from E.Coli (18265-017, Life Tech.) were taken from 
-80°C freezer on ice to thaw. They were aliquoted (10 µl) into 4 sterile 1.5 ml 
eppendorfs and transformed with pMD-2G, pWPT-GFP (or modified pWPI) and 
pCMV plasmids (7271, 1 2225, 15785, Addgene). PUC 19 control DNA (15364-011, 
Life Technologies) was used to verify the efficiency of this transformation. Briefly, 
each plasmid (1 µl) was added to DH5α cells, incubated on ice for 30 min and then 
shocked by heating the vials for 20 seconds to 42°C and immediate transfer to ice for 
additional 2 minutes.  
 
2.6.2. Growing of DH5α colonies 
 
S.O.C (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, and 20 mM glucose.) medium (950µl) (15544034, Life Tech.) with 
50 mg/ml ampicillin (or other rich broth like LB - L7658, Sigma) was added to 
transformed DH5α cells and incubated for 1h in 37oC with shaking at 225 rpm. Then 
two different amounts of colonies (20 - 200 µl) were added to previously-prepared 
pre-warmed selective plates and spread. DH5α cells (not transformed) were used as 
control. All plates were further incubated in 37°C overnight. 
 
2.6.3. Selection of plasmid-positive colonies 
 
Antibiotic resistance was used to select the colonies that have acquired the plasmids 
of interest during cells growth. All selective plates were freshly prepared with 50 
µg/ml ampicillin in LB agar (L2897, Sigma) on sterile Petri dishes. Only the cells 
transformed with plasmids that confer the gene for ampicillin resistance were able to 
grow. 
 
2.6.4. Amplification of DH5α colonies 
 
Amplification of plasmid-positive DH5α colonies was performed in two steps. First 
one colony from each agar plate was inoculated into sterile Falcon tubes with 10 ml 
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of LB or 450 µl S.O.C media, each containing 50 mg/ml ampicillin. The tubes were 
placed on shaker for 5 h at 225 rpm, 37°C. Content of each tube was then poured into 
bigger 1L flask of LB medium containing 50 mg/ml ampicillin. The amplification 
was continued overnight (16 h altogether) in 37
o
C with shaking at 225 rpm. 
Absorbency at 600 nm was measured to estimate the phase of cell growth. Incubation 
for more than 16 h was not recommended because the cells began to lyse and 
plasmid yields could be reduced. 
 
2.6.5. Extraction of plasmids’ DNA  
 
Extraction of plasmids’ DNA was performed with QIAfilter Plasmid Midi Kit 
(12243, Qiagen). All buffers and solutions used for this procedure are described in 
Appendix 7.3. Briefly, LB culture was harvested by centrifugation for 15 min in 4°C 
(6000 g) and the supernatant removed. The remaining bacterial pellet was 
homogeneously resuspended in 25 ml of buffer P1, containing 100 µg/ml RNAse A. 
Then 4 ml of lysis buffer (P2) was added and the tubes, vigorously inverted 4-6 times 
before incubation for 5 min. at the room temperature. During this time QIAfilter 
Midi Cartridge was prepared and the tip equilibrated by applying 4 ml of 
equilibration buffer (QBT) for gravity flow through the column. Then, 4 ml of 
neutralization buffer (P3) chilled to 4 °C was added to the tubes and thoroughly 
mixed. Bacterial lysate was poured into Falcon tubes and centrifuged 10 min at 1620 
g before applying it into the cartridge. It was left there for 10 min and filtered into 
the Qiagen-tip for further binding, washing and eluting procedure. Gravity flow of 
the lysate through the column was allowed and the tip was then washed twice with 
10 ml of wash buffer (QC). DNA was eluted with 5 ml of elution buffer (QF) into the 
sterile tube. Precipitation of plasmids’ DNA was achieved by adding 3.5 ml of 
isopropanol at the room temperature and centrifugation of the mixture at 15000 g for 
0.5 h at 4°C. After removing the supernatant, the DNA pellet was washed with 2 ml 
of 70% EtOH and centrifuged at 15000g for 10 min. To finish this procedure, the 
supernatant was carefully discarded and the tubes air-dried. After that DNA was 
dissolved in TE buffer which is routinely used to solubilize DNA or RNA to  protect 
them from degradation. 
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2.6.6. Quality check of plasmids’ DNA  
 
Concentration of DNA was measured and purity assessed by 260/280 nm and 
260/230 nm ratios using NanoDrop 1000 with 1.8 value reflecting pure DNA in first 
measurement and 2-2.2 ratio corresponding to pure DNA in the second measurement. 
Three readings of the same sample were averaged before calculation of DNA 
concentration.  
The plasmids’ DNA size was verified after restriction-digest reactions, designed with 
the enzymes specific for each plasmid and represented on the plasmid restriction 
maps attached (Appendix 7.4). The following restriction enzymes: BamH1 for 
pWPT-GFP plasmid, Pst1 for pMD-2G and EcoR1 with XhoR1 for pCMV  [R0136, 
R0140, R0101 and R0146, respectively; all from New England (NE) BioLabs] were 
utilized. The reaction mixture contained 10 µl of plasmid DNA, 0.1 – 0.2 µl of 
appropriate enzyme, 0.1 – 0.2 µl of NE compatible buffer, 7.6 – 7.8 µl of H2O and 
0.2µl of BSA (B9000, NE BioLabs). Restriction-digest was carried out in 37°C for 2 
h continuously or sequentially in case of two enzymes for the one plasmid. The size 
of each plasmid after digestion was checked on 1% agarose gel with ethidium 
bromide (E7637, Sigma) in TAE buffer (Apendix 7.4.) against molecular ladder 
(N3232S, New England BioLabs) and non-digested version of each plasmid. 
 
2.6.7. Preparation of human embryonic kidney (HEK) 293FT cells 
 
HEK 293FT cells were retrieved from liquid nitrogen, thawed and quickly 
transferred to T-25 sterile flask containing growth medium [DMEM (D6429, Sigma), 
10% FBS (F9665, Sigma) and 1% penicillin/streptomycin/antimycotic (15240, Life 
Tech.]. After few hours, when most of the cells were attached to the bottom of the 
flask, the rest of DMSO from cryo-protecting medium (DMEM; 14.5 g/L glucose, 
10% FBS, 8% DMSO) was removed and replaced with fresh, pre-warm growth 
medium. HEK 293FT cells were kept in optimum growth conditions (37°C, 5% CO2) 
and split every 2- 4 days when reaching 80 – 90 % confluence. Splitting the cells 
involved removing of the old medium, washing cells twice with PBS, PH=7.4, 
detaching cells from plastic with trypsin-EDTA solution (25300104, Life Tech) (1-3 
min in 37°C) and transferring the desired number of cells to a bigger flask with 
growth medium. HEK 293FT were usually reseed at 2 × 104 cells/cm2 density 
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2.6.8. Safety precautions for lentivirus handling  
 
Production and handling of the LVs demanded special care. Open tubes were 
handled inside class II cabinet in level 2 containment laboratory and taken out only 
when closed and sprayed with 75% EtOH. The infected cells were kept in incubator 
designated for viral work. All solid waste and plastics were discarded in biological 
safety yellow bags and autoclaved thereafter. Liquids were aspirated into a liquid 
waste bottle containing fresh bleach and spilt into the sink after neutralization. The 
Biosafety Committee at Dublin City University approved the procedures for the 
production and handling of LVs; an emergency response plan was written and 
submitted to the above Committee.  
 
2.6.9. Transient transfection of HEK 293FT cells and lentivirus collection 
 
One the day before transfection HEK 293FT cells were seeded at the density 1-3 
x10
6 
cells/Petri dish in RPMI-Glutamax medium (61870036, Life Tech.) with 10% 
FBS and 1% antibiotic. On transfection day (when HEK cells reached 80 % 
confluence), the above medium was removed and replaced with 9 ml of the same 
medium but without serum and antibiotic for each Petri dish. Transfecting solution 
was prepared separately in Falcon tubes with 1.2 ml of RPMI-Glutamax medium 
calculated per plate. In total DNA plasmids (9 µg) was added to this tube in ratio 
4:3:1 for the following plasmids pWPT-GFP, pCMV-, pMD-2G. The mixture was 
combined with 45 µl of PEI (23966, Polyscience) per dish and vortexed immediately. 
After 15 min of incubation at room temperature, it was added to the HEK 293FT 
cells dropwise and spread over the dish gently. Transfected cells were incubated 2 h 
in 37°C and the medium was then enriched with 20% FBS and incubated for 
additional 2 days in 37°C, 5% CO2. After that time, the medium was collected and 
centrifuged for 15 min at 1620 g. The supernatant was carefully transferred to glass 
tubes and ultracentrifuged for 2 h at 70409 g. The pellet was resuspended in 50-100 
µl of PBS and stored in -80°C freezer. 
 
2.6.10. Confirmation of lentiviral titter with p24 assay 
 
The titter of lentiviral vectors was confirmed with p24 assay. This assay is based on  
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two sided sandwich ELISA in which p24 antigen (from the virus capsid) is captured  
from detergent lysate of virions by polyclonal antibodies, adsorbed to a solid phase. 
The method was previously described by Moore and McKeating (1990). Bound p24 
antigen is detected by alkaline phosphatase, conjugated anti-p24 monoclonal 
antibody and chemiluminescent detection system. Briefly, each experimental and 
control well of 96-well microtiter plate were coated in duplicates with 100 µl mixture 
of sheep polyclonal antibodies (D7320, Aalto Bio Reagents) (5 µg/ml), which react 
with p24 gag structural protein of HIV-1. The plate was incubated overnight at room 
temperature and washed twice with TBS (200µl per well). Then 100µl/well of 2% 
milk in TBS, pH=7.5 was applied for 1 h at room temperature to block non-specific 
binding sites. In some cases, plates prepared in such way were frozen in -20°C and 
stored for several week to be thawed directly before use. The milk containing buffer 
was discarded and wells washed with TBS, pH=7.5 and tapped dry. Then 100 µl/well 
of p24 standards (AG 6054, Aalto Bio Reagents) was applied in duplicates as well as 
controls and supernatant of interest in the same amounts. Recombinant HIV-1 p24 
antigen (p24 standard) was diluted in 1% FCS (4781, Sigma) in TBS to 100 µg/ml 
and then 1:1000 with 0.1% Empigen (45165, Sigma) prior to use. The assay involved 
few 1:3 dilutions down of this mixture also with 0.1% Empigen. Experimental 
samples were treated with 1% Empigen prior to assaying to inactivate the virus and 
linearize the proteins. Blank wells filled with 0.1% TBS served as controls. The 
incubated assay was leaved for 3 h at room temperature. The plate was then washed 
twice with TBS and tapped dry. Then 100µ/well of conjugate consisting of 1:1000 
secondary monoclonal anti-HIV-1-p24 antibody coupled to alkaline phosphatase (BC 
1071-AP, Aalto Bio Reagents), 20% sheep serum (S-7773, Sigma) and 0.05% TBST 
was incubated at room temperature for 1 h. The wells were washed 4 times with 
0.1% Tween 20 (P9416, Sigma) in PBS, tapped dry and then washed 2 times with 
TROPIX wash buffer (EL100CX, Aalto Bio Reagents) and dried again. For 
detection, the chemiluminescent substrate for alkaline phosphatase (CSPD with 
Sapphire-II) (50 µl/well) was added and incubated for 0.5 h in dark at room 
temperature before reading the plate. The absorbance was measured at 450 nm 
against 690 nm wavelength using dual mode BioTek Synergy HT multifunction 
reader equipped with Gene 5 software programme. The experimental and control 
samples were read in duplicates and the plate background was subtracted from these 
readings. Quantification of p24 antigen was measured by endpoint evaluation and 
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form a standard curve. The viral titter was calculated from this curve (Figure 65A) 
according to the equation below.  
 
Titter in IU/mL = (cells at starting time) x (dilution factor) x (percent infection)/(vol 
virus solution added expressed in mls); f.e (4x10
5
 cells/ml) x (100 times dilution) x 
(5.0%/100)/(0.0025ml) = 8.0 x 10
8
 IU/ml 
 
2.7. Construction of anti-p75
NTR
-LentiGFP vector 
2.7.1. Biotinylation of LentiGFP 
 
Sulfosuccinimidyl-2-[biotinamido]ethyl-1,3-dithiopropionate (sulfo-NHS-SS-Biotin) 
(21328, Thermo Scientific), a thiol-cleavable amine-reactive reagent was used for 
biotinylation of the LVs produced earlier. The conditions for this reaction were 
optimized and biotinylation was carried out for 2 h on ice with an excess of biotin or 
overnight in 4°C with an extensive mixing of the LVs and the biotinylation reagent. 
Non-reacted Sulfo-NHS-SS-Biotin was removed later by dialysis. The membrane for 
dialysis utilized 12-14 kDa MWCO, that was cleaned by heating in 2% NaHCO3 and 
1 mM EDTA at 80°C for 30 min. The tubing was then rinsed thoroughly in distilled 
water. Biotinylated LVs were introduced into the tube membrane and clipped at both 
ends. Then tube membrane was fixed to the edge of the flask containing PBS, 
pH=7.4. for dialysis, performed with gentle mixing at 4°C overnight. 
The amount of biotin incorporation to the LVs was estimated with 2-(4’-
hydroxyazobenzene)-2-carboxylic acid (HABA)/Avidin reagent (H2153, Sigma). 
The assay was based on binding of HABA dye to avidin and the ability of biotin to 
displace this dye in stoichiometric proportions. In principle, the maximal absorption 
of HABA/Avidin complex at 500 nm decreases when biotynylated molecule is added 
to the solution. The change in absorbance relates to the amount of biotin in the 
sample. Readings for blank wells were deducted from the assay and a dilution factor 
for HABA/Avidin calculated upon an addition of the sample or control (without 
biotin) (http://www.piercenet.com/haba/habacalcmp.cfm) (Green et al., 1970). 
 
2.7.2. Conjugation of streptavidin to anti-p75 IgG 
 
Lightning-LinkTM conjugation kit (708-0015, Innova Biosciences) was used to  
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conjugate streptavidin to anti-p75 antibody (07-476, Millipore). The antibody was 
prepared first as the previous dialysis steps might interrupt the traditional protein 
conjugation procedure. Therefore, 1µl of LL-Modifier was added for each 10µl of 
anti-p75 IgG and the mixture was kept for 3 h at room temperature or overnight in 
the cold room, 4°C. After this time 1µl of LL-Quencher reagent was applied for 
every 10 µl of anti-p75 IgG and left for additional 30 min on ice. Equal amounts of 
such prepared anti-p75 IgG and Lightning-LinkTM mix containing LL-Streptavidin 
were combined. There was no need to purify the conjugate because the chemicals 
used in Lightning-LinkTM are deactivated by the quencher as well as other by-
products and do not need to be removed. 
 
2.8. Stereotactic intra-ventricular (icv) injections into the rodent brain 
2.8.1. Practice and quality control of icv injections 
 
Icv injection is a skilful procedure which demands appropriate training; it involves 
animal handling, stereotactic surgery and post-operational care. The experiments 
should be carry out only if necessary and if they cannot be replaced with other 
methods. In this study icv injections were utilized for delivery of 192-IgG-Cy3 (5μl 
0.4 mg/ml) to label cholinergic neurons in vivo (Chapter 3.3.), 192-IgG-SAP (2.5 
μg/ml) to achieve cholinergic cell loss (Chapter 3.5.6.) and lentiviral vectors for 
targeting of p75
NTR 
(5 µl, 7.0 x 107 IUs/ml) (Chapter 5.4.2.) into the rodents brain. 
Stereotactic icv injections of Aβ or saline were applied to mimic the excessive Aβ 
load and chemically-induce AD model in rats (Chapters 3.5.2. – 3.5.4.). Due to the 
use of expensive reagents and also to minimize failure during the experiments three, 
21 days old rats were injected with Coomassie blue dye for the training purpose 
(Chapter 3.3.). 
 
2.8.2. Preparation for the surgery 
 
Adequate preparation is important step for the success of the whole surgery: 
researcher, instruments and animals needs to be prepared correctly prior to the each  
procedure.  
I was trained to carry out the surgery and performed in vivo experiments when 
confident with the procedure, which minimized the distress to the animal. 
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I autoclaved the surgical tools prior to the surgery and decontaminated thereafter and 
during the procedure with ethanol if necessary. S Hamilton syringe was washed 
several times in PBS to ensure easy flow of the reagents. Adequate chemicals and 
active ingredients were prepared prior to injections and kept close to the surgery site. 
In case of using viral aliquots, they were spun down before use and loaded into a 
Hamilton syringe in Class II microbiological safety cabinet. 
Each rat was tail-marked and weighted prior to the surgery. While taking the animal 
from the cage it was important to leave the other rodents together with full access to 
food and water. To minimize distress, some rats were injected with medetomidine 
(Domitor®, Pfizer) 0.4mg/kg (s.c.) prior to anaesthesia. For easier access to the 
animal’s skull, the fur on the head was gently trimmed and skin (the surgical field) 
cleaned with Betadine® (Santa Cruz Biotech.). Once taken from the cage the animal 
was monitored until full recovery from the sedative. 
 
2.8.3. Anaesthesia for icv injections 
 
The experiments were conducted under general anaesthesia (ketamine, Velatar ™, 
Pfizer) (50 mg/kg, i.p.). 5-7 minutes after injection, rats were checked for the 
absence of tail pinch response prior to the surgery. The depth of anaesthesia was also 
monitored in the course of the surgery. In some cases (e.g. to close the re-opened 
wound after surgery) anaesthesia was induced with 5% isofluran vaporizer in oxygen 
1L/min, connected to the glass chamber and maintained at 3% through the tubing. 
The recovery of the animal was quick after removal of the isofluran mask.  
 
2.8.4.  Stereotactic surgery 
 
During surgery, rats were placed on a warm pad and body temperature was 
maintained at 37°C throughout the procedure. The rostrum of the animal was fixed 
within stereotactic frame (Stoelting, Leica Vernier stereotaxic apparatus) in the 
horizontal position with head supported by the ear bars. When immobilized, 2-3 
subcutaneous injections of 10 µl local anaesthetic (5mg/ml, Bupivacaine, Antigen 
Pharmaceuticals) were given to the skin of rat’s head, to the place where small 
longitudinal incision was made later (after 2-5 minutes) in order to gain access to the 
bregma of the skull. Using bregma as a reference point, the coordinates for various 
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brain structures were determined, according to the rat’s brain atlas (Paxinos and 
Watson, 1998). A Hamilton syringe, equipped with 33 gauge needle was fixed to the 
stereotactic frame and positioned accordingly. The place for injection was marked 
and a hole made in the skull with dental drill. 28 G needle was then utilized to 
puncture the dura. Icv injections of the desired material were slowly performed 
(1µl/min). The needle was removed very gently to avoid reflux along the needle 
track and wound sutured after injection, using absorbable vicryl. Additional 
antibiotic (Betamox LA, Norbrock) was applied over the closed wound to prevent the 
infection. 
 
2.8.5. Post-operative care 
 
Animals after surgery were kept on 24 light/dark cycles in properly labelled cages 
with easy access to food and water. Often the cages were kept warm with absorbent 
paper. The animal was continuously monitored until it recovered from the sedative. 
The researcher, responsible for post-operative care, monitored the animals health and 
wellbeing regularly, on the daily basis (according to monitoring check list pro-forma 
attached to each cage). Any signs of pain or distress of animal were immediately 
reported to Biological Research Unit stuff and alleviated. In case of re-opening the 
wound, isofluran anaesthesia (Materials and Methods, Chapter 2.8.3.) was applied to 
suture the wound.  
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Chapter III. Chemically-induced rat model of  
AD revealed involvement of cholinergic neurons 
in Aβ clearance – results with discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
3.1. Review of AD animal models with reference to Aβ-induced models 
 
One of the main obstacles in AD therapy is complexity of the disease (Chapter 1.5). 
The available animal models are useful for studying some but not all aspects of AD 
and are used for mimicking and preclinical evaluation of the treatments directed at 
Aβ or tau. Different scientific questions demand creating specific animal models that 
allow addressing particular problems. In  other words no engineered animal model 
has yet reproduced the full spectrum of AD phenotypes in a manner closely similar 
to the human disease, despite the significant effort that has been made to create such 
models. However, partial reproduction of AD neuropathological phenotype with 
cognitive deficit has been achieved with genetic and pharmacological approaches.  
In regards to transgenic animals, modelling of AD has been most heavily pursued in 
mice within the framework of amyloid cascade hypothesis. Genetic modification 
techniques have taken advantage mostly of mutations in APP and PSEN (Sawamura 
et al., 2000; Ashe, 2001; van Groen et al., 2006; Elder et al., 2010). Nevertheless, rat 
AD transgenic models have also been made and tested (Folkesson et al., 2007; Flood 
et al., 2009). These models exhibit age-dependent deposition of Aβ plaques in the 
hippocampus and neocortex and present extensive axonal dystrophies with 
inflammatory responses.  
Neuronal loss and formation of NFTs is not evident in all models (Takeuchi et al., 
2000; Richardson and Burns, 2002), however, models reflecting tau pathology have 
been also successfully made. These are often double transgenic mice that express 
both mutant human APP and tau (Lewis et al., 2001; Boutajangout et al., 2004), but 
single transgenic mice overexpressing tau do also exist (Adams et al., 2009). Such  
models allow to study mechanisms of Aβ and tau accumulation and enable studies of 
the relationship between these two key pathogenic proteins.  
Non-transgenic animal models provide a complementary alternative to transgenic 
ones. They involve administration of exogenous Aβ through icv injections or chronic 
Aβ infusions. Most Aβ introductions were performed using synthetic Aβ (1-40) or 
Aβ (1-42) peptides, which are found in abnormally high level in neuritic plaques. 
The effects of such attempts are variable due to numerous reasons e.g. differences in 
brain structures targeted, concentration and aggregation state of Aβ peptides 
delivered, animal strain and handling procedures (Table 4).  
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Injected brain 
region 
Type of injection, 
concentration of Aβ 
and its form/ organism 
Time of 
effects 
 
Main results/(reference) 
 
Retrosplenial 
granular cortex 
 
single unilateral micro- 
injection of 2 μg/μl Aβ 
(1-40) fibrilliar /female 
Wistar albino rat 
 
10 days 
 
Significant loss of cholinergic and 
glutamate-immunoreactive neurons in 
MSDB complex. Reduction in fibers and 
terminals immunoreactive for substance 
P, neurotensin and glutamate (Gonzalo-
Ruiz and Sanz, 2002). 
 
cingulate cortex, 
particularly the 
retrosplenial 
cortex 
 
single unilateral micro-
injection of  2 μg/μl Aβ 
(1-42) oligomers/ 
female Wistar rat 
 
24h and 
72h 
IC analysis revealed an intense Aβ 
immunoreactivity in cortical cells, 
particularly in frontal and temporal 
cortices at 24 h,  hippocampus and other 
cortical areas, increasing at 72 h. 
Activation of astrocytes was also 
observed in a time-dependent manner 
(Perez et al., 2010) 
 
Hippocampus 
 
bilateral injections of  
10μg/2μl Aβ (1-42)/ 
male Wistar albino rat 
 
10 days 
Glutathione levels were significantly 
increased in temporal cortex and BF 
while malondialdehyde and NO levels 
were increased in temporal cortex and 
BF but without statistical significance 
(Cetin and Dincer, 2007). 
 
dorsal 
Hippocampus 
6-8 days of bilateral 
injections of 200pM 
Aβ(1-42)/Avertin 
mouse 
 
4 days 
Picomolar concentrations of Aβ (1-42) 
enhance LTP, whereas high nanomolar 
concentrations reduce hippocampal-
dependent memory (Puzzo et al., 2008) 
 
Medial Septum 
Single injection 2 μg/μl 
Aβ (1-40) oligomers/ 
male Sprague Dawley 
rat 
 
7 days 
57% decrease in cholinergic and 53% 
drop in glutamatergic neurons were 
reported with 49% reduction in 
hippocampal theta rhythm (Colm et al., 
2010) 
 
Cerebral 
ventricle 
Continuous 3 days 
infusion of Aβ (1–42) 
10, 20 μg/ male Fischer 
rat. 
 
3 days 
Dose-dependent and a time-dependent 
impairment in spatial working memory 
and spatial reference memory as well as 
in non-spatial long-term memory. The 
reduction in ChAT activity up to 85 days 
was observed in hippocampus and 
striatum (Nakamura et al., 2001). 
 
Table 4. Chemically- induced AD model - successful attempts of Aβ injections into the rodents’ brain  
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However, lack of significant differences between the Aβ peptide and the vehicle 
control injections were also reported in rodents’ brain (Games et al., 1992; Stein-
Behrens et al., 1992) with conclusions that simple intraparenchymal injection of Aβ 
is not an appropriate model of AD-related neurotoxicity. Similar negative results 
were also found in adult rhesus monkeys (Podlisny et al., 1993).  
Other pharmacological approaches have also been utilized in creating animal models, 
which reflect AD pathology. The mostly known is scopolamine-induced amnesia 
(Ebert and Kirch, 1998), which increased knowledge about the role of cholinergic 
system in cognition. Scopolamine is a tropane alkaloid drug with muscarinic 
antagonist effects (Rush, 1988), but blocking of both muscarinic and nicotinic 
receptors has given even better results (Levin et al., 1990).  
A number of lesion models for studying AD pathology have also been developed. 
These lesions are performed in different brain structures, depending on the objective 
of the study (Gray and McNaughton, 1983; Glenn et al., 2003; Sloan et al., 2006; 
Castañé et al., 2010). They include quinolic, kainic, N-methyl-D-aspartic, ibotenic 
and quisqualic acids lesions (Page et al., 1993; Morimoto et al., 1998; Guillemin and 
Brew, 2002; Zheng et al., 2011; Toledana and Alvarez, 2010). The immunotoxins 
like cholinotoxin AF64 (Männistö et al., 1994), and the immunotoxin 192 IgG-
saporin (192 IgG-SAP) have been also used with the latter ribosome-inactivating and 
specific for cells expressing p75
NTR 
(Schliebs et al., 1996). Intraventricular injection 
of 192-IgG-SAP results in almost complete elimination of p75
NTR
-positive cells in 
MSDB, nucleus basalis of Meynert, and Purkinje neurons of the cerebellum in rat 
(Wiley et al., 1991 and 2001). It provides researchers with a powerful tool - more 
specific and effective than chemical, surgical or electrolytic lesions. 192-IgG-SAP 
eliminates cholinergic cells, while sparing neighbouring neurons. The damage is not 
only selective but also permanent, what makes it an important animal model for 
study the plasticity, behavior, neuronal loss and other systems’ responses. It is also 
important for replacement therapy and drug effects preclinical testing. Some other 
chemically-induced AD models utilize endotoxins, like lipopolysaccharide (Hauss-
Wegrzyniak et al., 1998) or proinflammatory cytokines (Wenk et al., 2003) to study 
brain inflammation or other specific pathophysiological pathways e.g. glucose 
metabolism in neurodegeneration. 
The aim of this chapter was to create AD model in rat useful for testing potential 
neurotherapeutics protecting BFCNs against damage of Aβ during the disease. 
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3.2. Brain structures involved in learning and memory – a Nissl staining study 
in the rat brain 
 
Brain structures involved in learning and memory and affected by AD (Introduction, 
Chapter 1.4.) were visualised with Nissl staining of coronal sections (50 µM) from 
rat brain with cresyl violet acetate (Materials and Methods, Chapter 2.1.9.). The MS 
area of BF with vertical and horizontal limbs of diagonal bands of Broca (HDB and 
VBD) were labelled (Figure 16A). Additionally, the myelin rich structures such as 
anterior commissures (AC) were strongly stained (Figure 16A). The single neurons 
of BF were visible together with Nissl granules (negatively charged RNA in blue) on 
enlarged photos of HDB area (Figure 16B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure16. Nissl staining of rat brain areas involved in learning and memory. A. BF coronal 
section; AC - anterior comissure; MS – medial septum; HDB – horizontal limbs of Broca; VDB – 
vertical limbs of Broca. B. Enlarged HDB area with visible  Nissl granules. C. Hippocampal 
formation: DG – dentate gyrus; CA1, CA2, CA3 – Cornu Ammonis areas 1,2,3. D. Schematic 
representation of connections between parts involved in learning and memory (Schultz et al., 
1998). EC – enthorinal cortex; CA1, CA3 areas; DG – dentate gyrus; MF – mossy fibres; PP – 
prefrontal fibres; SC – Schaffer collaterals; SHP – septo-hippocampal pathway 
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Structural parts of the hippocampus, which play a role in the formation and storage 
of new memories (Scoville and Milner, 1957; Bliss and Collingridge, 1993) were 
also distinguished and marked on the Figure 16C. The pronounced hippocampal 
atrophy occurs in AD (Pennanen, 2004; Lazarow, 2010). CA1 and CA3 pyramidal 
neurons are more vulnerable in the disease than dentate gyrus granule neurons. This 
differential neuronal vulnerability might be explained, in part, by the fact that dentate 
granule neurons express high concentrations of the neuroprotective Ca
2+ 
binding 
protein - calbindin, whereas pyramidal neurons contain little or none (Mattson et al., 
1991). 
Additional schematic shown on Figure 16D (Schultz et al., 1998) explains the 
connections of these areas. Briefly, the entorhinal cortex (EC) serves as a gateway 
for all neocortical inputs to the hippocampus and sends perforant pathway fibres (PP) 
to the dentate gyrus (DG) and CA3 hippocampal areas, from where DG granule 
mossy fibres (MF) project to CA3 pyramidal cells that develop axons to CA3 and to 
CA1 areas through the Schaffer collaterals (SC). CA1 pyramidal cells project back to 
layer V of EC and to the subicular complex (not depicted on this Figure). The septum 
and the hippocampus are heavily interconnected through the fimbria-fornix and are 
functionally coupled (Bland and Colom, 1993), with projections connecting these 
key limbic structures referred further in this work as the septo-hippocampal pathway 
(SHP). Principal cells of DG, CA3 and CA1 receive cholinergic input via the SHP. 
This pathway is the main source of ACh important for memory encoding, retrieval 
and consolidation (Introduction, Chapter 1.5.3.2.). Other connections (not depicted in 
the Figure 16D) can enhance memory consolidation e.g. amygdala in relation to 
stress and emotionality associated with experience (Hadad-Ophir, 2014). 
Obviously, the anatomy of the above connections does not fully explain the 
complexity of signals influencing learning and memory. Aminergic neurotransmitters 
with diffuse neuromodulatory system (Introduction, Chapters 1.5.6.) should be taken 
into account while considering memory processes and AD pathology. 
 
3.2.1. BFCNs distinguished from non-cholinergic neurons 
 
BFCNs were visualised on coronal sections containing BF area and distinguished 
from non-cholinergic neurons (Figure 17) with use of specific markers described in 
Introduction Chapters 1.5.3.2. and 1.5.4. 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Characterisation of BF population with reference to BFCNs. A. Fragment of coronal 
section from Paxinos and Watson rat brain atlas (1998). BF area is highlighted within the red square. 
MS – medial septum; HDB - horizontal limbs of diagonal bands of Broca; VDB - vertical limbs of 
diagonal bands of Broca, LSV – lateral septal nucleus. B. MSDB area double labelled with anti-
ChAT IgG (green) and anti-parvalbumin IgG (red). C. Double labelling of the same area with anti-
ChaT IgG (green) and anti-calbindin IgG (red). Arrows point to calbindin positive cells – CALB (+) 
and arrow heads to ChAT positive cells – ChAT (+). D. Enlarged region from picture B showing 
lack of co-localization for ChAT and parvalbumin expressing cells. Arrows point to parvalbumin 
positive cells - PV (+) and arrow heads to ChAT positive cells - ChAT (+). E. Counts of cholinergic 
neurons versus non-cholinergic cells stained with calbindin (E) and parvalbumin (F). 
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Double stainings with anti-ChAT and anti-parvalbumin or anti-calbindin antibodies 
were utilized in these experiments (Materials and Methods, Chapter 2.1.6 and 2.1.7).  
ChAT and calbindin positive cells were counted in MSDB area (Figure 17A) on 
slices taken from brains of 21 days old Sprague-Dawley rats (n=3), also parvalbumin 
cells were counted in the same area on slices from 21 days old rats of the same strain 
(n=3) (Figure 17B). Double fluorescence labelling with ChAT/calbindin or 
ChAT/parvalbumin is shown on the enlarged areas Figure 17C and 17D. It has 
revealed that parvalbumin- or calbindin- containing non-cholinergic neurons do not 
co-localize with ChAT positive cells in MSDB area and follow different distribution 
patterns. They were usually detected more laterally than cholinergic neurons and had 
tendency to become smaller caudally. From analysis of cell number almost equal 
amount of ChAT and parvalbumin positive neurons were counted (Figure 17F) (7 
slices) (n=177 and n=178), which is in the agreement with previously reported data 
(Gritti et al., 2006). Calbindin-positive cells were much smaller than parvalbumin 
containing neurons and their number much exceeded the amount of ChAT positive 
cells (Figure 17E) (5 slices) (n= 352 and n=206 respectively). Calcium binding 
proteins are known for their protective role in BF (Lacopino et al., 1994). Loss of 
their Ca
2+
 buffering properties were postulated to leave the neurons vulnerable to 
damage in neurodegenerative disorders (Geula et al., 2003) and these findings were 
recently confirmed for calbindin (Kook et al., 2014). Selective loss of this protein 
from BF or DG was earlier reported in the aged and AD brains (Wu and Geula 1997, 
Palop et al., 2003). Also depletion of parvalbumin from EC and certain hippocampal 
regions (CA1, CA2, DG) is known while other hippocampal subfields (CA3) remain 
less sensitive (Brady and Mufson, 1997). In contrast to calbindin, parvalbumin 
immunoreactive cells are reduced only after substantial loss of projection neurons in 
AD diseased brain (Solodkin et al., 1996).  
 
3.3. BFCNs revealed strong enrichment with p75
NTR 
(+) cells in MSDB region
 
 
Pre-labelling of BFCNs was performed by unilateral icv injection of 192-IgG-Cy3 (5 
µl of 0.4 mg/ml) (Materials and Methods, Chapter 2.1.5.1.) of 21 days old rats (n=3), 
according to the stereotactic coordinates as follows: AP = -0.8 mm, ML = 1.2 mm, 
DV = 3 mm. The injection coordinates were optimised using Coomassie blue dye as 
shown on Figure 18A and B. 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
48-72h after injections, rats were perfused (Materials and Methods, Chapter  2.1.3.) 
and coronal sections (35 μm), containing BF nuclei were cut according to the rat 
brain atlas (Paxinos and Watson, 1998). The slices were kept in PBS pH 7.4 in 
darkness, mounted, air dried and coverslipped for viewing. Robust staining was 
visible in MSDB areas of the injected and contralateral sides (Figure 19A). The 
higher magnification revealed punctate pattern in the cell bodies (Figure 19B) and 
processes (Figure 19C), which is in agreement with the uptake and accumulation of 
192-IgG-Cy3 within endosomes (Härtig  et al., 1998; Kacza et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Quality control of icv injection 
with Coomasie blue dye. A. Ipsilateral side 
injected to the lateral ventricle (Br -0.8 
mm, L 1.2 mm, D 3 mm) with Coomasie 
blue dye. Arrow point to the needle track. 
B. Contralateral side. CA1, CA3 - Cornu 
Ammonis areas 1,3; CC – Corpus 
Callosum; DG – dentate gyrus; FX – 
fornix; LV – lateral ventricle. 
Figure 19. Cholinergic neurons of MSDB area pre-labelled with 192-IgG-Cy3. A. Enlarged area of 
DBB area stained with 192-IgG-Cy3. C. Single cholinergic cell – punctate staining observed in cell 
bodies and neurites after 192-IgG-Cy3 icv injection. 
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The same slices were then also stained for ChAT (Figure 20), according to the 
protocol (Materials and Methods, Chapters 2.1.6.and 2.1.7.) and the number of cells 
that co-localize both markers was counted (Materials and Methods, Chapter 2.2.2.)   
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Double immuno-staining of ChAT positive neurons with 192-IgG-Cy3 confirmed the 
exclusive expression of p75
NTR
 in the cholinergic population. The vast majority of 
ChAT positive neurons in MSDB were labelled with 192-IgG-Cy3 (97.4±1.9%) and 
vice versa, almost all 192-Cy3 cells were labelled for ChAT (98.7±1.1%). The 
results mean that with no exception, all 192-IgG-Cy3 (+) cells were immuno-reactive 
for ChAT but small fraction of ChAT (+) cells did not show 192-IgG-Cy3 labelling.  
Figure 20. Double labelling of BFCNs with reference to p75
NTR
. A. Cholinergic neurons of DBB area 
pre-labelled with 192-IgG-Cy3 in vivo. B. Same field co-stained for ChAT. C. Merged image - double 
labelling in DBB area with exception of vascular elements stained with 192-IgG-Cy3only (arrows). D. 
Plots indicating the percentage of co-labelled ChAT positive cells with 192-IgG-Cy3 and vice versa 
[The total population of cells (n=297) is taken as 100% (white bars)]. E. Enlarged view of MS area - 
cholinergic cells pre stained in vivo with 192-IgG-Cy3 (E) and co-stained with ChAT (F) as shown in 
the merged area (G). 
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3.4. BF cholinergic markers profile quantified by WB  
 
Cholinergic neuronal markers of BF are connected to the production, metabolism and 
transport of ACh (Introduction, Chapter 1.5.3.2.) and the level of these markers is 
significantly decreased during the course of AD (Quirion, 1993). Controversy 
persists over the changes in specific marker for cholinergic neurons – p75NTR with 
some research indicating increase of its level during aging and AD (Hu et al., 2002; 
Mufson and Kordower, 1992), while others suggesting its significant reduction 
(Salehi, 2000) or no difference in expression of p75
NTR
 in the diseased brain 
(Ginsberg et al., 2006). I isolated rats’ brains (Materials and Methods, Chapter 2.3.1.) 
and optimized antibodies dilution and protein load for the detection of ChAT, AChE, 
VaChT, p75
NTR
 in BF area as well as [Beta III tubulin, CNPase (myelin associated 
enzyme), Snap25] that served as internal WB controls (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Optimized detection of cholinergic markers from rat brain. A. Example of ChAT 
detection from BF. Different protein loads are indicated. Molecular marker values (in kDa) are 
shown on the right side of WB. B. Detected bands for other proteins specific for BFCNs and internal 
controls. Lanes 1, 2, 3 reflect various protein loading (30, 20, 10 ng, respectively). C. Optimised 
antibodies dilution for the detection of cholinergic markers in BF by WB. D. Optimised antibodies 
dilution for detection of internal control proteins. 
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Molecular weights of these proteins were assigned using semi log plot (Gene Tool 
programme from SynGene) that compares sizes of the detected bands to the 
molecular marker (161-0373, BioRad) and automatically measures the intensity. 
These data were then exported to Excel for further analysis (Figure 22B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 22. Quantitative analysis of cholinergic markers in BF. A. WB for ChAT/CNP. Lanes 1,2,3 
show same protein load (20 ng) from BF of 3 rats. B. Example of semi log plot measurement in Gene 
Tool programme (Syn Gene). C. Quantification of ChAT level in MSDB. D. Quantification of ChAT 
level in hippocampus. E. Proportions of cholinergic markers in BF. 
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3.5. Chemical induction of AD in a rat model 
 
Since Aβ is known to be neuro-toxic in vitro, it has been also applied in vivo by icv 
injections or local injections into defined brain structures (Chapter 2.8.). While the 
first approach has been used to study general effects, the second was utilized to 
determine Aβ effects on specific neuronal populations. Since the primary goal of this 
study was to obtain research platform to study AD, chemically-induced rat model 
was proposed. Local injections of oAβ preparation (Chapter 3.5.1.) to MS and its 
projecting areas: hippocampus (H) and prefrontal cortex (PC) were performed. The 
experiments were conducted according to the following plan (Table 5). 
 
 
All samples were analysed 2 weeks after icv injections. In all cases WB for ChAT 
versus control protein were performed (example Figure 23A and B) and analysed as 
previously described in (Materials and Methods, Chapter 2.3.2.). Bradford protein 
assay was conducted before loading of samples on polyacrylamide gel. 
 
 
 
 
 
 
 
 
 
 
 
 
Place of injection Concentration of oAβ (1-42) 
preparation (Chapter 3.4) 
Number of 
rats 
processing 
Medial Septum  3 nmol 5 IC and WB 
Hippocampus 3 nmol 3 WB 
Lateral ventricle 3 nmol 3 WB 
Lateral ventricle 6 nmol 5 IC and WB 
 
 
Figure 23. WB analysis of Aβ induced rat model of AD. Blue frame contains ChAT bands for saline 
injected rats while green frame include much weaker ChaT bands after oAβ injection. CNP (48 kDa) 
serves as internal WB control. Molecular weight of protein marker are given on the right side.  
150 
100 
75 
 
 
50 
 
37 
 
 
 
25 
 
20 
 
 
15 
 
 
10 
 
 
Table 5. Experimental plan of Aβ chemical induction for rat model of AD. 
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3.5.1. Preparation and analysis of Aβ oligomers for induction of AD in rat  
 
Aβ oligomers (oAβ) were prepared from Aβ (1-42) peptide (73537, AnaSpec) 
according to the previously described methods (Dahlgren et al., 2002). Standard 
quality control analysis was performed with every new lot of this peptide. Samples 
were diluted in NuPage sample buffer and separated by SDS-PAGE on a 12% 
NuPage Bis-Tris gel (NP0342PK2 , Life Tech). Coomasie blue staining was used to 
visualize Aβ oligomers on the gels, which were scanned using imaging and analysis 
system G: BOX from SynGene and GeneTool programme (Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this way, mix of Aβ peptides comparable to Aβ oligomers previously reported in 
literature has been achieved (Dahlgren et al., 2002). The aggregation state of Aβ 
peptides was crucial for further experiments in which these proteins were injected 
into the rat’s brain or applied to primary BF cultures in vitro. Aβ oligomers are most 
neurotoxic variants (Walsh and Selkoe, 2007) correlating highly with hallmarks of 
AD (McLean et al., 1999). However, Aβ preparations may differ in stability, 
enrichment of different sized oligomers and most importantly reproducibility, despite 
using the consistent protocol. Therefore, each new batch of oAβ aggregates should 
be tested before an experimental application.    
 
Figure 24. Quality control analysis of the created Aβ oligomers. A. Sizes of individual bands are 
assigned by semi-log plot in Gene Tool programme from SynGene compared to protein standard (Bio 
Rad). B. Enlarged area from picture A (left side), L-fragment of  protein standard (BioRad), Aβ  - 
oligomers experimentally achieved. The gel is compared to WB reported by Dahlgren et al., 2002 
(right side) where lane 1 – shows Aβ oligomers, lane 2 -. Aβ fibrils separated by SDS-PAGE on a 
12% NuPage Bis-Tris gel and probed with monoclonal antibody 6E10. 
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3.5.2. Reduction of cholinergic markers in septo-hippocampal pathway (SHP) 
and prefrontal cortex (PC) after injections of oAβ  
 
Local icv injections of oAβ (prepared as in Chapter 3.5.1.) to MS and hippocampus 
(H) of wild type rats revealed reductions in ChAT protein level in all areas of 
cholinergic innervation that were subject to the study as compared to saline injected 
control rats (Figure 25A-F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Local injection of oAβ mix to MS (3 μl, 0.1 mg/ml) show 47.58 % decrease of ChAT 
in BF samples (p=0.003) (Figure 25A), lowering ChAT up to 36.58 % and 22.38 % 
in hippocampus and prefrontal cortex (PC) areas (p=0.0008; p=0.02) (Figure 25B 
and C) as compared to controls. Same amount of oAβ mix injected to the 
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Figure 25. Reduction of ChAT level in SHP and PC after oAβ local injections (3 nmol) to MS and 
hippocampus as compared to saline injected controls. CNP serves as internal control of WB. Colour 
code: saline injected controls (blue), MS samples (red), H samples (violet), PC samples (green). 
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hippocampus revealed largest 42.04 % decline of ChAT in H samples (p=0.0006) 
(Figure 25E) while MS and PC tissue show smaller decrease  of ChAT (20.16 % and 
26.74 % respectively, p=0.04 and p=0.0004) (Figure 25D and F, respectively). The 
reductions of ChAT were also observed in MS, H and PC areas after injections of 
oAβ mix (3 μl, 0.1 mg/ml) into the lateral ventricle as compared to saline injected 
control rats (Figure 26A-C) with even bigger drop of ChAT achieved with repeated 
injections of oAβ mix to lateral ventricle (6 nmol in total) (Figure 26D-F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As illustrated in histograms significant loss of ChAT has occurred in BF tissue as 
compared to saline injected controls: 37.49 % (p=0.003) (Figure 26A), 31.36 % 
(p=0.0007) in hippocampus (Figure 26B) and 24.79 % (p=0.004) in PC (Figure 26 
C). Loss of ChAT was increased with second injection of the same oAβ amount of (6 
Figure 26. Reduction of  ChAT level in SHP and PC after oAβ icv injections (3 nmol and 6 nmol) as 
compared to saline injected controls. CNP serves as internal control of WB. Colour code: saline 
injected control rats (blue), MS samples (red), H samples (violet), PC samples (green).             
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nmol in total) and caused 44.48% drop of ChAT in BF (p=0.0003) (Figure 26D); 
36.56% fall in hippocampus (p=0.0006) (Figure 26E) and diminish ChAT protein in 
PC up to 27.83% (p=0.0004) (Figure 26F). Summary of the reduction in ChAT level 
induced by local and icv injections of oAβ mix are shown in the Table 6. 
 
 
 
Overall, these results suggest that rats, subjected to oAβ injections suffered from 
progressive cholinergic dysfunction making this model useful for evaluating the 
effects of the integrity of cholinergic innervations under the deposition of Aβ in AD.  
 
3.5.3. Non significant cholinergic cell loss in oAβ induced AD model  
 
Despite the considerable reductions in ChAT level throughout the brain, the number 
of cholinergic neurons in MSDB area did not change significantly (p=0.97), 2 weeks 
post oAβ icv injections (Figure 27B) as compared to saline injected control rats 
(Figure 27A) (n=3 rats for each group). However, the decrease in cell number was 
observed as damage of 13.5% of cholinergic neuronal population (stained with anti-
ChAT IgG) while sparing GABAergic neuronal population (labelled with anti-
parvalbumin IgG). Saline control injections has confirmed that cholinergic cell loss 
was specific to oAβ not to the transitory injuries. 
 
 
 
 
 
 
 
 
Injection place BF samples H samples PC samples 
local to MS 47.58 ± 0.93% 36.58 ± 0.58% 22.38 ± 0.5% 
local to H 20.16 ± 0.59% 42.02 ± 0.15% 26.74 ±0.74% 
Lateral ventricle 37.49 ± 1.75% 31.36 ± 0.4% 24.79 ± 0.56% 
Lateral ventricle 44.48 ± 0.18% 36.56 ± 1.16% 27.83 ±0.23% 
Figure 27. Loss of cholinergic neurons in MSDB area in chemically-induced rat AD model. A. 
Number of ChAT (green bars) and parvalbumin (red bars) positive cells after saline icv injection that 
served as control for this experiment. B. ChAT and parvalbumin cell number after oAβ icv (3 nmol). 
Table 6. Summary effect of local and icv injections of oAβ in different brain areas. The table 
include results shown as % drop in ChAT level versus saline injected controls. 
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3.5.4. Oligomeric Aβ damaged cholinergic synapses in the rat AD model  
 
Synaptic plasticity is crucial for the process of learning and memory formation, with  
synaptotoxicity involved in the early stages of AD. The number of damaged synapses 
correlates better with the level of memory impairment in AD patients as compared to 
the number of senile plaques or NFTs (Introduction Chapter, 1.4). Therefore, the 
density of cholinergic synapse was estimated in brain slices of Aβ-induced AD 
model (Chapter 3.5.3.) with use of vesicular acetylcholine transporter (VAChT) 
immunostaining (Figure 28A and B). VAChT is a transmembrane protein associated 
with synaptic vesicles in the cholinergic nerve terminals and responsible for the 
refilling of ACh in synaptic vesicles, making it available for synaptic release. This 
process is driven by proton exchange mechanism whereby 2 protons (transported into 
the vesicle from the cytoplasm by vacuolar ATPase) are exchanged for one molecule 
of acetylcholine and it is coupled to VAChT mediated transport of ACh into the 
synaptic vesicles located in the terminals (Roghani et al., 1994). In the present study 
the density of cholinergic terminals was measured in CA1, CA3 and DG of 
hippocampus and compared to saline injected controls (n=3 rats per each group). 
 
 
 
 
 
 
 
 
 
 
 
. 
 
The highest density of VaChT positive fibers was found in CA3/DG of controlled 
rats, which is in line with literature (Aznavour et al., 2002). The effect of 3 nmol Aβ 
icv injection on VaChT fibers in various hippocampal regions is illustrated below 
(Figure 29) . 
 
Figure 28. VAChT immunocytochemistry on hippocampal slices (example). A. Punctate staining of 
cholinergic synapses visualised with anti-VAChT IgG (AB1588 Millipore, 1:500) and developed with 
goat anti guinea pig Alexa 594 IgG (A-11076, LifeTech.1:1000). B 3D image of staining hippocampal 
slice with VAChT. 
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Figure 29. Quantification of cholinergic synapse loss in hippocampal formation after oAβ icv 
injection. A. 29.23 % loss of cholinergic fibers in CA1 area. B. 25.75% drop in cholinergic fibers 
density of CA3 area. C. 25.75% damage of cholinergic innervation in hilus of DG. D.16.68 % fall of 
VAChT staining in the tip of DG. All values are compared to saline injected rats. (n=6 represent 
number of brain slices in which the synapse density was measured, averaged from 3 different rats) 
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The loss of cholinergic synapse was significant already after 3 nmol of oAβ icv 
injection as revealed by VAChT immuno-cytochemistry with comparable p values = 
0.008 in CA1 and CA3 areas giving 29.23 % and 25.75 % of cholinergic fibers loss 
(Figures 29A, B) respectively. The other significant values were achieved in hillus 
and tip of DG (p=0.02; p=0.05, respectively), corresponding to 25.75% and 16.68% 
loss of cholinergic fibers in these areas (Figures 29C, D).  
 
3.5.5. Distribution of HiLyte Fluor 488 labelled Aβ (1-42) signal in the forebrain 
after icv injections  
 
Aβ (1-42) is known to be the most toxic fragment of peptides generated from APP 
cleavage (Introduction Chapter, 1.5.1.1.). I monitored the spread of HiLyte Fluor 488 
labelled Aβ (1-42) (Materials and Methods, 2.1.5.1.) after bilateral icv injections of 
2-5 μl (1mg/ml) into the rat brain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The bulk of the signal was observed in the ventral pallidum that lies within the 
substantia innominata of BF (Introduction Chapter, 1.5.3.1.) and receives efferent 
connections from the ventral striatum (the nucleus accumbens and the olfactory 
tubercle). It projects to the dorso-medial nucleus of the dorsal thalamus, which, in 
turn, projects to the prefrontal cortex. It also projects to the pedunculopontine 
nucleus and tegmental motor areas. 
 
Figure 30. The effect of bilateral Alexa 488 Aβ (1-42) icv injection. A. Signal observed in ventral 
pallidum. B. Needle track. C. enlarged image of cell stained with Aβ (1-42) labelled with Alexa 488. 
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3.5.6. Selective loss of MSDB neurons after lesion with 192-IgG-SAP  
 
192-IgG-SAP provided more specific cholinergic lesions in BF than oAβ. This 
immunotoxin consists of the monoclonal antibody 192 IgG coupled through 
disulphide-bond to saporine, the ribosome-inactivating protein derived from the plant 
Saponaria officinalis. The antibody component is directed against rat low-affinity 
p75
NTR
, which ensures the specificity of this toxin to cholinergic cells (Book et al., 
1994; Schliebs et al., 1996). Following receptor binding and internalization, saporin 
enzymatically inactivates the large ribosomal subunit, blocking protein synthesis and 
ultimately resulting in cell death. The irreversible neurodegenerative process can be 
considered as completed in about 2 weeks. Therefore I injected 2.5 μg /ml of 192-
IgG-SAP into the lateral ventricle of 21 days old rats (stereotactic coordinates: AP = 
-0.8 mm, ML = 1.0 mm, DV = 2.5 mm) and perfused them 2 weeks post-injection. 
The brains were processed with anti-ChAT-HRP staining (Materials and Methods 
Chapter 2.1.6.) and cell number counted versus age-matched controls (Figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant loss of cholinergic cells expressing p75
NTR
 (p=0.0002) corresponding to 
57.78% was observed in MSDB area in rat. This is in agreement with previously 
reported data (Schliebs et al., 1996; Szigeti et al., 2013), thus providing very robust 
and reproducible rat model of AD that is quite quick to achieve.  
  
   
 
*p= 0,0002 
 
Figure 31. The effect of 192-IgG-SAP lesion on BFCNs in MSDB area. A. MS area of BF stained 
with anti-ChAT IgG developed with HRP (control rat). B. Same area after 2 weeks from 192-IgG-
SAP injection. C. Enlarged cholinergic cells stained with ChAT-HRP. D. Plot of cholinergic cell 
number neurons before and after icv injection of 192-IgG-SAP. 
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3.5.6.1. 192-IgG-SAP lesion of cholinergic neurons increases Aβ (1-42) load in 
cortex and hippocampus  
 
Lesion of cholinergic neurons was performed with 192-IgG-SAP as previously 
described in Chapter 3.5.6. Two weeks after the injection, the experimental and 
control samples (from saline injected rats) were collected and checked for the 
presence of cholinergic cells in MSDB area with anti-ChAT staining Materials and 
Methods, Chapter 2.1.6.) (Figure 32A and B). Same slices were  then stained with 
anti-Aβ IgG (55922, AnaSpec), which is able to label core of amyloid plaques and 
diffused Aβ (1-42). The results show presence of astrocyte-shaped cells in the cortex 
(Figure 32D) as compared with saline injected controls (Figure 32C). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 32. Lesion of cholinergic neurons increase Aβ (1-42) load in cerebral cortex. A. MSDB area of 
BF with cholinergic cell bodies labeled with ChAT (control rat). B. ChAT staining of MSDB area 2 
weeks after 192-IgG-SAP icv injection. C. Immuno-histochemistry for Aβ (1-42) in the cortex 2 
weeks after saline icv injections. D. The effect of 192-IgG-SAP icv injections on Aβ (1-42) load after 
2 weeks. Arrow heads point to astrocyte-shaped cells. 
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Similar changes were observed 2 weeks after 192-IgG-SAP icv injections (2.5 μg/μl) 
in all hippocampal regions (Figure 33B, D) as compared to saline icv injected control 
rats (Figure 33A, C). Interestingly, on enlarged photos of hippocampal areas, Aβ (1-
42) staining was visible in neurons of saline injected rats (Figure 33E) or astrocyte-
shaped cells of 192-IgG-SAP injected rats (Figure 33F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 33. Lesion of cholinergic neurons increase Aβ (1-42) load in hippocampus. A. Aβ (1-42) IC of 
DG (saline injected rats). B. Aβ (1-42) IC of DG (192-IgG-SAP injected rats). C. CA1 stained with 
Aβ (1-42) in saline injected rats compared to same area in 192-IgG-SAP injected rats in D. Arrows 
point to astrocyte-shaped cells. E. Closer view on neurons (CA2) in control samples versus astrocyte 
–shaped cells in experimental samples F. 
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3.6. Discussion of the results achieved with AD rat models  
 
The cholinergic system of rat BF was used as a model for the homologous region in 
humans. The structures involved in learning and memory were distinguished 
(Chapter 3.2.) and stayed in agreement with previously published literature. This part 
of the brain is highly susceptible to neuropathological changes occurring in AD 
(reviewed in Chapter 1.4.). Immuno-histochemical techniques were implemented in 
the first part of this study to visualize and count neurons of rat BF. BFCNs were 
marked with anti-ChAT antibodies and coronal forebrain sections containing MS and 
DBB were imaged. In line with published literature ChAT positive cells occupied 
lateral areas of MS, while in DBB resided predominantly in the medioventral 
portions. Labelling of cholinergic neurons was confirmed with 192-IgG-Cy3 
antibody characterised in Chapter 2.1.5.1. However, not all cholinergic cells were 
stained for both markers (ChAT and p75
NTR
). 192-IgG-Cy3 did not label all ChAT 
positive profiles in caudal nuclei of BF due to the fact that not all cholinergic neurons 
there express p75
NTR
, which agrees with the previous data (Ferreira et al., 2001). To 
distinguish cholinergic from non-cholinergic cells, the latter were stained with 
calbidin or anti-parvalbumin antibody and show similar profiles to the already 
reported in literature. Results of these stainings were acknowledge in publication 
(Ovsepian et al., 2012). Cholinergic and non-cholinergic neurons were counted in 
healthy rats. The aim of these experiments were to establish a reference point of 
cholinergic cell loss for further induction of AD model in rats. Cholinergic cells are 
susceptible to damage during neuropathological changes occurring in AD (reviewed 
in Chapter 1.4. and 1.5.3.), while non-cholinergic neurons remain more resistant to 
the disease processes (Solodkin, 1996). Similarly, the level of key cholinergic 
markers was measured (Chapter 3.4). Same experiments were conducted for rats icv 
injected with Aβ oligomers (prepared as in Chapter 3.5.1.) in chemically-induced AD 
rat model. Aβ is believed to be a primary factor in the pathogenic pathway leading to 
AD, according to the amyloid cascade hypothesis (reviewed in Chapter 1.5.1.). 
Decrease in ChAT-protein in septo-hippocampal pathway as well as in prefrontal 
cortex was confirmed in this model (Chapter 3.5.2.). However, the reduction of 
ChAT protein was not reflected by the cholinergic cell bodies loss in MSDB areas. 
These data although seem to be conflicting, remain in agreement with previous 
research suggesting that senile impairment of the cholinergic system in rats manifests 
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in decrease of ChAT-protein expression (perhaps due to loss of cholinergic synapses 
and axons in the cerebral cortex) rather than an acute degeneration of neuronal cell 
bodies (Niewiadomska et al., 2000). This also confirm that loss of neurons happens 
in later stages of the disease, which is in line with the previous literature (Glimor et 
al., 1999; Schliebs and Arendt, 2006). Thus injections of oAβ into the lateral 
ventricle confirmed the induction of early AD model in rats as they caused 
significant cholinergic synapse loss in BF, prefrontal cortex and hippocampus, 
visualised by VAChT immuno-histochemistry of hippocampal area (Chapter 3.5.4.). 
Cholinergic synapse loss is known to correlate best with the severity of dementia 
(DeKosky and Scheff, 1990) thus making this model highly valuable for further 
applications. 
In regards to the local injections of oAβ to MS and hippocampus these resulted in 
more profound decline in ChAT protein level in the injected areas, with the diffusing 
effect along nerve terminals. These seem to be similar to the effects of oAβ seeding 
and spread of misfolded protein (Harper and Lansbury, 1997; Kane et al., 2000; 
Riddley et al., 2006; Rosen et al., 2012). However, although very interesting, this 
results were not exploited in further details in terms of cell or synapse counts in the 
affected structures, due to time limitation.  
Cholinergic cell bodies were completely abolished within 2 weeks post injection of 
192-IgG-SAP directed specifically towards p75
NTR
, selectively expressed by BFCNs 
(Chapter 3.5.6.). Interestingly, this model stained with anti-Aβ (1-42) IgG showed an 
increase in the deposition of Aβ (1-42) in cortex and hippocampal areas, with Aβ 
staining seen mainly in astrocyte-shaped cells (Chapter 3.5.6.1.). Interestingly, the 
increased number of astrocytes and microglia was also observed in demented 
individuals with AD as compared to controls (Perez-Nievas et al., 2013), however, 
whether or not astrocyte activation substantially contributes to structural damage and 
impaired cognition in AD remains unknown. This result however stays in agreement 
with recent in vivo work on transgenic mice, similarly lysed with cholinergic 
immunotoxin mu-p75-saporin. These show the increase in number of amyloid plaque 
load in hippocampus and prefrontal cortex as well as elevated levels of tau and 
phospho-tau (Laursen et al., 2013; Härtig et al., 2014). Deposition of Aβ around 
cerebral blood vessels after lesion of cholinergic neurons with anti-p75 IgG 
conjugated with saporin was also found in the earlier studies in rabbits (Roher et al., 
2000). In humans, AD brain autopsies also support topographic overlap between the 
99 
 
areas undergoing extensive loss of cholinergic projections and those with Aβ load 
(Davies and Maloney, 1976; Geula et al., 1998). 
The depositions of Aβ after cholinergic cells loss suggest a new role of BF 
cholinergic system in Aβ clerance, beyond normal function of BFCNs for ACh 
supply to the targeted brain areas (reviewed in Chapter 1.5.3.2.). This idea was also 
discussed I the recent publication (Ovsepian et al., 2016).  
Additional icv injections of HiLyte Fluor Alexa 488 Aβ (1-42) were performed to 
verify this process (Chapter 3.5.5.). Quite unexpectedly the injected amount of 
HiLyte Fluor Alexa 488 Aβ (1-42)  did not show labelling of MSDB area (Chapter 
3.5.5.). The signal was visible instead in other BF regions e.g. ventral pallidum. This 
result can be interpreted in favour of the above hypothesis suggesting the preferential 
role of neurons in Ch1-Ch3 areas for Aβ clearance (Chapter 1.5.3.1.). These cells are 
known to be enriched in p75
NTR
. However, binding of Aβ (1-42) can also possibly 
occur by other multiple receptors suggested by the literature e.g. metabotropic 
glutamate, nicotinic, muscarinic, insulin growth factor receptors (Patel and 
Jhamandas, 2012). Therefore further research is needed to decipher the mechanisms 
that underlie possible Aβ clearance by BF cholinergic cells. These mechanism may 
also explain high vulnerability of cholinergic system to deleterious Aβ effects in AD. 
Mu p75-saporin Tg2576 mice model was recently proposed as a new tool to study 
the interrelations between cholinergic deficits and Aβ burden (Gil-Bea et al., 2012, 
Laursen et al., 2014). However this model still does not allow to find out the role of 
p75
NTR
 in possible Aβ clearance by BFCNs as saporin damage completely 
cholinergic cells through their ribosomal inactivation. Therefore other models with 
partial or complete knock-down of p75
NTR
 are needed to decipher the involvement of 
this receptor in Aβ clearance. Such models were already used to show changes in the 
number of cholinergic neurons not Aβ load (Naumann et al., 2002). Later studies 
with use of APPSwe/PS1dE9/p75
NTR/ExonIII-/- 
mice implicated p75
NTR
 in the regulation 
of Aβ deposition by increased production and inhibited aggregation of this peptide 
by p75
NTR
 extracellular domain (Wang et al., 2011). This study is the most 
supportive so far for establishing the new role of p75
NTR
 in Aβ clearance from brain. 
Interestingly, although these triple transgenic mice revealed the extensive Aβ 
depositions in the hippocampus and cerebral cortex they did not show memory 
deficits, which supports dissociation of cognitive functions from amyloid load. 
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Chapter IV. New role of P75
NTR
 in homeostasis  
and clearance of Aβ - results with discussion 
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4.1. The p75
NTR
 system in AD 
 
The role of mature p75
NTR
 in adult brain remains controversial especially in BF that 
is one of the region most vulnerable to AD (McKinney and Jacksonville, 2005). As 
mentioned in introduction (Chapter 1.5.3.2.1.) p75
NTR
 has number of functions, 
depending on ligands it binds to. Except that, studies of p75
NTR
 knock-out mice with 
the truncated insertion in the exon 3 or 4 of p75
NTR, 
coding extracellular domain of 
this receptor, revealed an increase in number of ChAT positive neurons including 
septo-hippocampal pathway (Naumann et al., 2002), suggesting apoptotic role of 
p75
NTR
 in basal forebrain. However, recent studies implicate that p75
NTR
 has broad 
non-apoptotic anti-neurotrophic actions in BF that are more extensive than induction 
of apoptosis and do not support apoptotic role of p75
NTR 
(Greferath et al., 2011). The 
role of p75
NTR
 in AD remains unexplored despite many therapies boosting 
cholinergic system of BF (Chapter 1.6.).  
Binding of Aβ to p75NTR is believed to be the most relevant feature of p75NTR to AD. 
High affinity binding of Aβ to p75NTR was initially reported by Yaar (Yaar et al., 
1997) in immuno-precipitation experiments using cortical neurons and NIH-3T3 cell 
line, stably expressing p75
NTR
. Subsequent studies suggested a role of p75
NTR
 in Aβ-
induced neurodegeneration in human neuroblastoma cells (Kuner et al., 1998) and 
hippocampal neurons (Sotthibundhu et al., 2008). However, how exactly Aβ causes 
degeneration of neurons and if it directly inhibits neurotransmission or indirectly 
alters synaptic activity remains unknown (Coulson et al., 2006).  
P75
NTR
 is widely expressed during development and gradually switched off in 
adulthood. However, upon several types of injury and cellular stress, including AD, 
p75
NTR
 is thought to be re-expressed. Quantitative analysis revealed unchanged level 
of p75
NTR
 during early and moderate stages of AD (Ginsberg et al., 2006) while 
reduction in the expression of TrkA and down regulation of TrkB and TrkC were 
significant. The level of p75
NTR
 increases whereas TrkA decreases in aging 
(Costantini et al., 2005). This elevated expression of p75
NTR
 increases the binding of 
Aβ to p75NTR. Currently research of P75NTR and Aβ interaction and accumulation of 
toxic species are key interest in the field (Jian et al., 2016). 
The aim of this chapter is to analyse the mechanisms that govern the endocytosis and 
transport of IgG-Cy3 labelled p75
NTR
 as well as internalization of this receptor with 
Alexa 488 labelled Aβ 1-42 in cholinergic neurons of primary BF cultures. 
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4.2.3. Characteristics of BF cultured cells 
 
The quality of neuronal cultures was assessed by light microscopy (Nikon Eclipse TS 
100) utilizing the differential interference contrast (DIC) optics (Figure 34A and B) 
and also with the use of laser scanning microscope LSM 710, Carl Zeiss. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthy growth of BF neurons was critically dependent on cell density and the 
absence of non-neuronal cells. Therefore, each time before plating the number of live 
neurons was counted with tryptan blue in a haemocytometer. Optimal growth of BF 
cells was achieved with 0.5 – 1x106 plating density (9.62 cm2/35 mm dish) (Figure 
34A). Cell clusters negatively-influenced longevity of the BF culture [e.g. clusters, 
1.2 x 10
6 
plating density (9.62 cm
2
/35 mm dish)] (Figure 34B). 
Relatively pure cultures of BF neurons were obtained with the inclusion of 10 µM 
(final concentration) cytosine-β-D-arabinofuranoside (AraC) - applied to the cultures 
on the second day after plating; this reduced proliferation of non-neuronal cell types 
such as glia and macrophages (Figure 35B), facilitating more direct influence of 
experimental compounds on neurons. Serum-free medium provided precisely-
defined experimental conditions eliminating unknown components which are usually 
introduced through FBS. 
 
 
Figure 34. DIC of 6 day old BF culture. A. Arrows point to BF neurons (culture density 0.7 x 10
6
 over 
35 mm dish). B. Arrow heads point to cells clusters (culture density 1.2 x 10
6
 over 35 mm dish). 
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The development of neuronal cultures was regularly monitored and half of the 
growth medium was changed every 3-5 days to maintain the neuronal health and 
overall good culture quality (Figure 36). Maintenance of BF cultures was dependent 
on vitamins and supplements. The presence of NGF was crucial for the growth and 
differentiation of cholinergic cells. The concentrations of NGF were optimized 50 
and 200 ng/ml for 2.5S and 7S units, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Figure 35. The effect of AraC treatment on cultured BF neurons. A. BF culture 48h after plating 
whithout AraC. B. Same culture 72 h post plating – after AraC treatment.  
 
 
  
Figure 36. Development of cholinergic phenotype in BF culture. A. Cholinergic neuron p14 stained  
with 9.4 nM 192-IgG-Cy3 (red). B. DIC image of cholinergic neuron p21. 
A B 
20 µm 
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4.2.4. Viability of primary BF cultures 
 
The viability assay was performed on BF cultures with use of Nuclear-ID™ 
Blue/Green cell viability reagent (53004-C100, Enzo Life Sciences). This compound 
is a mixture of blue and green fluorescent nucleic acid dye suitable for staining live 
and dead cells, respectively. The amount of cell-permeable (blue) and cell-
impermeable (green) signals were counted with use of use of Photoshop CS4 v11 at 
24h, 48h, p7 and p14 time points and analysed with Excel software (Figure 37A, B). 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to progressive increase of dead neurons in cultures, I limited my experimental 
analysis to the young cultures (p5-p7). 
Figure 37. A. BF culture viability assay. DIC/fluorescent image of BF culture stained with Nuclear –
ID
TM
 Blue/Green cell viability reagent. Black arrow heads point to live cells (blue) while arrows 
point to dead cells (green). The image shows viability assay at 48h. B. Analysis of cell viability in BF 
culture. Plot of cell numbers expressed as percentage of live versus dead cells at different time points  
- 24h, 48h, p7, p14. 
  
  
B 
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4.2.5. Primary BF cultures retain high level of p75
NTR 
 
  
Anti-p75
NTR
 IgGs (FL-01 or FL-05, ATS) were used to identify cholinergic neurons 
in primary rat or mice BF cultures; these antibodies (4.7 nM or 3 nM, respectively) 
were applied to 2 ml of BF cultures for 2h and 24 h (Figure 38) to yield the best 
signal. The medium was removed after that time and cells were fixed with 4% PFA, 
pH=7.4 for half an hour in darkness and then washed a few times in phosphate 
buffered saline (PBS), pH=7.4. Labelled BF culture dishes were further processed for 
ChAT immuno-cytochemistry (Materials and Methods, Chapter 2.1.6 and 2.1.7).  
Cholinergic phenotype of neurons in rat and mice primary BF cultures was identified 
on the basis of ChAT and p75
NTR
 expression in the same cell as shown in Figure 38 
and 40, co-stained with a nuclear marker - DAPI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In regards to primary rat BF culture cholinergic neurons, these were counted with 
Photoshop CS4 v.11 as described in Materials and Methods, Chapter 2.2.2 (Figure 
39). Counting of double-labelled neurons revealed that only 40 % of cholinergic cells 
were positive for both markers (ChAT and 192-IgG-Cy3). Similarly to brain slices, 
all 192-IgG-Cy3 positive neurons were immuno-reactive for ChAT, but ~25 % of 
ChAT positive cells were not labelled with 192-IgG-Cy3. 
 
Figure 38. Characteristic of cholinergic phenotype. Image of cholinergic neuron from p7 rat BF 
culture co-labelled with 192-IgG-Cy3 (red) and anti-ChAT (green), fixed and mounted with DAPI 
(blue). Detailed explanation of different colours in various areas – B, C, D. 
 
 
 
A 
B 
C 
D 
20 µm 
20 µm 
20 µm 
   DAPI 
   192-IgG-Cy3 
     ChAT 
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Similar results were achieved with Cy3-labeled anti-murine NGFr IgG (Chapter 
2.1.5.1.) for BF cultures from C57/BL6 and CD1 mice strains (Figure 40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Identification of cholinergic neurons in BF of C57/BL6 mice. A. ChAT/DAPI staining of 
p7 BF culture. B. Representative cholinergic neuron stained with ChAT/DAPI.C. Cholinergic neuron 
stained with Cy3-labeled anti-murine NGFr IgG. D. Cholinergic neuron stained with ChAT(green) 
and Cy3-labeled anti-murine NGFr IgG.   
 
A 
Figure 39. The proportion of cholinergic neurons in rat BF culture. Histogram is based on counting 400 
neurons from 3 BF culture dishes. Cy3(+) - cells positive for 192-IgG-Cy3, ChAT(+) - cells positive for 
ChAT. DAPI - all cells. 
 
C D 
10 µm 10 µm 
 
B 
 
  
107 
 
4.2.6. p75
NTR
 uptake and trafficking in cholinergic neurons 
 
Both primary BF rat and mice cultures displayed robust uptake of anti-p75
NTR
 
antibodies (FL-01 and FL-05, 4.7 nM and 3 nM in 2 ml of BF culture, respectively) 
within first 2 h and did not show significant increase in the uptake of these antibodies 
by neuronal cells up to 24 h (example Figure 41), therefore limiting further 
experimental analysis to this time frame. 
 
 
 
 
 
 
 
 
 
 
Trafficking of p75
NTR
-192-IgG-Cy3 vesicles was observed in cholinergic cells with 
use of live confocal microscopy (LSM 710, Zeiss) (Figure 42). BF cell cultures were 
washed to remove excess of anti-p75
NTR
 IgG by re-freshing culture medium before 
viewing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The observed punctate Cy3 signal in soma and neurites reflected vesicles, moving bi-
directionally with various speed. The details of their size and velocity are described 
in Chapter 4.3.2.  
  
 
0.00 s 
0.50 s 
 
Figure 42. Trafficking of p75
NTR
-192-IgG-Cy3 in rat BFCNs. Arrows point to the moving vesicles 
(example). 
 
1.40 s 
Figure 41. Time course of anti-p75
NTR
 IgG uptake in BFCNs. The histogram show uptake of 192-
IgG-Cy3 by rat BFCNs in time. The bulk of this antibody - 78.1% was internalised within 2h of 
exposure and this number did not change significantly within 24h (p=0,23) 
5 μm 
  5 μm 5 μm 
 
  
 0.50 s 
8.33 s 
 5 μm 
           192-IgG-Cy3 
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4.3. Co-localization of p75
NTR
 and Aβ in cholinergic neurons   
 
HiLyte fluor 488 Aβ (1-42) (78673, AnaSpec) (0.1- 0.3 µM) were co-applied with 
192-IgG-Cy3 (4.7 nM) of to 2ml of p7 BF culture for 24 h incubation at 37°C, 5% 
CO2. After that time, cells were fixed in 4% PFA, buffered in PBS, pH=7.4 for half 
an hour and then washed with 0.1 M PBS, pH=7.4, before viewing. Co-localization 
of p75
NTR
 and Aβ(1-42) was defined by the presence of two fluorescent labels within 
the same pixel in digitally acquired images by LSM710, Zeiss (Figure 43A). Co-
localization co-efficients were automatically calculated with ZEN software, that 
estimated the degree of co-localization within the selected region of interest using a 
co-localization algorithm (Chapter 2.2.1) (Figure 43B). 
 
z 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of randomly-defined regions revealed strong co-localization of HiLyte 
Fluor 488 Aβ (1-42) and 192-IgG-Cy3 in perykarion and neurites, with closely 
matching co-efficients (0.91±0.07 versus 0.96±0.1, neurites versus soma). Reversed 
assessment of 192-IgG-Cy3 and HiLyte Fluor 488 Aβ (1-42) showed significantly 
lower co-efficients (0.36±0.05 versus 0.48 ±0.08, neurites and cell bodies, 
respectively), suggesting the crucial role of p75
NTR for the uptake of Aβ by BFCNs.  
Figure 43. Co-localization study of  p75
NTR
 and Aβ (1-42) in cholinergic cell. A. representative 
cholinergic neuron showing co-localization of Aβ (1-42) Alexa 488 (left) and 192-IgG-Cy3 (middle) 
merged on the right panel. B. Plots of Aβ-Alexa488/192-IgG-Cy3 (and vice versa) co-localization in 
bar pairs from soma  and  neurites. 
 
Aβ (1-42) Alexa 488 192-IgG-Cy3 merged 
10 µm 
 
A B 
Neurites Cell bodies 
 
10 μm 
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4.3.1. Compartmented cultures of superior cervical ganglionic neurons (SCGNs) 
confirmed retrograde trafficking of Aβ (1-42) and p75NTR  
 
The above findings were also confirmed in peripheral nervous system, where 
examined by looking at superior cervical ganglion neurons (SCGNs) in 
compartmented neuronal culture. Isolation of SCGNs from neonatal rat pups, 
enzymatic dissociation of the neurons and their maintenance in culture were 
performed as described before (Mahanthappa and Patterson, 1998; Banker and 
Goslin, 1998). Neurones were seeded into compartmented cultures following 
published procedures (Campenot, 1982) and using chambers supplied by the Tyler 
Research Corporation (Alberta, Canada). HiLyte fluor 488 Aβ (1-42) (0.3 µM) and 
192-IgG-Cy3 (4.7 nM) (Chapter 2.1.5.1.) were utilized in this experiment. 
Trafficking of both molecules was observed in live cells from distal to the central 
(cell bodies) compartment, using LSM 710, Zeiss (Figure 44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. SCGNs traffic p75
NTR
 to the cell body. A Cell body from central compartment of SCGNs 
culture containing co-localized vesicles of 192-IgG-Cy3 (red) and Alexa 488 labelled Aβ (1-42) 
(green), merged image of B and C. B. 192-IgG-Cy3 (red) in the central cell bodies compartment. C. 
Alexa 488 labelled Aβ (1-42) in central – cell bodies compartment. D. Distal compartment of SCGNs 
culture were both molecules (High Light Fluor Aβ (1-42) and 192-IgG-Cy3 were co-applied. 
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4.3.2. Parameters of trafficking Aβ (1-42) and p75NTR loaded vesicles in BFCNs 
 
Parameters of p75
NTR
 and Aβ (1-42) trafficking were assessed in BFCNs using live 
microscopy (Figure 45). The experiment was performed with 0.3 µM of HiLyte 
Fluor 488 Aβ (1-42) and 4.7 nM of 192-IgG-Cy3 co-applied for 2 h to 2 ml of rat BF 
cultures and delicately washed with re-feeding medium before viewing. The 
diameters of vesicles containing fluorescent Aβ (1-42) and 192-IgG-Cy3 within 
BFCNs were measured for about 200 vesicles (hundred for each channel) using ZEN 
software (Figure 46A). The speed of these vesicles was determined from time lapse 
live microscopy images for around 30 vesicles. The distance of migration of each 
vesicle was compared between the frames in a row, separately for vesicles containing 
HiLyte Fluor 488 Aβ (1-42) or 192-IgG-Cy3. The values were then averaged and 
analysed statistically (Figure 46B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I observed double labelled round - slow and fast moving vesicles (0.05-4.2 μm/s)  in 
both directions (somato-petal and somato-fugal) (Figure 45). Analysis of randomly 
defined images revealed closely matching average movement velocity of Cy3 and 
Alexa 488 labelled vesicles (3.18±0.7 μm vs. 2.81±0.8 μm, p=0.81). There were also 
stationary and oscillating double-labelled vesicles observed within both neurites and 
 
Figure 45. p75
NTR
 (labelled with 192-IgG-Cy3) and Aβ (1-42) (labelled with Alexa 488) traffics 
together in BFCN. Arrows point to the  rapidly moving vesicles while arrowheads mark the slowly 
moving vesicles, in addition to the stationary or oscillating ones. 
 
111 
 
perykarion. The average sizes of Cy3 and Alexa moving organelles were similar 
(0.8±0.06 versus 0.71±0.08 μm, respectively; p=0.34)  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4. Mechanisms of Aβ and p75NTR internalization by BFCNs   
 
 
The uptake of Aβ by BFCNs can be important in the context of toxicity of these 
peptides in BF. Many receptors have been proposed to play role in  Aβ 
internalization (Patel and Jhamandas, 2012) with some reviewed in Chapter 1.5.1. 
However, there is no detailed study of the internalization of p75
NTR
, independent of 
TrkA. On the basis of microscopic observations from Chapter 4.3.2, we hypothesised 
that Aβ (1-42) may highjack the existing p75NTR transport pathway for entering and 
propagation within BFCNs. Confirming this hypothesis as well as deciphering the 
mechanism of p75
NTR 
and Aβ uptake may be crucial for validation of p75NTR as a 
molecular target for AD therapy. For this purpose the following experiments were 
undertaken.  
 
4.4.1. p75
NTR
 uptake does not depend on regulated endocytosis  
 
Firstly, rat BFCNs in culture were treated with 50 mM KCl (P9333, Sigma), 10 min 
at 37°C, 5% CO2,  prior to the addition of 4,7 nM 192-IgG-Cy3 to 2ml of same 
culture for 2 h and compared to not depolarised control (5.33 mM, K
+
). Experimental 
and control samples were then washed in PBS, pH=7.4, fixed with 4% PFA for half 
Figure 46. The average speed and size of vesicles loaded with 192-IgG-Cy3 and Aβ (1-42) –Alexa 488.  
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an hour and washed again with PBS, pH=7.4, before microscopic analysis. The result 
showed significant increase in the uptake of p75
NTR 
in soma and neurites of
 
BFCNs 
(89±18.2%, p=0.0071) as compared to non-stimulated controls (Figure 47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, when Na
+
 channels were blocked with tetrodoxin (TTX), (1069, Tocris 
Bioscience), in experiment where 500 nM of TTX was applied 10 min prior to the 
addition of 192-IgG-Cy3 (4.7 nM) to 2 ml of rat BF culture and incubated at 37°C, 
5% CO2 for 2 h, the effect was not significant (2.1±17.1%, p=0.24) as compared to 
the controls. Failure of TTX to alter the basal uptake of 192-IgG-Cy3 suggested 
independence of p75
NTR
 from regulated synaptic activity. 
To prove this directly, the effects of recombinant Clostridial Botulinum neurotoxins 
(BoNT/A and BoNT/B), expressed and purified in ICNT, DCU, on p75
NTR
 
endocytosis were examined. These neurotoxins were applied in concentrations that 
normally block SNARE-dependent exo/endocytosis BoNT/A (5 nM) or BoNT/B (10 
nM) half an hour before addition of 192-IgG-Cy3 (4.7 nM) for 2h incubation in 
37ºC, 5% CO2. The addition BoNTs was omitted in control samples. Both 
experimental and control samples were washed after 2h of incubation in PBS, 
pH=7.4, fixed with 4% PFA for half an hour and washed again with PBS, pH=7.4, 
before microscopic analysis. As shown on Figure 48A and B loading of BFCNs with 
Figure 47. P75
NTR
-192-IgG-Cy3 uptake by BFCNs is enhanced by depolarisation but the resting 
uptake is not susceptible to a Na
+
 channel blocker. A. Representative images of BFCNs under high 
[K
+
] or in the presence of tetrodoxin (TTX) compared to the control neuron in resting state. All 
neurons show uptake of 192-IgG-Cy3. B. Plots of fluorescence intensity signal generated by neurons 
under depolarisation and Na
+
 channel blocking conditions versus BFCNs in resting state.  
 
 
 
A 
 
B 
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192-IgG-Cy3 was not compromised with either BoNT/A or BoNT/B proteases 
4.8±7.2% and 9.2±12% reduction, p=0.53 and p=0.16, respectively). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2. Ca
2+
 homeostasis play major role in p75
NTR
 internalization  
 
Because Ca
2+
 homeostasis is altered in AD (Introduction, Chapter 1.5.1.2.) the 
effects of Ca
2+
 channel blockers and chelators on p75
NTR
 endocytosis have been 
analysed. I assessed if 192-IgG-Cy3 internalization changes in the presence of broad 
spectrum of internal: cyclopiazonic acid (C1530, Sigma),  thapsigargin (T9033, 
Sigma), and external: EGTA (E3889, Sigma), CdCl2 (208299, Sigma), mibefradil 
(M5441, Sigma), nifedipine (N7634, Sigma) Ca
2+
 channel blockers (Tsien et al., 
1998). These substances were incubated for half an hour at 37°C, 5% CO2 with rat 
BFCNs, in subsequent experiments, prior to the addition of 192-IgG-Cy3 (4.7 nM) to 
2 ml of same cultures, for the additional 2 h of incubation. Ca
2+
 blockers and 
chelators were omitted from control dishes to which 192-IgG-Cy3 only was applied. 
After incubation time, all samples were washed in PBS, pH=7.4 and fixed with 4% 
PFA for half an hour, before washing them in PBS, pH=7.4, prior to microscopic 
analysis. 
Chelation of Ca
2+
 with EGTA (200 µM), strongly supressed basal endocytosis of 
p75
NTR
 (61.2±2.1% decrease, p=0.0081) as compared to control samples. 
Indiscriminate blockade of high-voltage Ca
2+ 
gated channels with CdCl2 (50µM) 
 
Figure 48. Basal internalization of p75
NTR
-192-IgG-Cy3 by BFCNs is independent of SNARE-
regulated exo/endocytosis. A. Representative images of BFCNs treated with BoNT/A or BoNT/B in 
concentrations that normally block vesicles turnover. B. Plots of fluorescence intensity signals 
generated in these cells during experiments with BoNTs versus control BFCNs. 
 
  
A B 
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only marginally inhibited the loading of cholinergic neurons with 192-IgG-Cy3 
(9.6±6.3% reduction, p=0.41) (Figure 49A). This contrasted with the effect of 
selective low-voltage T-type Ca
2+
 channel blocker – mibefradil (MIB), (10 µM), 
which significantly diminished the uptake of 192-IgG-Cy3 (75.4±3.1% reduction, 
p=0.004) as compared to the controls (Figure 49B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, high voltage, L-type Ca
2+
 channels were also found to significantly 
reduce p75
NTR
 uptake (74.39±4,23%, p=0,0003) as shown by studies with nifedipine 
(10 µM) (Figure 50).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 49. Internalization of p75
NTR
-192-IgG-Cy3 by BFCNs depends on extracellular Ca
2+
. A. 
Representative images of BFCN blocked with CdCl2 and  mebefradil (MIB) compared to control 
neuron in resting state. B. Plot of fluorescence intensity signals generated by 192-IgG-Cy3 in BFCN 
exposed to CdCl2 or mibefradil versus control BFCNs.  
 
A 
 
 
 
Figure 50. Contribution of L-type channels to endocytosis of p75
NTR
-192-IgG-Cy3 by BFCNs. A. Z-
stack of BFCNs cluster pre-treated with 10µM nifedipine. B. The same neuronal cluster imaged with 
DIC. C. Plot of fluorescence intensity signals generated by p75NTR-192-IgG-Cy3 in BFCNs exposed to 
nifedipine versus control BFCNs. 
 
NIF Control 
* 
A 
B 
C 
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Additionally, similar inhibitory effects of 192-IgG-Cy3 endocytosis were observed 
upon blockade of sarco-endoplasmic reticulum (SERCA) ATPase with cyclopiazonic 
acid (CPA), (10 µM), (51.2±6.4%, p=0.021) or thapsigargin (TG), (1 µM), 
(59.2±1.4%) as shown on Figure 51A and B as compared to the controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5. Aβ oligomers compete with 192-IgG-Cy3 for binding to p75NTR  
 
Binding of Aβ oligomers to p75NTR was assessed in compartmented SCGN cultures 
described in Chapter 4.3.1. for neurons: somata localised in the central compartment 
and neurites developing in distal compartment. Aβ oligomers, prepared as in Chapter 
3.5.1 (1.2 μM) and 192-IgG-Cy3 (4.7 μM) were sequentially applied for 1h each at 
4°C to the experimental samples. The addition of oAβ was omitted from control 
samples. Then experimental and control samples were processed in the same way. 
SCGNs from central compartment were washed carefully three times by exchange of 
the culture medium with PBS, pH=7.4. They were lysed in NuPage LDS sample 
buffer (NP0007, Life Tech.) afterwards and separated by SDS-PAGE on a 12% 
NuPage Bis-Tris gel. Samples were taken from two distal compartments with a small 
amount of ddH2O (20 μl) and ultracentrifuged in 4 °C at 180 000 g for 15 minutes 
before heating them in loading buffer for 5 min to 95ºC and resolving on a SDS-
PAGE 12% NuPage Bis-Tris gel. The gels were imaged using Fujifilm laser scanner 
 
 
 
 
A B 
Figure 51. Internalization of  p75
NTR
-192-IgG-Cy3 by BFCNs relies on intracellular Ca
2+
. A. 
Representative images of BFCNs treated with general Ca
2+
 chelator (EGTA) and SERCA ATPase 
pump inhibitors – CPA and TG. D. Summary of the average fluorescence intensities (FI) pooled 
from experimental groups imaged on picture C versus the control BFCNs. 
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(FLA-5100) and analysed with advanced image data analyser (AIDA) programme 
(Figure 51B). WB was also performed to confirm this result (Figure 52C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above experiment indicate that Aβ oligomers compete with 192-IgG-Cy3 for 
binding to p75
NTR
. Image J analysis of the above gels show 47.13% and 33.3% 
(axons and cell bodies, respectively) of signal reduction in 192-IgG-Cy3 binding to 
p75
NTR
, for samples where oAβ (1-42) was added prior to their exposure to 
fluorescent antibody (192-IgG-Cy3). This was confirmed by WB analysis, which 
detected 49.41% decrease in 192-IgG-Cy3 bands intensity of SCGNs somata (central 
compartments) and 46.84% reduction in 192-IgG-Cy3 bands intensity of SCGNs 
neuritis (distal compartments), where oAβ were added. 
 
4.5.1. Oligomeric Aβ inhibits endocytosis of p75NTR  
 
Aβ oligomers previously prepared as in Chapter 3.5.1. were applied in subcytotoxic 
concentrations (6 nM – 630 nM) to postnatal (P5) rat BF cultures and pre-incubated 
for 24 h in humidified incubator at 37°C in 5% CO2 before the addition of 192-IgG-
Cy3 (4.7 nM) to 2ml of cultures for 2 h. Cells were then fixed with 4% PFA in PBS, 
pH=7.4 for half an hour and then washed few times with PBS, pH=7.4, before 
microscopic analysis. 
 
Figure 52. Aβ oligomers compete with 192-IgG-Cy3 for binding to p75NTR. A. internal control of 
12% NuPage Bis-Tris gel imaged by FLA-5100 – samples from the wash. Abbreviation: A – axonal 
distal compartment, CB – cell bodies (central compartment). B. diminished 192-IgG-Cy3 signal in 
Aβ samples as compared to the controls (without Aβ).Abbreviations Aβ – samples with preliminary 
Aβ binding, C – samples with omission of Aβ (192-IgG-Cy3 only), L – molecular size marker. C. 
WB of same experiment. The previous abbreviations applied. 
A B C 
C C       L 
 
C          C 
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Pre-exposure of cultures to oAβ significantly diminished the basal uptake of p75NTR-
192-IgG-Cy3 as compared to controls. This effect was concentration dependent. 
Figure 53 shows, significant decrease in the basal p75
NTR
 uptake observed for 60 and 
600 nM of oAβ (p=0.004 and p=0.008, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The uptake of p75
NTR
-192-IgG-Cy3 was inversely proportional to the amount of oAβ 
applied, suggesting the existence of negative feedback loop in Aβ uptake by BFCNs 
but also homeostatic role of p75
NTR
 in regulating Aβ level in BF as well as in the 
areas to which BFCNs project (Chapter 1.5.3.1.). This phenomenon may be 
important for Aβ clearance process, which is disrupted in AD (Chapter 1.5.1.1.). 
 
4.6. p75
NTR
 co-localizes with Cs-HC-TeTx in BF culture  
 
Normally TeTx toxin (TeTx) shows tropism to peripheral nerve ending at 
neuromuscular junction and its retrogradely transported to the spinal cord and brain 
stem, with p75
NTR 
implicated in this process (Lalli and Schiavo, 2002; Ovsepian et 
al., 2015).  
 
Figure 53. Oligomeric Aβ diminishes p75NTR-192-IgG-Cy3 uptake by BFCNs. A. Representative 
images of BFCNs in the presence of different amounts of Aβ oligomers as compared to the control. B. 
Histogram showing fluorescence intensity signals of 192-IgG-Cy3 in BFCNs in the presence of 
different concentrations of Aβ oligomers versus control. 
 
 
A B 
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TeTx composed of heavy chain (HC), responsible for binding and translocation of 
the toxin and protease domain, both linked by a disulphide bond (Pellizari, 1999); 
was re-engineered using recombinant technology and site-directed mutagenesis 
(O’Leary et al., 2013). HC of TeTx was fused to core streptavidin (CS)-generating  
Cs-HC-Tetx molecule (Figure 54A). 
High (19.4 nM) and low (9.7 nM) amounts of Cs-Hc TeTx were added to 2ml of (P6) 
BF rat primary culture together with 192-IgG (9.5 pM) and incubated for 2h at 37°C, 
5% CO2. In control dishes, Cs-Hc-TeTx was omitted. The cultures were fixed in 4% 
PFA in PBS, pH=7.4 and immuno-cytochemistry with anti-streptavidin mouse 
monoclonal IgG was performed, as described in Materials and Methods, Chapter 
2.1.6. High degree of co-localization was observed for both molecules (Cs-Hc-Tet 
and 192-IgG-Cy3) (Figure 54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Schemat of  Cs-Hc-Tet engineering 
 
  
 
Figure 54. Colocalization of Cs-Hc TeTx with 192-IgG-Cy3 in BFCN. A. Construction of the fusion 
protein Cs-Hc-TeTx. B. Fluorescence intensity measurement from LSM 710 (ZEN) showing co-
localization of Cs-Hc-TeTx with p75
NTR
-192-IgG-Cy3 in vesicle crossed by arrow in C. C. 
Colocalization of Cs-Hc- TeTx (green) with 192-IgG-Cy3 (red). Red arrow crosses the vesicle which 
co-localizes both  molecules.  
 
A 
B C 
Cs-Hc-TeTx 
20 μm 
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4.7. Aβ oligomers are sorted for lysosomal degradation in BFCNs 
 
Immunocytochemistry for early (EE1), recycling (Rab 11) and late (Rab7) 
endosomal proteins as well as lysosomes (Lamp1) were performed on BFCNs pre-
labelled for 2 h with 192-IgG-Cy3 (4.7 nM), added to 2ml of (P7) rat cultured BF 
cells. The cultures stained for Rab7, Rab11 and Lamp1 were incubated with those 
IgGs overnight, while cultures stained with EE1 were incubated for 2 h at 37°C, 5% 
CO2. All dilutions of primary and secondary antibodies were previously tested and 
described in Materials and Methods, Chapter 2.1.6. These cultures were fixed in 
0.4% PFA in PBS, pH=7.4 for half an hour and washed with 0.1M PBS before 
microscopic analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The double labelling revealed that only small fraction of 192-IgG-Cy3 was present in 
early endosomes (7.7±6.7%) and higher - 25.1±11% were positive for 192-IgG-Cy3 
and Rab 11. This suggests that a substantial fraction of 192-IgG-Cy3-p75
NTR
 
carrying endosomes are sorted to trans-Golgi network and recycled. Strong labelling 
of 192-IgG-Cy3 with late endosome (Rab7) or lysosome protein (Lamp1) 
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Figure 55. Location of  p75
NTR
-192-IgG-Cy3 in intracellular compartments of BFCNs. Representative 
images of  double labelling  in various endosomal/lysosomal compartments in BFCNs with 192-IgG-
Cy3 and early endosomal marker - EE1 (A), recycling endosomal marker - Rab11 (B), late endosomal 
marker - Rab 7 (C), lysosomal protein - Lamp1 (D). E. Summary plots showing the average co-
localization coefficients of 192-IgG-Cy3 with EE1 and Rab11. F. Similar plots for Rab 7 and  Lamp1.  
 
 
E 
F 
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(56.1±3.2% and 82.1±5.9%, respectively) suggested that the bulk of p75NTR with its 
cargo is guided for degradation in BFCNs (Figure 55). 
 
4.8. Exocytosis of p75
NTR
  
 
Not only the uptake but the release of amyloidogenic peptides is a matter of great 
interest especially in light of their  trans-neuronal spread of AD pathology.  
In previous chapters, I demonstrated that p75
NTR
 can mediate the uptake of Aβ and 
sort it for degradation by BFCNs but it was also found that some of the p75
NTR 
carriers get sorted into the recycling pool of vesicles. Therefore, there is the 
possibility that recycling vesicles can get fuse back with the membrane and release 
their content to the extracellular space. These investigations of Aβ exocytosis may 
lead to the discovery of the mechanisms by which Aβ spreads during the course of 
the disease, if hijacking the existing p75
NTR
 endocytic pathways. 
The initial experiments were conducted in postnatal CD-1 mice BF cultures with Cy3 
labelled anti-murine NGFr (Chapter 2.1.5.1.) (3 nM) added to 2ml of cultures for 2 h 
and kept in humidified incubator 37ºC, CO2. The samples were then washed with 
medium and imaged live by LSM710. Then they were incubated for additional 
period of time: 2; 5,5; 29h. At each time point BFCNs were imaged again. Images 
from 49 cells (368 frames) were analysed. The data were normalized versus the same 
area. The results are shown in Figure 56.  
 
 
 
 
 
 
 
 
 
A declining trend in Cy3 labelled anti-NGFr IgG intensity was observed within the 
first 31h; however, these changes were not significant (p=0,2). Further experiments 
are required to establish the time point at which the signal significantly drops down 
and to answer what are the mechanism of p75
NTR
 cargo release.  
Figure 56. Trend in p75
NTR
-cargo decrease. The data show analysis of Cy3 labelled anti-NGFr 
antibody in  CD-1 postnatal mice BF culture.  
 
 
 
 
  2h                4h                7,5h             31h 
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4.9. Discussion of p75
NTR
 internalization by BFCNs in the context of AD  
 
p75
NTR
,
 
expressed exclusively by BFCNs throughout the adulthood was investigated 
in rat and mice primary BF cultures, which retain high level of this receptor (Chapter 
4.2.5.). Development of BFCNs in these cultures was strictly dependent on 
exogenous supply of NGF as in agreement with previously reported data (Banker and 
Goslin, 1998). Such trophic support did not clash with further analysis of p75
NTR
 
because NGF and 192-IgG-Cy3 (main monitoring ligand used in this study) bind to 
different extracellular epitopes (Taniuchi and Jonson, 1985), giving the opportunity 
to observe p75
NTR
 in various experimental conditions.  
Although much is known about release of p75
NTR
 cargo as e.g. neurotrophins 
(Hartmann et al., 2001; Dean et al., 2009), only little studies focus on their uptake 
(Campenot, 2009, Wong et al., 2015). These studies mostly consider TrkA co-
operation with p75
NTR
. However, it is known that p75
NTR
 can act independently from 
Trk signaling. This unique receptor lack enzymatic activity and exerts its function 
depending on ligands it binds to as reviewed in Chapter 1.5.3.2.1. This is particulary 
interesting in case of non-neurotrophic ligands binding, especially Aβ binding in 
regards to AD, as this peptide is known from its deleterious effects on cholinergic 
cells during the course of this disease (reviewed in Chapter 1.5.1.1.). Therefore I 
focused my studies on p75
NTR
 endocytosis independent on TrkA.  
Using primary BF cultures I demonstrated for the first time with live confocal 
microscopy data, rapid and robust internalization of Aβ (1-42) together with p75NTR 
as revealed with use of HiLyte fluor tagged peptide and labelled antibodies (192-
IgG-Cy3) (Chapter 4.3). The retrograde trafficking of both molecules was also 
confirmed in different neuronal setting e.g. with use of SCGNs compartmentalized 
cultures (Chapter 4.3.1.). The analysis of trafficking Aβ (1-42) and p75NTR loaded 
vesicles in BFCNs revealed their movement in both directions with some stationary 
oscillating vesicles in neurites and perykarion (Chapter 4.3.2). The endocytosis of  
p75
NTR
 was further analysed (Chapter 4.4). While active at rest conditions this 
process was significantly accelerated under K
+
 induced depolarisation. Interestingly, 
same vesicles turnover was insensitive to inhibitors of regulated synaptic activity 
such as TTX. To demonstrate this directly the effects of potent inhibitors of synaptic 
exocytosis - Clostridial Botulinum neurotoxins (BoNT/A and /B) were examined 
(Chapter 4.4.1.). Loading of vesicles with 192-IgG-Cy3 was not compromised by 
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these proteases, suggesting segregation between the processes governing the uptake 
of p75
NTR
 ligands including Aβ from those contributing to the membrane recovery.  
Because Ca
2+
 is ubiquitous regulator of membrane turnover at both axonal terminals 
and dendrites (Ovsepian and Dolly, 2011) I assessed if the uptake of 192-IgG-Cy3 
relies on the increase of the intracellular Ca
2+
. BFCNs are known to express a range 
of voltage-gated Ca
2+
 channels (Griffith et al., 1994) and undergo increased calcium 
buffering during aging (Murchison and Griffith, 1998). In my experiments the 
indiscriminate blockade of high-voltage gated Ca
2+
 channels with cadmium (CdCl2, 
50µl) (Tsien et al., 1988) only marginally inhibited the loading of BFCNs with 192-
IgG-Cy3. This contrasted with blockade of low and high-voltage activated Ca
2+
 
influx by mibefradil and nifedipine, respectively which significantly decreased the 
basal endocytosis of p75
NTR 
(Chapter 4.4.2.). Similar results were evident under 
global chelation of BFCNs with EDTA. The involvement of internal calcium stores 
into p75
NTR
 uptake was also examined. The smooth endoplasmic reticulum (SER) 
was investigated with the SER ATPase Ca
2+ 
uptake blockers -  thapsigargin and 
cyclopiazonic acid. The depletion of internal Ca
2+
 stores by inhibitors of the SERCA 
 pump suggests the involvement of these structures in endocytosis of p75
NTR
. In 
conclusion all the above experiments confirmed the important role of Ca
2+  
in p75
NTR 
correct functioning what has a meaning particulary in aging and AD, where calcium 
homeostasis is altered (reviewed in Chapter 1.5.1.2.). 
Because amyloid hypothesis implicates Aβ as the main culprit of pathogenic events 
leading to AD, I examined influence of this peptide on p75
NTR
 endocytosis in various 
sub-cytotoxic concentrations. In these experiments monomeric and oligomeric 
mixture of Aβ (1-42) reduced basal uptake of p75NTR in dose dependent manner as 
revealed in Chapter 4.5.2. This occurs by yet unidentified mechanisms, suggesting 
however, the new homeostatic role of p75
NTR
 in Aβ uptake. In other words BFCNs 
may keep check on Aβ level in BF and through their diffuse ascending projections in 
the cerebral cortex and hippocampus (Chapter 1.5.3.1.). Overloading of this system 
with excess of Aβ during AD may cause disruption of degradation mechanisms and 
cause preferential deposition of Aβ peptides in the areas of cholinergic projections. 
Such hypothesis would also explain preferential vulnerability of BFCNs in the 
pathological processes of AD (Ovsepian and Herms, 2013). On the other hand oAβ 
was found to compete with 192-IgG-Cy3 for binding to p75
NTR 
(Chapter 4.5.1.), 
conflicting the previous result. Therefore further experiments e.g. with truncated 
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forms of p75
NTR
 or its silencing are needed to confirm the hypothesis of Aβ clearance 
by p75
NTR
. In vivo experiments with knock-down parts of p75
NTR
 or the whole 
receptor would be also beneficial. However, due to limitation of time and resources I 
did not conducted those experiments. In the analysis of p75
NTR
 trafficking I found 
however the lysosomes as a primary destination of p75
NTR
 cargo
 
(Chapter 4.7.) what  
suggests it degradation by BFCNs. Interestingly, in set of those experiments p75
NTR
 
was found not to co-localize with early endosomal marker (EE1), which is in 
agreement with previous literature data, showing Aβ (1-42) apart from EE1 marker 
and caveolin (Saavedra et al., 2007).  
Although Aβ entry to BFCNs remains elusive there is no doubt that this neurotoxic 
peptides hijack p75
NTR 
pathway for trafficking within cholinergic cells. P75
NTR
 
particulary enriched in axons of these neurons are
 
definitely sorting this deleterious 
peptide for degradation in lysosomes, what happens in addition to other processes 
known for Aβ clearance (reviewed in Chapter 1.5.1.1.). This observation is in 
agreement with the reports viewing disruption of lysosomal system as the main cause 
of neurological disorders including AD (LaFerla et al., 2007; Nixon et al., 2008). 
It should be of notion, that pool of p75
NTR
 was found in the recycling vesicles 
(Chapter 4.7.). These vesicles may get fuse back to the membrane and release their 
neurotoxic cargo outside the cell. This is especially interesting in the context of 
spreading Aβ pathology and should be important aspect to consider for further 
studies. Possible exocytosis of Aβ or other escape routes from lysosomal degradation 
should be the matter of further research as explained in more details in Chapter 4.8. 
The possible p75
NTR
 trafficking with its cargo is illustrated in Figure 57.  
 
 
 
 
 
 
 
 
 Figure 57. Possible routes of p75NTR trafficking with its cargo. 
After internalization of p75
NTR
 with its cargo to the early endosomes 
(EE), the fraction of loaded vesicles is recycled back to the plasma 
membrane (recycling endosomes - RE), while the rest is sorted to the  
signalling endosomes (SE). Other fraction get fused with  
multivesicular bodies (MVB), which maturate to late endosomes 
(LE) and within lysosomes (LS) degrade most of the content. It is 
possible however that not all material is degraded and can escape 
lysosomal route of degradation. In this case p75
NTR
 with its cargo 
e.g, Aβ can be released outside the cell through exososmes. Other 
abbreviations: ER – endoplasmic reticulum, Nuc - nucleus 
 
exosomes 
 P75
NTR
  with its cargo e.g Aβ  
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Chapter V. Targeted lentivirus transduce 
BFCNs in vivo - results with discussion 
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5.1. Targeting of neuronal cells by lentiviral vectors   
 
Lentiviral vectors (LVs) have been widely used in fundamental biological research, 
functional genomics and gene therapy (Dugal and Choudhary, 2012). They are 
important tools for gene transfer because of possessing the ability to transduce a 
number of cell types without the need for host cells to be dividing (Blömer et al., 
1997; Ausubel et al., 2012). The biggest advantage of LVs over other viral delivery 
systems is their large capacity. Lentiviruses can integrate up to 8 kb of transgene into 
the host genome (Davidson and Breakefield, 2003). Moreover, innate immune 
responses are not very problematic for LVs as only minimal and asymptomatic 
inflammation has been observed in animal models after their administration 
(Kordower et al., 2000). Generation of recombinant LVs targeting BFCNs through 
recognition and binding of p75
NTR
 was undertaken in this study with intention to 
clarify if p75
NTR
 can provide  novel therapeutic target for AD therapy. To achieve 
that, I used second generation hybrid viral vector system (Tiscorniaet al., 2006) made 
from the core proteins and enzymes of human immunodeficiency virus type I (HIV-
1), pseudotyped with vesicular stomatitis glycoprotein (VSV-G). An infectious 
retroviral particle of this virus comprised RNA genome that carries cis-acting 
sequences necessary for packaging, nuclear translocation and transcription as well as 
trans-acting sequences, encoding viral structural proteins (gag end env genes) and the 
enzymatic product of pol gene (schematic drawing Figure 57) (Rohll et al., 2002, 
Delenda 2004). Due to the separation of cis and trans acting elements, this lentivirus 
has a high biological safety profile and is replication deficient. The chances of 
crossing this lentivirus with eventual native HIV viruses are reduced by replacement 
of native lentiviral envelope protein with VSV-G envelope protein. Deletion of 
native HIV promoters in the packaging construct and their replacement by a 
heterologous constitutive promoter (resulting in the presence of only 3 of the original 
HIV proteins) further lowers the biohazard level (Biosafety level 2). The resulting 
LVs are also self–inactivating because of the U3 region being deleted from long 
terminal repeats (LTR), which are duplicated when the virus infects the host cell. The 
duplication of this deletion results in transcriptional inactivation of the virus 
(Zufferey et al., 1998).  
The production of LVs was achieved by simultaneous transfection of HEK293 cells  
with three different plasmids: pMD-2G, pCMV and pWPI or pWPT-GFP (Figure 58) 
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The recipient cells incorporated into their genome the sequences encoded by these 
plasmids and maintained stable expression of the gene of interest thanks to very 
efficient eukaryotic promoter – elongation factor 1 (EF-1) (found in the transfer 
plasmid), while other cytomegalovirus promoters (CMV) of envelope and packaging 
plasmid underwent  gradual silencing (Radhakrishnan et al., 2008).  
In the transfer plasmid (pWPT-GFP) internal ribosome entry site (IRES) for co-
expression of GFP, a reporter of viral genes expression or the gene of interest was 
flanked with post-translational regulatory element (WPRE), that promotes an 
effective polyadenylation of the transcript and can increase the total amount of the 
required product (Li et al, 2012). The plasmid contained also rev responsive element 
(RRE) – regulatory protein essential for post-transcriptional transport of the 
unspliced and incompletely spliced viral mRNAs from nuclei to cytoplasm (Lesnik et 
al., 2002), flanked with highly conserved ψ – encapsidation signal and sequences for 
central polypurine tract (cPPT), protecting lentiviruses from editing by cytidine 
deaminases (Wurtzer et al., 2006).  
The envelope plasmid (pMD2G) encoded vesicular stomatitis virus glycoprotein 
(VSV-G) that increased the viral tropism for neurons and ended with human globin 
poly-adenylation site (hGlob-pa) which affects stability, translation and efficiency of 
viral transfection/transduction (Beaudoing et al., 2000).  
Integration of viral elements was possible due to the pol sequence (incorporated into 
the pCMV plasmid) that encodes reverse transcriptase (REV), integrase and RNAase 
H activity (Samlon and Trono, 2006). Reverse transcription followed sequential 
steps, during which first (minus) strand of DNA uses genomic viral RNA as a 
 
Figure 58. Schematic representation of pMD-2G, pWPT-GFP and pCMV plasmids. DNA sequences 
encode the following proteins: CMV – cytomegalovirus promoter, VSV-G – vesicular stomatitis virus 
glycoprotein, hGlob-pA – human globin poly- adenylation site, LTR – long terminal repeats, ψ – 
encapsidation signal, RRE – rev responsive element, cPPT – central polypurine tract, EF-1 – 
elongation factor 1, GFP – green fluorescence protein, WPRE – woodchuck post-translational 
regulatory element, GAG – group specific antigen, TAT/REV – reverse transcriptase. hins-pA – 
human insulin polyadenylation sequence (Raghunath et al., 2008). 
Envelope plasmid 
Transfer plasmid 
Packaging plasmid 
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template and is initiated by a tRNA primer that defines the 3′ boundary of the U5 
region of the long terminal repeat (LTR). The second (plus) strand of DNA uses 
minus-strand DNA as a template (Smith et al., 1984). pCMV plasmid contained also 
gag gene, which is a codon for optimum efficiency of viral matrix proteins, RNA 
genome binding proteins and other proteins comprising the nucleoprotein core 
particle (Raghunath et al., 2008). In addition, TAT protein acts as a transcriptional 
factor and RRE is required for expression of unspliced, packageable transcripts. The 
structure of packaging plasmid ended with human insulin polyadenylation sequence 
(hins-pA), playing role in the effective transfection/transduction of this construct 
(Levy et al., 1995). As mentioned before, the end sequence, coding the surface 
glycoprotein is completely deleted from this plasmid to reduce the virus 
pathogenicity and making this system very safe and efficient tool that to transduce 
neurons in vivo in rodents (Galimi and Verma, 2002; Azzouz et al., 2004, O’Leary et 
al., 2013).  
The novel experimental strategy was adapted to re-direct the tropism of lentiviruses 
to BFCNs (Figure 59). Briefly, biotynylated LentiGFP was combined through 
streptavidin to anti-p75
NTR
 IgG, conjugated to streptavidin. The reaction of biotin 
with streptavidin occurs within seconds and is one of the strongest non-covalent 
interactions known in nature, which enabled to prepare anti-p75
NTR
-LentiGFP vector. 
This vector was tested on BFCNs in vitro and in vivo to verify p75
NTR
 as a molecular 
target for gene therapy of BFCNs in AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59. Strategy for LVs delivery of GFP into BF cholinergic neurons. A. Principle of LVs 
biotinylation. NHS ester group on this regent reacts with amine or lysine residues of protein to 
produce a stable product. B. Schematic of conjugating biotynylated LVs to anti-p75IgG through 
streptavidin. C. Illustration of icv injection of 192IgG-LentiGFP particles into ventricle of rodents’ 
brain. 
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5.2. Optimization of  lentiviral vectors titter 
 
Lentiviral particles were produced according to procedures described in Chapter 2.6. 
Pure DNA proved to be critical for production of high number of lentiviral vectors. 
DNA quality was justified as described in Chapter 2.6.6., example Figure 60. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In result of using high quality material I doubled the number of LentiGFP viral 
vectors produced initially (Figure 61C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60. Quality check of lentiviral plasmid DNA before cells transfection. DNA sizes of pWPT-
GFP (9495bp), pMD-2G (5824bp), and pCMV (11921bp) plasmids (lanes 1) confirmed with 
restriction-digest reactions with Bam H1 (lane 2), Pst1 (lane 4) and EcoR1, with XhoR1 (lane 6) 
compared to DNA ladder marker.  
Figure 61. Optimization of LVs titter. A. Standard curve typical for chemiluminescent reading of p24 
antigen standards with CSPD substrate for alkaline phosphatase. B. Detection of p24 lentiviral protein 
on WB of 12% polyacrylamide gel. C. Lentiviral titters improved across the production of different 
batches. D. Schematic of HIV-1with p24 core protein highlighted. 
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5.2.1. The viability of LentiGFP virus in HEK 293FT cells 
 
The viability of LentiGFP virus was checked with HEK 293FT cells, prepared as in 
Chapter 2.6.7., which were infected with different dilutions of freshly made 
LentiGFP viruses. The presence of GFP was assessed by fluorescent microscopy 
after 24 and 48h (Figure 62A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
The viability of LentiGFP viruses was also checked on neuronal cells in BF cultures. 
2 µl of 9.0 x 106 IUs/ml LentiGFP vectors was kept up to 48 h on culture dishes. 
Then medium was removed and cells were stained with 4',6-diamidino-2-
phenylindole (DAPI) and fixed with 4% PFA in PBS for 30 min. After this step, 
dishes were washed and coverslipped (Figure 63A and B) 
 
 
 
 
 
 
 
 
 
 
 
Figure 63. Viability of Lentiviral vector in p7 BF culture. Mouse BF culture infected with 2µl of 
LentiGFP (9.0 x 10
6
 IUs/ml), co-stained with DAPI. B. Enlarged view of a neuron infected with 
lentivirus expressing GFP and stained with DAPI. 
  
  
Figure 62. Transient transfection of  HEK 293FT cells with lentivirus expressing GFP. A. HEK293FT 
cells in culture. B. Fluorescent image of HEK293FT cells 48 h after transfection with LentiGFP 
viruses (7.0 x 10
6
 IUs/ml ). 
130 
 
5.2.2. Efficiency of viral infection 
 
The extent of HEK 293FT cells infection was measured after 48 h by flow cytometry 
(BD FACS Aria I), which sorted cells expressing green fluorescence protein (GFP), 
encoded by the lentiviral vector from the ones that did not get infected (Figure 64). 
For this experiment, infected and control HEK 293FT cells were transferred to FACS 
solution containing 10% FBS in PBS, pH=7, 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lentivirus (1 µl) (7.0 x 106 IUs/ml) was able to transduce 28.9 % cells as shown in 
Table 7 versus total cells (all events) sorted. 
Figure 64. Extent of infection by LentiGFP checked by fluorescence activated cell sorting (FACS). 
A1. Dot plot showing HEK293FT cells infected with 1 µl of LentiGFP (7.0x 106 IUs/ml) after 48h  
compared to the control in B1 [A2, B2 – forward scatter (FSC) threshold gate].  
  
  
 
Table 7. FACS data from LentiGFP infection of HEK293FT cells. Abbreviations: FITC – fluorescein 
isothiocyanate, P1 – infected cells, SSC – side scatter. 
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5.3. Optimization of anti-p75
NTR
-LentiGFP viral production 
 
Anti-p75
NTR
-LentiGFP viral vectors were produced according to the procedures 
described in Chapters 2.7. However to get high quality, effective particles these 
procedures were optimized. The critical steps involved using high quality material 
verified by biochemical assays (HABA) and WBs (Figures 65 A-D). Purification of 
biotynylated LVs by dialysis was also critical.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During this process, the titter of original lentivirus dropped as shown in Figure 65A, 
lane 2. The biotynylation of envelope proteins were additionally confirmed with anti-
VSV-G antibody as indicated on Figure 65B, lane 3. Full anti-p75
NTR
-LentiGFP 
construct was run on the gel shown on Figure 65C, lane 5 and compared with non 
targeted vector. However, because only the fragment of p75
NTR
 IgG was detected in 
targeted construct,  the original anti-p75
NTR
 IgG from Millipore was shown on Figure 
65D before and after streptavidin conjugation process. Full verification of 
constructed anti-p75
NTR
-LentiGFP vectors included their viability testing in BF 
cultures  and in vivo. 
 
 
Figure 65. Construction of anti-p75
NTR
-LentiGFP vector targeting cholinergic neurons of BF. A. p24 
antigen (MW=24kD) detected in the sample with raw lentivirus (Lane 1) and biotynylated lentiGFP 
vector (Lane 2). B. VSV-G protein (MW=57kD) detected with anti-VSV-G IgG in raw (Lane 4) and 
biotynylated (Lane 3) lentiGFP vector. C. Backbone (fragment of 2 heavy and 2 light IgG chains) of 
p75IgG detected with anti-p75IgG in anti-p75
NTR
-LentiGFP construct (Lane 5) against raw lentiGFP 
particles (Lane 6). D. Original anti-p75IgG from Millipore (Lane 7) run against streptavidin 
conjugated one (Lane 8). All WBs were run on 12% polyacrylamide gels along with standard 
molecular marker (Materials and Methods)  
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5.4. Transduction of anti-p75
NTR
-LentiGFP vectors in BFCNs in vitro  
 
The anti-p75
NTR
-LentiGFP vectors produced earlier were tested onto cholinergic 
cells in rat primary BF culture. Anti-p75
NTR
-LentiGFP (2 μl) (9.0 x 106 IUs/ml) were 
added for 48 h to primary rat BF cultures [2ml volume (0.7 x 10
6
 plating density 
(9.62 cm
2
/35 mm dish)]. After that time, dishes were fixed with 4% PFA, pH=7,4 for 
30 min and washed with PBS, pH=7,4 before viewing. These vectors were able to 
transduce BFCNs as confirmed by double staining of BFCNs with 192-IgG-Cy3 (4.7 
nM) added for 2h to the culture dishes before fixing them  as usual (Figure 66). 
 
 
 
 
 
 
 
 
 
 
5.5. Anti-p75
NTR
-LentiGFP vectors transduce cholinergic neurons in vivo   
 
All surgical procedures were conducted in accordance to SOPs written for ICNT on 
basis of the literature available (Cetin at al., 2006.) and approved by the Research 
Ethics and Biosafety Committees of DCU. The experiments were licensed by the 
Department of Children and Health, Ireland and based on pilot data (Figure 67).  
 
 
 
 
 
 
 
 
 
 
Figure 66. Enlarged view of BFCN transduced by anti-p75
NTR
-LentiGFP vector in rat primary BF 
cultures. A. Neuron from p7 rat BF culture infected with anti-p75
NTR
-LentiGFP (9.0 x 10
6
 IUs/ml). B. 
Same cell fixed with 4%PFA and stained with 192-IgG-Cy3. C. Merged image of A and B. 
Figure 67. Trend in anti-p75
NTR
-LentiGFP expression level compared to 192-IgG-Cy3 based on cell 
counting  in MSDB area. 
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The constructed anti-p75
NTR
-lentiGFP vector (5 µl, 7.0 x 107 IUs/µl) was unilaterally 
injected (0.2 µl/min) into 21 days old Spraque Dawley rats (3 groups, n=5) according 
to stereotactic coordinates: AP = -0.8 mm; ML=1.2 mm; DV = 3 from Paxinos and 
Walsh rat brain atlas (1998) and left for recovery time (2, 4, 6 weeks). A group of the 
same animals (n=3) received also icv injections of 192-IgG-Cy3 (5µl) a week later 
(Materials and Methods, Chapter 2.5.). This time point was concluded from 
preliminary experiment illustrated in Figure 67. Control experimental group was 
injected with saline (0,9% NaCl) and non-targeted LentiGFP (5 µl, 7.0 x 107 IUs/µl) 
(n=3 for each group). The animals were perfused at the time point (2, 4 and 6 weeks 
post initial injection) (Materials and Methods, Chapter 2.1.3.) and coronal sections of 
their brains cut (30 µm) before mounting and viewing (Figure 68). 
 
 
 
 
Brief discussion of lentiviral vector targeting cholinergic cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S6A 
S6D 
Figure 68. Transduction of BFCNs by anti-p75
NTR
-LentiGFP in vivo. A. Control injection of 192-IgG-
Cy3 marking BFCNs. B. Anti-p75
NTR
-LentiGFP signal in cholinergic cells of MSDB. C. Enlarged 
view of BFCNs labelled with 192-IgG-Cy3. D. BFCNs transduced by anti-p75
NTR
-LentiGFP vector (5 
µl, 7.0 x 107 IUs/µl) – enlarged area (same area) as in C. E. Control MSDB area without any 
injections. 
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The signal for anti-p75
NTR
-LentiGFP vector was detected in medial septum (MS) and 
the nuclei of the diagonal band of Broca (DBB) with vertical and horizontal limbs 
areas (VDBB (Ch2) or HDBB (Ch3), respectively. GFP–positive and p75NTR positive 
cells were counted at experimental time points 2, 4 and 6 weeks. (Figure 69). 
 
 
 
 
 
 
 
 
 
 
 
 
Counting of cholinergic neurons revealed that all GFP-positive neurons in BF were 
also labelled for 192-IgG-Cy3. These neurons exhibited enhanced GFP labelling over 
time (Figure 69). GFP labelling was also visible along the injection track through the 
motor cortex (M2) with the green signal present within ventral corpus callosum and 
ventricular wall and few green neurons scattered within the dorsal septum, ventral 
areas of pallidum and caudate areas (Figure 70). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70. GFP-fluorescence along the injection track and adjacent areas. BF regions in dashed boxes. 
Arrow heads point to lateral ventricle while arrows show ventral corpus collosum in higher 
magnification image. Abbreviations: LV- lateral ventricle, CpU – caudate putamen, AC nucleus 
accumbens, MCPO – magnocellular preoptic area, CCx – cerebral cortex, DBB – diagonal bands of 
Brocca 
 
Figure 69. Quantification of neurons labelled with anti-p75
NTR
-LentiGFP and 192-IgG-Cy3. Strong 
co-labelling of Cy3-positive neurons with GFP reporter at later time points (4 and 6 weeks). 
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In controls intraventricular injections of non-targeted LentiGFP also caused 
pronounced labelling of cells of ventricular wall and underlying glia with sparse 
GFP-positive neurons visible in adjacent dorsolateral and medial part of caudate 
nucleus. In regards to MS and DBB, GFP-labelled cells constituted around 5% and 
0.4% of cholinergic cell population respectively (n=3, 6 weeks post injection) as 
revealed by ChAT-staining (figure 71). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altogether these data demonstrate that p75
NTR
 can robustly facilitate transduction of 
viral vectors to BFCNs. The increase of GFP signal in transduced neurons over time 
was most probably caused by gradual accumulation of GFP protein in BFCNs. This 
finding is significant for AD gene therapy, which so far struggle with targeting 
therapeutics into BF. Best treatment for AD is up to now achieved with NGF 
(reviewed in Chapter 1.6), however this molecule binds not only p75
NTR
 but also 
other TrkA receptors elsewhere and may lose its binding abilities when biotynylated 
as was already reported (Rosenberg et al., 1986). 
 
 
Figure 71. Double labelling of cholinergic neurons transduced with targeted (TG) versus non targeted 
(NTG) LentiGFP vectors revealed by ChAT staining. A. MS area of BF. B. DBB area of BF. C. 
Example of double immunohistochemistry for ChAT and  GFP protein in the above areas. Arrows 
point to non-targeted cholinergic cells. 
 
 
 
A B 
C 
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5.6. Discussion on the role of lentiviral vectors in AD therapy  
 
In this chapter, replication-deficient LVs pseudotyped with VSVG were successfully 
constructed from three independent plasmids: pMD-2 G, pWPT-GFP or modified 
pWPI and pCMV as already reported (Tiscorniaet al., 2006). The high titter of these 
viruses enable robust transduction of HEK 293FT cells and neurons in primary BF 
cultures. The best effects were achieved within 24 - 48 hours expression of the 
LentiGFP viruses.  
Same viruses was targeted to cholinergic neurons of BF. For this purpose I utilized 
unique biological feature of BFCNs – the expression of p75NTR (reviewed in Chapter 
1.5.3.2.1.). I  modified lentiviral particles to target this receptor. This was achieved 
through biotynylation of lentivirus containing the reporter protein GFP and 
combining it with anti-p75
NTR
 antibody through biotin – streptavidin covalent bond. 
Conjugation of anti-p75
NTR
 with streptavidin antibody had proceeded this step. 
Effective conjugates of small fluorescent probes and active proteins to anti-p75
NTR 
192 IgG were shown earlier, confirming the stability of this approach (Wiley et al., 
1991; Rossner et al., 1995; Hartig et al., 1998). Streptavidin-biotin conjugates have 
been also successfully applied before for targeting vectors in various experimental 
models (Lesch et al., 2010; Waehler et al., 2007). The virus after the biotynylation 
was purified using dialysis to achieve high quality of vectors targeting BFCNs. These 
vectors successfully transduced cholinergic neurons of BF in rat primary culture 
prior to in vivo verification. 
To find out if p75
NTR
 can facilitate transduction of viral vectors to BFCNs in vivo  I 
injected the anti-p75
NTR
-LentiGFP construct and naive LentiGFP vectors into lateral 
ventricle of the rats’ brains. The receptor-antibody-virus complex get internalized by 
cholinergic terminals and underwent retrograde trafficking to the cell bodies where it 
yield robust expression of GFP in MSDB areas, seen best 7 days after the injection 
and monitored up to 6 weeks post injection. Non targeted vectors caused pronounced 
labelling of cells of ventricular wall with some cells scattered in dorsolateral and 
medial direction. Thus the proof of principle was obtained for the effective and 
selective targeted transduction BFCNs through p75
NTR
 in vivo.  
This is a very promising result for further research of AD and eventual gene therapy 
to AD. Thanks to large capacity of lentiviral viruses (reviewed in Chapter 5.1) 
further genes can be introduced along with GFP reporter protein to counteract 
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deleterious effects of Aβ, tau hyperphosphorylation, modulate AChE activity or 
enhance lysosomal or mitochondrial function.  
The protection of BFCNs from harmful Aβ effects could be achieved for instance by 
introduction of Fe65 genes while using the above strategy. Fe65 belongs to family of 
adaptor, scaffolding proteins acting downstream APP signalling, which are reported 
to reduce the risk of development late onset of AD (Hu et al., 2002; Lambert et al., 
2000) if associated with the expression of full-length variant of Fe65 protein (Wang 
et al., 2004). The Fe65 family consists of three members: Fe65, Fe65-like 1 (Fe65L1) 
and Fe65L2 (Bressler et al., 1996; Blanco et al., 1998) from which Fe65 is expressed 
exclusively in brain (Hu et al., 1999; Kesavapany et al., 2002) while Fe65L1 or 
Fe65L2 are more widely distributed. Fe65 protein has a multi-domain structure as 
illustrated on Figure 72. 
 
 
 
 
 
 
 
 
 
 
Fe65 forms complexes with a variety of  binding partners to exert a number of 
functions in the brain that may include modulation of APP processing (Sabo et. al., 
1999; Pietrzik et al., 2004; Hu et al., 2005) plasma membrane dynamics (including 
neurite outgrowth and neuronal positioning) (Sabo et. al., 2001 and 2003; Guenette 
et. al., 2006; Ikin et al., 2007) and transcriptional activation (Cao and Sudhof, 2001; 
Yang et. al., 2006). The functional significance of these interactions require 
additional research and especially roles of Fe65 isoforms in learning and memory 
needs to be determined. 
By this occasion it is important to discuss the feasibility of using viral vector gene 
delivery as a treatment for AD in the clinic. Generally it offers unique advantages 
over the traditional therapeutic methods as it theoretically permits generation of 
active drugs at the sites where they are mostly needed. The attempts have been made 
Figure 72. Schematic illustration of Fe65 isoforms. A. The full length Fe65 (p97Fe65) contains three 
domains: WW important for Fe65 transcriptional function (Cao and Sudhof 2001; Minopoli et.al., 
2001) and two C-terminal phosphotyrosine interaction domains (PID1 and PID2) important for AICID 
binding ability B. Fe65short isoform (p60Fe65) that lacks WW. 
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so far to deliver NGF using adeno-associated viruses (Mandel et al., 1999) and 
lentiviruses (Blesch et al., 2005) or improved tetracycline-dependent lentiviral 
vectors, regulating transgene expression in vivo (Vigna et al., 2005). However, all 
these systems lack of adequate efficacy. In some cases they brought unexpected and 
undesirable side effects. In general, the magnitude and consistency of their clinical 
benefits were disappointing. By far the most consistently proposed reason for their 
side effects and poor efficacy has been inadequate dosing and delivery. The creation 
of CERE-110 (AAV2-NGF) vector system for dose dependent delivery of NGF has 
been reported (Bishop et al., 2008). Recently AAV2-NGF vectors were stereotaticly 
injected to nucleus basalis of Meynert in clinical trial Phase 1 clinical study to AD 
(Rafii et al., 2014). However these vectors still have broad tropism to the neuronal 
cells. Given very complex nature of the BF region they may cause not favourable 
side effects in the longer term. Therefore the method presented in this thesis offers 
better choice for targeting BFCNs, due to the unique expression of p75
NTR
. 
Moreover, LVs can efficiently deliver genes of interest due to their large capacity. 
They are also able to maintain long-term expression. What is important, these vectors 
can be easy generated in high titters, and do not give immunological complications. 
This means they can be safely produced for clinical applications. By far many animal 
studies have demonstrated the effectiveness of LVs to deliver therapeutic genes into 
the nervous system, as well as to model human diseases (Shaughnessy et al., 2005; 
Nanou and Azzouz, 2009). Certain limitations of LVs can be even beneficial e.g. 
they limited intra-axonal mobility. Only few GFP-positive cells were found scattered 
in this study after LentiGFP icv. The lack of retroaxonal transport already proved to 
be beneficial in other applications of these vectors (O’Leary et al., 2013; Ovsepian et 
al., 2015). More and more human gene therapy clinical trials are underway using 
LVs in a wide range of human diseases (Escors and Breckpot, 2010; Kumar and 
Woon-Khiong, 2011). Lentiviral vectors applications proved to be beneficial 
especially in those trials where other method were difficult to apply (Kantor et al., 
2014). Moreover, these vectors can be used to reprogram cells, generate iPSCs and 
silence genes by combination with siRNA and microRNA-based technologies what 
is putting them at forefront of gene delivery systems for research and clinical 
applications (Rubinson et al., 2003; Nethercott et al., 2011). Therefore the use of 
proposed targeted LVs for potential delivery of therapeutic genes into BFCNs 
becomes fully justified, given high complexity of cholinergic system of BF. 
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Chapter IV. Summary and Final Conclusions 
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There is no doubt that AD is one of the most complex illnesses known of the aged 
human brain. It is characterised by specific neuropathological changes in certain 
brain regions, (reviewed in Chapter 1.4.) but a cascade of molecular events leading to 
these alterations remains elusive, despite many years of scientific investigations. Last 
century brought numerous hypothesis of AD (reviewed in Chapter 1.5.) with amyloid 
cascade hypothesis prevailing in this area of research (Chapter 1.5.1). Although this 
hypothesis is based on the solid data it does not explain why Aβ is preferentially 
deposited in the certain sections of brain, while sparing the others. Similarly 
cholinergic hypothesis (reviewed in Chapter 1.5.3.) is not fully able to explain this 
phenomenon. Likewise, it does not clarify why cholinergic projections not the others 
are vulnerable to the disease process. Moreover, it is of note that Aβ plaques does not 
always correlate with severity of cognitive decline. Importantly also the cholinergic 
drugs (e.g. AchE inhibitors reviewed in Chapter 1.6.) meet only with partial success 
in the treatment of AD. Even more challenging are the reports doubting the selective 
loss of cholinergic neurons as well as the causal relationship between the 
degeneration of cholinergic projections with plaque- or tangle-related pathology. 
Recent theories undertake these challenges and are viewing the basal high metabolic 
activity of certain areas of brain as main cause of region-specific Aβ depositions (e.g. 
DMN hypothesis reviewed in Chapter 1.5.7.), which is supported by previous 
research suggesting the causal relationship between synaptic activity and Aβ 
production (Cirrito et al., 2005). This hypothesis however does not explain why 
sporadic AD strikes some individuals not the others. There is also poor overlap 
between DMN hypothesis and cholinergic one, particulary in regards to the 
susceptibility of cholinergic neurons to AD. In summary further research is needed to 
decipher still unknown mechanisms of AD. There is great scope for investigations of 
novel molecular targets and designing new therapeutics to fight with this devastating 
disorder. 
In this research I focused on p75
NTR
 because this receptor is unique for cholinergic 
neurons and it is expressed not only during brain development but also throughout  
adulthood by these cells. The level of p75
NTR
 is significantly elevated with aging and 
further activated by Aβ in AD brain, with the meaning of this appearance remaining 
unclear (Zeng et al., 2011). P75
NTR
 has a number of functions in the BF which 
include neuronal apoptosis, cell survival and differentiation, neurite outgrowth and 
others (reviewed in Chapter 1.5.3.2.1.) that depend on ligands it binds to. NGF gene 
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therapy is currently viewed as very promising approach for the treatment of AD in 
the clinic (Tuszynski et al., 2015), which is pointing further to the relevance of 
p75
NTR
 as an important molecular target. P75
NTR
 biology is unique for TNFRSF as 
this receptor interacts with non-neurotrophic ligands including Aβ – main culprit of 
AD. Interestingly Aβ binds to p75NTR with even higher nanomolar affinity than NGF 
(Kd=12nM for Aβ; Kd=7nM for NGF), stressing further the importance of p75NTR to 
neurodegenerative processes in AD. All these facts made p75
NTR 
worth investigation, 
despite the existence of others multiple receptors implicated in AD pathology.  
Surprisingly, not much research was done up to date for p75
NTR
 internalization, 
especially its uptake apart from TrkA co-receptors that mediate neuronal survival. 
Therefore this thesis constitute valuable asset to the knowledge of p75
NTR
 biology 
and function. My experiments confirmed that Ca
2+
 influx through T-type and L-type 
channels with mobilization of intracellular Ca
2+
 stores are needed for triggering the 
endo/exocytosis of p75
NTR
. Indeed, the specific calcium channels blockers 
(mibefradil and nifedipine for T and L type Ca
2+
 channels, respectively) significantly 
decreased p75
NTR
 uptake by BFCNs in culture (Chapter 4.4.2.). Likewise, the 
inhibitors of SERCA pump ATPase – thapsigargin or cyclopiazonic acid, brought 
similar effects. Chelating extracellular Ca
2+
 in cultured medium with EGTA also 
inhibited the endocytosis of p75
NTR
. These findings are important as they are linking 
p75
NTR
 biology to the Ca
2+
 homeostasis, that is known to be altered during AD 
(reviewed in Chapter 1.5.1.2.). 
Other experiments supported basal constitutive endo/exocytosis of p75
NTR
 that is 
increased by K
+
 depolarization but seems to be independent from regulated synaptic 
activity as found by tests with potassium channel blocker – TTX (Chapter 4.4.1.) and 
confirmed later with Clostridial Botulinum neurotoxins BoNT/A and BoNT/ B  - the 
potent inhibitors of the membrane turnover.  
Because Aβ, the product of endogenous cleavage of APP (process reviewed in 
Chapter 1.5.1) is a culprit of neuronal death I investigated the influence of oligomeric 
forms of Aβ on the endocytosis of p75NTR. These forms of Aβ are known to be the 
most neurotoxic and have higher affinity for p75
NTR
 than soluble amyloids. The 
experiments were design carefully with sub-cytotoxic concentrations of aggregated 
Aβ not to cause BFCNs death. In these experiments I found out that oligomeric 
forms of Aβ inhibit p75NTR uptake in a dose dependent manner (Chapter 4.5.1.). 
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P75
NTR
 trafficking together with Aβ (1-42) was also followed by confocal 
microscopy in live BFCNs and SCGNs with parameters of this movement 
established (Chapter 4.3.1. and 4.3.2.). Although p75
NTR
 entry to these cells remains 
elusive, with no doubt p75
NTR
 is directing its cargo for degradation in lysosomal 
compartments of BFCNs as shown by investigation of p75
NTR
 immobilization in 
different endosomes (Chapter 4.7). This is in agreement with previous literature 
suggesting that phosphorylation of p75
NTR
 is a sorting signal for delayed degradation 
of neurotrophins after retrograde axonal transport (Butowt and Bartheld, 2009). This 
finding was also confirmed in chemically induced animal model with 192-IgG-SAP, 
resulting in the increased deposition of Aβ (1-42) in hippocampal and cortex 
formation after deletion of cholinergic neurons through their ribosomal inactivation 
(Chapter 3.5.6.1.) and discussed in Chapter 3.6.  
In summary these results suggest possible Aβ clearance by cholinergic neurons and 
together with in vitro results showing p75
NTR
 uptake dependent on the amount of Aβ 
oligomers, they suggest a new role of p75
NTR
 in maintaining Aβ homeostasis in the 
brain through the diffuse cholinergic projections. This challenge the traditional view 
of cholinergic system, seen so far as neuromodulatory arrangement coordinating 
ACh supply to the targeted brain areas (reviewed in Chapter 1.5.3.1. and 1.5.3.2.). 
Thus the new role of cholinergic system beyond the cholinergic transmission is 
proposed and described in the recent publication (Ovsepian et al., 2016). Cholinergic 
fibers enriched with p75
NTR
 and lacking post-synaptic specifications seem to be 
ideally suitable for maintaining physiological concentrations of Aβ in brain. Such 
view could also explain high selective vulnerability of BFCNs to Aβ damage during 
AD. The disrupted calcium homeostasis in aging could put the whole system of Aβ 
clearance into overdrive, causing disturbance of the clearance mechanisms and high 
vulnerability of cholinergic neurons to damage in AD in consequence. However 
further research is warranted to confirm these hypothesis. 
In the light of the recent reports and clinical trials (Chapter 1.6.) p75
NTR 
become the 
valuable target for gene therapy to BF. By combining streptavidin biotin technology 
with modifications of lentivirus and anti-p75
NTR
 antibodies, I proposed designing of 
LVs targeting BFCNs (Chapter 5.1). These vectors effectively transduced BFCNs in 
culture (Chapter 5.4.1.) as well as in vivo (Chapter 5.4.2.) proving usefulness of this 
strategy for targeting LVs into BF, discussed in Chapter 5.5. Further research is 
currently ongoing on p75
NTR
 as a new molecular target (Tanaka et  al., 2016).  
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7.3. Buffers and solutions used  
 
AP buffer (5X) 
14.6 NaCl; 30.25 g Tris; MgCL2x6H2O 
Adjust pH to 9.5 with HCl 
 
Brain tissue extraction buffer: 
20mM Tris-HCl; 145 mM NaCl, 10% glycerol; 5 mM EDTA; 0.5% Nonidet 
Before use add protease inhibitor cocktail (539134, Calbiochem) 
 
PBS (10X)  
0.02M NaH2PO4 (monobasic); 0.077 M Na2HPO4 (dibasic); 1.4M NaCl 
 
4% PFA 
Heat less than 100 ml H2O and add 4g paraformaldehyde (weight with face mask 
on). Stir and heat to get clear solution. Add few drops 1M NaOH until the solution 
gets clear. Filter the solution through 0.45 μm filter. Add 10 ml (10X) PBS. Adjust 
pH to 7.4 with HCl or NaOH 
 
Polyacrylamide gel (12.5%) (composition for 2 gels) 
resolving gel: 3.75 ml Tris-SDS, pH=8.8; 4.75 ml H20; 6.35 ml acrylamide; 12.5 μl 
Temed; 10 % APS 
Stacking gel: 1.7 ml Tris-SDS, pH=6.8; 4.9 ml H20; 925 μl acrylamide; 7.5 μl 
Temed; 75μl 10% APS  
 
QIAfilter Plasmid Midi Kit buffers: 
P1: 50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 µg/ml RNase A 
P2: 200 mM NaOH, 1% SDS (w/v) 
P3: 3.0 M potassium acetate, pH 5.5 
QBT: 750 mM NaCl, 50 mM MOPS, pH 7.0; 15% isopropanol (v/v); 0.15 % Triton  
          X-100 (v/v) 
QC: 1.0 M NaCl, 50 mM MOPS, pH 7.0; 15% isopropanol (v/v) 
QF: 1.25 M NaCl, 50 mM Tris-Cl, pH 8.5; 15% isopropanol (v/v) 
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SDS-PAGE buffer (1L) 
1M MOPS; 1M Tris base; 69.3 mM SDS; 20.5 mM EDTA 
Or  Tris base (30g); glycin (144g); SDS (10g) 
 
TAE (Tris-acetate-EDTA buffer) (10X) 
48.4 g of Tris Base, 11.4 ml of glacial acetic acid (17.4 M); 3.7 g of EDTA, disodium 
salt; deionized water up to 1L 
 
TBS (10X) 
50 mM Tris-HCl; 150 mM NaCl  
pH to 7.4 with HCl or NaOH 
 
TBST buffer for 1 L  
100ml of TBS(10X) + 900 ml ultra-pure H2O and 1ml of Tween 20 
 
TE (Tris-EDTA buffer) 
10 mM Tris, bring to pH 8.0 with HCl, 1 mM EDTA 
 
Tris-SDS for polyacrylamide gels 
Tris for resolving gel (1 L): Tris base 181.7 g; 10 % SDS, pH=8.8 
Tris stacking gel for (1 L): Tris base 60.6 g; 10 % SDS, pH=6.8 
 
WB transfer buffer for 1 L 
100 ml Methanol; 3.04 g Tris base; 15 g glycine 
 
All reagents were purchased from Sigma Aldrich: 30 % acrylamide (A3574), APS 
(A3678), EDTA (E6758), glacial acetic acid (1005706), glycerol (G6279), HCl 
(H1758), isopropanol (I9516), methanol (34860), MgCL2x6H2O (M9272), MOPS 
(69947), Na2HPO4 (30412), NaH2PO4 (S8282), NaCl (S7653,Sigma), NaOH 
(S0399), Nonidet (74385), Paraformaldehyde (P6148), Potassium acetate (P1190), 
SDS (L3771), Temed (T7024), Tris-HCl (T3253), Triton X-100 (T9284), Trizma 
base (93349), Tween 20 (P1379). 
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7.4. Plasmids’ chart 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
http://www.addgene.org/browse/sequence/7271/ 
http://www.adgene.org/12255 
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C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic representation of pCMV-d-8.74 from ICNT library 
 
 
D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
http://www.snapgene.com/resources/plasmid_files/basic_cloning_vectors/pUC19 
 
Figure 70. Schematic representation of plasmids DNA with most important restriction sites indicated. 
A. pMD2G – envelope plasmid. B. pWPT-GFP – packaging plasmid. C. pCMV – helper plasmid. D. 
pUC19 – control plasmid. The source of each plasmid restriction map is given underneath each 
plasmid. 
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7.5. Posters  
 
 “Basal forebrain cholinergic neurons as a target for gene therapy in 
Alzheimer’s disease” 
 
(Bio)pharmaceutical and Pharmacological Sciences Conference Dublin City 
University, Ireland (2011) 
 
 “p75NTR endocytosis as a potential route for amyloid β internalization in 
cholinergic neurons of basal forebrain” 
 
11th International Conference on Alzheimer’s and Parkinson’s Diseases 
(AD/PDTM 2013), Florence, Italy (2013) 
 
 “Targeting p75NTR by lentiviral vectors as prerequisite for AD gene therapy”  
 
Careers in Neuroscience Symposium, National University of Ireland,  
Galway, Ireland (2014) 
 
7.6. Publications and abstracts published 
 
 Ovsepian S.V., Antyborzec I., O'Leary V.B., Zaborszky L., Herms J., Oliver 
Dolly J. Neurotrophin receptor p75 mediates the uptake of the amyloid beta 
(Aβ) peptide, guiding it to lysosomes for degradation in basal forebrain 
cholinergic neurons. Brain Struct Funct. 2014, 219(5), 1527-41.  
 
 The publication was additionally mentioned in Targeting Trends 2013,14(4),3 
 
 Antyborzec I., O'Leary V.B., Dolly J.O., Ovsepian S.V. Neurotherapeutics. 
Low-affinity neurotrophin receptor p75 promotes the transduction of targeted 
lentiviral vectors to cholinergic neurons of rat basal forebrain. 2016 May 24. 
[Epub ahead of print] 
 
Abstract: 
 
 “P75NTR Endocytosis as a Potential Route for Amyloid β Internalization in 
Cholinergic Neurons of Basal Forebrain” published as a supplement to the 
Neurodegenerative Diseases Journal, 2013, Vol. 11, Suppl. 1 - Alzheimer's 
and Parkinson's Diseases: Mechanisms, Clinical Strategies, and Promising 
Treatments of Neurodegenerative Diseases – also available online 
http://adpd.ekonnect.co/ADPD_443/poster_53219/program.aspx 
 
7.7. Other contributions 
 
Immuno-cytochemistry and cell counting for the publication below 
 
Ovsepian S.V., Dolly J.O., Zaborszky L. Intrinsic voltage dynamics govern the 
diversity of spontaneous firing profiles in basal forebrain noncholinergic neurons. J 
Neurophysiol. 2012, 108(2), 406-18. 
 
